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Abstract
Frontotemporal lobar degeneration (FTLD) is an important cause of dementia in individuals under age 65.
Common variants in the TMEM106B gene were previously discovered by genome-wide association
(GWAS) to confer genetic risk for FTLD-TDP, the largest neuropathological subset of FTLD (p=1x10-11,
OR=1.6). Prior to its discovery in the GWAS, TMEM106B, or Transmembrane Protein 106B, was
uncharacterized. To further understand the role of TMEM106B in disease pathogenesis, we used
immortalized as well as primary neurons to assess the cell biological effects of disease-relevant levels of
TMEM106B overexpression and the interaction of TMEM106B with additional disease-associated
proteins. We also employed immunostaining to assess its expression pattern in human brain from
controls and FTLD cases.
We discovered that TMEM106B is a highly glycosylated, Type II late endosomal/lysosomal
transmembrane protein. We found that it is expressed by neurons, glia, and peri-vascular cells in diseaseaffected and unaffected regions of human brain from normal controls in a cytoplasmic, perikaryal
distribution. In brain from FTLD patients, we discovered a striking loss of subcellular localization with
highly disordered TMEM106B immunostaining patterns in a subset of FTLD-TDP cases. Evidence
suggests that TMEM106B variants increase risk for developing FTLD-TDP by increasing TMEM106B
mRNA and protein expression levels. We therefore investigated the cell biological effects of increased
TMEM106B expression. Increased TMEM106B results in a decrease in the average number of late
endosomes/lysosomes per cell, loss of lysosomal acidification, and impaired lysosomal degradation. In
addition, lysosomal deficits are accompanied by the appearance of enlarged organelles (>2-3μm)
demonstrating ultrastructural characteristics of late autophagic vacuoles (autolysosomes/amphisomes).
We observed these effects in both immortalized cell lines and in primary neurons overexpressing
TMEM106B. Furthermore, we show that the effects of increased TMEM106B expression can be
abrogated by (1) a single point mutation to a lysosomal sorting motif in TMEM106B newly identified here,
or (2) knockdown of C9orf72 protein. In sum, our results suggest that TMEM106B exerts its effects on
FTLD-TDP disease risk through alterations of lysosomal and autophagic pathways and that TMEM106B
and C9orf72 may interact in disease pathophysiology.
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ABSTRACT
INCREASED EXPRESSION OF FRONTOTEMPORAL DEMENTIA RISK FACTOR TMEM106B
ALTERS LYSOSOMAL AND AUTOPHAGOSOMAL PATHWAY
Johanna Busch
Dr. Alice Chen-Plotkin
Frontotemporal lobar degeneration (FTLD) is an important cause of dementia in
individuals under age 65. Common variants in the TMEM106B gene were previously discovered
by genome-wide association (GWAS) to confer genetic risk for FTLD-TDP, the largest
neuropathological subset of FTLD (p=1x10-11, OR=1.6). Prior to its discovery in the GWAS,
TMEM106B, or Transmembrane Protein 106B, was uncharacterized. To further understand the
role of TMEM106B in disease pathogenesis, we used immortalized as well as primary neurons to
assess the cell biological effects of disease-relevant levels of TMEM106B overexpression and the
interaction of TMEM106B with additional disease-associated proteins. We also employed
immunostaining to assess its expression pattern in human brain from controls and FTLD cases.
We

discovered

that

TMEM106B

is

a

highly

glycosylated,

Type

II

late

endosomal/lysosomal transmembrane protein. We found that it is expressed by neurons, glia,
and peri-vascular cells in disease-affected and unaffected regions of human brain from normal
controls in a cytoplasmic, perikaryal distribution. In brain from FTLD patients, we discovered a
striking loss of subcellular localization with highly disordered TMEM106B immunostaining
patterns in a subset of FTLD-TDP cases. Evidence suggests that TMEM106B variants increase
risk for developing FTLD-TDP by increasing TMEM106B mRNA and protein expression levels.
We therefore investigated the cell biological effects of increased TMEM106B expression.
Increased TMEM106B results in a decrease in the average number of late endosomes/lysosomes
per cell, loss of lysosomal acidification, and impaired lysosomal degradation. In addition,
lysosomal deficits are accompanied by the appearance of enlarged organelles (>2-3μm)
demonstrating

ultrastructural

characteristics

iii

of

late

autophagic

vacuoles

(autolysosomes/amphisomes). We observed these effects in both immortalized cell lines and in
primary neurons overexpressing TMEM106B. Furthermore, we show that the effects of increased
TMEM106B expression can be abrogated by (1) a single point mutation to a lysosomal sorting
motif in TMEM106B newly identified here, or (2) knockdown of C9orf72 protein. In sum, our
results suggest that TMEM106B exerts its effects on FTLD-TDP disease risk through alterations
of lysosomal and autophagic pathways and that TMEM106B and C9orf72 may interact in disease
pathophysiology.
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CHAPTER 1: INTRODUCTION
PREFACE:
This body of work aims to provide an initial characterization of Transmembrane Protein
106B, or TMEM106B – a protein associated with the neurodegenerative disease, frontotemporal
lobar degeneration (FTLD) – and to demonstrate how elevated levels of TMEM106B, as seen in
disease, perturb endolysosomal and autophagosomal pathways. In this Introduction, I will
describe FTLD, discuss known mutations that cause the disease, detail the discovery of
TMEM106B, and give an overview of endolysosomal/autophagosomal pathways and their role in
neurodegeneration.
1.1 PART I: Frontotemporal dementia and disease-associated mutations
1.1.1

Frontotemporal Lobar Degeneration
Frontotemporal lobar degeneration (FTLD), otherwise known by its clinical designation

“frontotemporal dementia (FTD),” refers to a clinically and genetically heterogenous group of
neurodegenerative disorders that are characterized by the selective and progressive
degeneration of the frontal and temporal lobes of the brain (Ratnavalli et al., 2002; Neary et al.,
2005). FTLD is the second most common cause of dementia in patients under the age of 65 after
Alzheimer’s, and accounts for approximately 5-15% of all patients with dementia (Seelaar et al.,
2011; Ratnavalli et al., 2002; Mercy et al., 2008). Reflecting the location of degeneration within
the brain, patients initially exhibit changes in behavior, language, and personality, in contrast to
the prominent memory impairments typically associated with Alzheimer’s disease (Mackenzie et
al., 2011). These changes are progressive and ultimately result in global dementia with a disease
duration of four to eight years from diagnosis to death (Garcin et al., 2009; Hodges et al., 2003;
Neary et al., 2005). There are currently no treatments for the disease; therefore, elucidating the
mechanisms underlying disease pathogenesis is important in order to identify potential
therapeutic avenues.
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1.1.2

Epidemiology
The mean age at onset of FTLD is ~58 years, but disease onset can range from ~40 to

75 years old (Hodges et al., 2003; Rosso et al., 2003). Some studies estimate equal incidence of
disease in men and women (Johnson et al., 2005), while others have demonstrated increased
incidence in men (Ratnavalli et al., 2002). In the 45- to 64-year-old population demographic, the
incidence of disease has been estimated to be 15 per 100,000 people (Ratnavalli et al., 2002),
although these estimates are likely to be conservative due to misdiagnosis of FTLD as psychiatric
illnesses due to the striking personality changes and loss of inhibition sometimes exhibited by
patients.
1.1.3

The ALS-FTLD disease spectrum
It has been increasingly recognized that FTLD and amyotrophic lateral sclerosis (ALS)

exist on a disease spectrum, with pure forms of the diseases at either extreme and clinical and
genetic overlap in between (Mackenzie and Feldman, 2005). ALS is classically described as a
neurodegenerative disease that selectively affects both upper and lower motor neurons and is
usually fatal between 3-5 years after diagnosis (Swinnen and Robberecht, 2014). Approximately
half of ALS patients exhibit functional loss in tests of frontal lobe function and ~15% of patients
have enough deficits to be diagnosed with FTLD (Ringholz and Greene, 2006). Conversely,
~40% of FTLD cases have some level of motor dysfunction, with ~15% meeting the criteria for
ALS diagnosis (Burrell and Hodges, 2010).
In addition to this clinical overlap, genetic and pathological evidence likewise support an
FTLD-ALS continuum. A major discovery came in 2006, when pathological inclusions of TARDNA binding protein 43 (TDP-43) were identified as the major ubiquitinated protein found in brain
tissue of both sporadic ALS and FTLD (Neumann et al., 2006; Arai et al., 2006). In addition,
disease-causing missense mutations in the gene encoding TDP-43 (TARDBP) were also found to
account for ~3% of familial ALS and a small number of FTLD cases (Borroni et al., 2009;
Sreedharan et al., 2008; Van Damme et al., 2008; Kabashi et al., 2008; Lagier-Tourenne and
Cleveland, 2009). Finally, in 2011, expansion of an intronic hexanucleotide repeat in C9orf72 was
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identified as the most common cause of both FTLD and ALS (DeJesus-Hernandez et al., 2011;
Renton et al., 2011; Beck et al., 2013). Mutations in TARDBP, C9orf72, and other diseaseassociated genes are described in further detail below.
1.1.4

Neuropathology
FTLD pathology includes atrophy of the frontal and temporal cortices with associated

neuronal loss, gliosis, and spongiosis (Sieben et al., 2012; Seelaar et al., 2011). There are two
major neuropathological subtypes of FTLD – FTLD with tau-positive inclusions (FTLD-tau) and
FTLD with TDP-43-positive inclusions (FTLD-TDP) (Mackenzie et al., 2011; Sieben et al., 2012;
Mackenzie et al., 2010). The genetic data to date suggest that there are likely distinct
mechanisms of disease pathogenesis for FTLD-tau and FTLD-TDP, with specific mutations
associated solely with each subtype. The neuropathological subtypes and their known diseaseassociated gene mutations are depicted in Figure 1.1. FTLD-tau represents approximately 45%
of FTLD and is characterized by abnormal accumulations of the microtubule-associated protein
tau in neurons and glia. In contrast, FTLD-TDP cases make up the largest proportion of FTLD, at
approximately 45-60% of total FTLD cases (Ling et al., 2013). FTLD-TDP is the neuropathological
subtype of most interest to this work, as TMEM106B variants were found to confer risk of disease
in the FTLD-TDP subtype. FTLD-TDP cases harbor neuronal inclusions of ubiquitinated,
hyperphosphorylated TAR DNA binding protein 43 (TDP-43) (Arai et al., 2006; Neumann et al.,
2006). Briefly, TDP-43 is an RNA/DNA binding protein which has been reported to regulate gene
expression, transcription, and multiple aspects of RNA processing and functioning; the role of
TDP-43 in disease will be discussed in further detail below. Other neuropathological subtypes
include FTLD-FUS (Fused in Sarcoma), which makes up ~9% of FTLD, and FTLD-UPS
(ubiquitin-protease system). These subsets are beyond the scope of this work, but notably lack
both TDP-43 and tau pathology (Ling et al., 2013).
1.1.5

Major disease-associated mutations
FTLD can be either sporadic or familial; approximately 40% of patients have a family

history positive for dementia or psychiatric diagnoses, but the inheritance pattern of FTLD is not
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always clear, with only 10-25% of patients exhibiting a clear Mendelian inheritance pattern
(Hodges et al., 2003; Knibb et al., 2006; Goldman et al., 2005). Currently, Mendelian FTLD has
been linked to mutations in many different genes, most notably MAPT, GRN, C9orf72, OPTN,
TARDBP, FUS, UBQLN2, VCP, and CHMP2B. Autosomal dominant mutations with high
penetrance in MAPT, GRN, C9orf72, together explain ~15% of familial FTLD. Disease-associated
mutations in MAPT correlate with FTLD-tau pathology whereas mutations in GRN and C9orf72
are associated with FTLD-TDP pathology. In addition, mutations in VCP and CHMP2B are
important

albeit

rare

causes

of

disease

that

hint

at

disturbances

of

endolysosomal/autophagosomal pathways in the development of disease (Sieben et al., 2012).
Mutations in MAPT, GRN, TARDBP, C9orf72, VCP, and CHMP2B are discussed in more detail
below, as they pertain most to this body of work. These genes implicate dysregulation of various
cellular pathways in the development of disease, including membrane trafficking, autophagy and
endolysosomal pathways, DNA/RNA processing, and accumulation of toxic aggregates; these
pathways are summarized in Figure 1.2. For additional genes implicated in FTLD, the reader is
directed to Bennion Callister 2014 for a comprehensive review (Bennion Callister and PickeringBrown, 2014).
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Figure 1.1:

Figure 1.1: Major disease-associated mutations
The major neuropathological subtypes of frontotemporal lobar degeneration are depicted in red.
The genes associated with each neuropathological subtype are depicted below in orange.

Figure 1.2:

Figure 1.2: Major genes and cellular pathways implicated in FTLD
Genes correlating with FTLD-TDP pathology are highlighted in yellow. Disturbances of membrane
trafficking and autophagosomal/endolysosomal pathways are one major theme; a second major
theme is alterations in DNA/RNA processing and metabolism.
Adapted from (Guerreiro et al., 2015).
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1.1.5.1 TARDBP
Human TDP-43 was first discovered in a screen as a transcriptional repressor of the
trans-activation response (TAR) element of HIV, earning its name TAR DNA Binding Protein
(TARDBP) (Ou et al., 1995). The protein encoded by TARDBP is thus named TDP-43 due to its
molecular weight of 43 kDa (Neumann et al., 2006; Ou et al., 1995). Disease-associated
mutations in TARDBP itself are a unifying cause of both FTLD and ALS; to date, 34 different
missense mutations in TARDBP have been reported in 131 ALS and FTD families (Cruts et al.,
2012). Additionally, hyperphosphorylated, ubiquitinated, and N-terminally truncated TDP-43+
inclusions were found in 2006 to be the pathological hallmark of all of FTLD-TDP, regardless of
the underlying mutation, thus, strongly implicating TDP-43 in FTLD-TDP pathogenesis (Neumann
et al., 2006). In normal states, TDP-43 is found predominantly in the nucleus, but shuttles back
and forth between the nucleus and cytoplasm. However, in postmortem samples from patients
with FTLD-TDP and ALS, TDP-43+ inclusions are often found mislocalized to the cytoplasm of
neurons within disease-affected regions of the brain (Neumann et al., 2006).
TDP-43 is a ubiquitously expressed DNA- and RNA-binding protein and has been shown
to have myriad functions, many of which are still being elucidated. TDP-43 has been shown to
play a major role in RNA processing and homeostasis (Lee et al., 2011a; Da Cruz and Cleveland,
2011; Buratti et al., 2010). Data supporting such a role are as follows. TDP-43 depletion from
mouse brain by anti-sense oligonucleotides resulted in changes in levels of 601 mRNAs,
including FUS and GRN (Polymenidou et al., 2011). Additionally, TDP-43 depletion was then
shown to result in altered splicing patterns of ~1500 RNAs in mammalian brain (Tollervey et al.,
2011; Polymenidou et al., 2011). To date, more than 6000 TDP-43 RNA targets have been
identified from in vivo studies in human brain (Tollervey et al., 2011), rat and mouse cortical
neurons (Sephton et al., 2011), a murine NSC-34 line (Colombrita et al., 2012) and a human
neuroblastoma cell line (Xiao et al., 2011). TDP-43 has been found to preferentially bind to
introns, 3’ UTRs, and non-coding RNAs (Tollervey et al., 2011); intriguingly, a number of TDP-43
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regulated targets have been shown to be involved in neuronal development or neurological
disease (Tollervey et al., 2011).
TDP-43 has also been implicated in ncRNA stability and miRNA biogenesis (Robberecht
and Philips, 2013; Kawahara and Mieda-Sato, 2012). Specifically, TDP-43 has been found in a
macromolecular complex containing Dicer (Gregory et al., 2004; Kawahara and Mieda-Sato,
2012) and Drosha (Ling et al., 2010); additionally, levels of TDP-43 have been reported to affect
the stability of Drosha, with knockdown of TDP-43 causing a 66% decrease in Drosha levels in
SK-N-BE cells (Di Carlo et al., 2013). TDP-43 binds directly to a subset of pri-miRNAs to promote
the production of their pre-miRNAs (Kawahara and Mieda-Sato, 2012), supporting a role for TDP43 in miRNA biogenesis. Corroborating this, Buratti et al. have reported that TDP-43 depletion
results in downregulation of let-7b miRNA (Buratti et al., 2010). Thus, evidence for a RNAregulatory role for TDP-43 comes from multiple different groups, working in cell culture, tissue,
and in vivo animal contexts.
Despite these advancements in our understanding of TDP-43 within the cell, much more
needs to be elucidated to begin to understand the pathogenic link between FTLD-TDP TDP-43
neuropathology and mutations in TDP-43, GRN, C9orf72, VCP and other genes.
1.1.5.2 MAPT
In 1994, initial genetic linkage evidence implicated a locus on chromosome 17q21 in
familial FTLD (Wilhelmsen et al., 1994). These cases harbored neuronal and glial inclusions that
contained the microtubule-associated protein tau. Intriguingly, the gene encoding tau, MAPT, is
located on 17q21; this led to the identification of multiple mutations in MAPT that were found to
segregate with FTLD (Clark et al., 1998; Hutton et al., 1998; Spillantini et al., 1998) in affected
family members. To date, there are >40 mutations in MAPT associated with disease, with cases
harboring these mutations all demonstrating FTLD-tau pathology. The tau protein normally
functions to promote the assembly of tubulin microtubules and to regulate axonal transport, with
six different isoforms expressed in adult brain (Goedert et al., 1989; Ebneth et al., 1998; SatoHarada et al., 1996). Half of these isoforms contain three repeats of a ~32 amino acid motif in the

7

microtubule-binding domain (3R tau), while the other half contain four repeats (4R tau); the 4R
tau isoforms exhibit a stronger association with microtubules than 3R tau isoforms. FTLDassociated mutations are predominantly missense or splice-site mutations, disrupting the ratio of
tau isoform expression with an overall increase in the ratio of 4R:3R tau isoforms (Gustke et al.,
1994; Ingelsson et al., 2007; Spillantini et al., 2006; Hutton et al., 1998). This alteration in the ratio
of tau isoforms favors tau aggregation, forming hyperphosphorylated tau filaments (Hutton et al.,
1998), with toxic consequences for the cell. In neurons in particular, mutations in MAPT may
interfere with axonal transport processes. Neurons are highly sensitive to dysregulation of axonal
transport, as they depend on it to deliver cellular components to the distal axon. Overexpression
of tau has been shown to alter the distribution of various organelles and to impair mostly plusend-directed (synapse-directed) transport (Ebneth et al., 1998; Trinczek et al., 1999).
1.1.5.3 GRN
Heterozygous loss-of-function mutations in the progranulin gene (GRN) were first
reported in 2006 (Baker et al., 2006; Cruts et al., 2006) and account for ~10% of FTLD-TDP
(Gass et al., 2006) and up to 20% of familial FTLD-TDP (Gijselinck et al., 2008). Diseaseassociated mutations cause haploinsufficiency of GRN’s protein product, progranulin (Cruts et al.,
2006). Over 90% of disease-associated mutations in GRN result in premature termination
codons, leading to nonsense-mediated decay and decreased levels of progranulin (Gijselinck et
al., 2008); other missense mutations may impair secretion of progranulin, which also results in
lower circulating levels of progranulin (Cruts et al., 2006; Shankaran et al., 2008; Mukherjee et al.,
2008). Indeed, progranulin levels in the serum or cerebral spinal fluid (CSF) of patients harboring
disease-associated GRN mutations are decreased by ~30-50% as compared to normal controls
(Van Damme et al., 2008; Finch et al., 2009; Ghidoni et al., 2008; Sleegers et al., 2009).
The GRN gene encodes a 593 amino acid secreted protein, progranulin. Progranulin is a
highly conserved, widely expressed growth factor with highest levels of expression in the rapidly
dividing cells of skin and gastrointestinal tract and in peripheral immune tissues (Daniel et al.,
2000). The protein contains seven and a half tandem repeats of a conserved cysteine-rich
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granulin domain; these granulin domains are separated by linker series that contain disulfide
bridges (He et al., 2002). These linker series can be cleaved by matrix metalloproteinase-14
(Butler et al., 2008), elastase (Zhu et al., 2002), proteinase 3, and neutrophil elastase
(Kessenbrock et al., 2008), resulting in individual granulin peptides. The functions of individual
granulins and full-length progranulin have still to be fully elucidated; intriguingly they exhibit
similar functions in some settings, but opposing effects in others (De Muynck et al., 2013). For
example, both progranulin and daughter peptide granulin E increase neuronal survival by 20-40%
when applied to cortical neuron cultures and also both positively regulate neurite outgrowth (Van
Damme et al., 2008); other investigators have also corroborated progranulin’s positive effect on
neuronal survival and neurite outgrowth (Laird et al., 2010; Gao et al., 2010; Gass et al., 2006).
However, in inflammatory processes, progranulin and individual granulins have been shown to
exhibit opposing effects (He et al., 2002; Zhu et al., 2002). For example, progranulin-deficient
human and mouse microglia secrete increased levels pro-inflammatory cytokines upon activation
with lipopolysaccharide (LPS) compared to controls, (Martens et al., 2012; Suh et al., 2012),
suggesting that progranulin normally attenuates pro-inflammatory responses. Granulins, on the
other hand, increase amounts of pro-inflammatory cytokines TNF-alpha and IL1-beta in human
monocyte-derived macrophages (Okura et al., 2010; Zhu et al., 2002; Plowman et al., 1992).
Within the CNS, progranulin is mainly expressed by microglia and a subset of mature
neurons, with high expression exhibited in the CA1, dentate fascia, and CA4 regions of the brain
(Ahmed et al., 2007; Baker et al., 2006; Mackenzie et al., 2006; Almeida et al., 2011; Daniel et al.,
2000). In addition, Hu et al. have demonstrated that progranulin is endocytosed at the surface of
murine cortical neurons by a neuronal receptor, sortilin, and subsequently targeted to lysosomes
(Hu et al., 2010). Sortilin is a member of the vacuolar protein sorting 10 protein (VPS10p) domain
receptor family (Marcusson et al., 1994), and was first identified in a biochemical screen for
orphan endocytic receptors in the human brain (Petersen et al., 1997). The same group later
identified a novel interaction between progranulin and prosaposin. Prosaposin is the precursor of
saposin peptides (A, B, C and D) that function as activators of lysosomal sphingolipid
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metabolizing enzyme (Matsuda et al., 2007; O'Brien and Kishimoto, 1991; Qi and Grabowski,
2001). They found that prosaposin facilitates the lysosomal targeting of progranulin via mannose
6-phosphate receptor (M6PR) and low density lipo-protein receptor-related protein 1 (LRP1), as
fibroblasts lacking prosaposin demonstrate loss of progranulin localization to lysosomes and
increased secretion to the extracellular space. This prosaposin-mediated pathway is independent
but complementary to the sortilin-mediated pathway (Zhou et al., 2015).
Initial investigations reveal that progranulin may play important roles within the CNS,
including maintaining neuronal survival. First, neurons from Grn knockout mice exhibit decreased
survival (Kleinberger et al., 2010). Secondly, exogenous administration of progranulin has been
shown promote neuronal survival and to enhance neurite outgrowth in cell culture contexts (Gao
et al., 2010; Van Damme et al., 2008). In addition, progranulin overexpression rescues TDP-43induced axonopathy in zebrafish (Laird et al., 2010), although the mechanism of these
neurotrophic effects remains unknown. Progranulin has been shown to be upregulated in the
brain in response to infection (Johnston et al., 2001) and injury (Kanazawa et al., 2015; Tanaka et
al., 2013). Its expression is also increased in activated microglia in neurodegenerative diseases
such as Creutzfeld-Jacob’s and Alzheimer’s (Baker et al., 2006; Pereson et al., 2009).
Recently, lentivirus-mediated progranulin overexpression was shown to decrease the
plaque burden and abolish the loss of hippocampal neurons when injected in 5xFAD mice, an
aggressive amyloid mouse model of familial Alzheimer’s disease (Minami et al., 2014).
Moreover, Grn ablation resulted in increased plaque load and impaired phagocytosis in microglia
in APPlow mice, a model which expresses low levels of hAPP (Minami et al., 2014). Indeed,
reduced progranulin may result in endolysosomal/autophagosomal disturbances. Notably,
complete loss of progranulin through homozygous GRN deletion mutations (c.813_816del
(p.Thr272Serfs*10)) found in a human sibling pair has been shown to result in adult-onset
neuronal ceroid lipofuscinosis (NCL), a fatal neuronal lysosomal storage disease with progressive
neuronal loss (Smith et al., 2012). These human findings complement prior findings in previous
Grn knockout mouse models, which demonstrate lipofuscin accumulation, ubiquitin, and p62
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protein aggregates, hallmarks of lysosomal dysregulation often found in lysosomal storage
diseases (Ghoshal et al., 2012; Petkau et al., 2010; Wils et al., 2012; Ahmed et al., 2007). The
data I present in Chapter 2 further implicates endolysosomal disturbances within the FTLD-TDP
subgroup with GRN mutations, thus adding to the growing evidence that reduced progranulin is
associated with alterations to endolysosomal pathways.
As mentioned above, disease-associated GRN mutations result in FTLD-TDP pathology
in human brain (Neumann et al., 2006). The link between mutations in GRN and the accumulation
of TDP-43 within the brain is one of the unresolved questions of research in FTLD. While the
relationship between these two disease-related proteins is still not well understood, TDP-43 binds
to the 3’UTR of GRN mRNA and decrease its stability with a subsequent decrease in progranulin
protein levels (Polymenidou et al., 2011). In addition, knockdown of TDP-43 in mice results in an
increase in GRN mRNA and also has been shown to lead to altered splicing of sortilin with
associated increased levels of progranulin protein (Polymenidou et al., 2011; Colombrita et al.,
2012).
Alterations in progranulin in turn appear to affect TDP-43. Knockdown of GRN has been
shown to result in a caspase-dependent cleavage of TDP-43 into fragments in neuroglioma cells
(Zhang et al., 2007). In addition, knockdown of GRN in neurons results in an increase of
cytoplasmic TDP-43 as compared to nuclear TDP-43 (Guo et al., 2010). Thus, much future work
will be needed to tease out the complex relationship between these two disease-related proteins.
1.1.5.4 C9orf72
More recently, noncoding hexanucleotide repeats with the sequence GGGGCC (G 4C2) in
the C9orf72 gene have been found to be the most common genetic mutation in both ALS and
FTLD, with C9orf72-associated FTLD brain exhibiting TDP-43 pathology (DeJesus-Hernandez et
al., 2011; Renton et al., 2011; Beck et al., 2013). While healthy controls have <33 repeats,
C9orf72-associated FTLD and ALS cases harbor expansions ranging from 800-4,400 repeats
(van Blitterswijk et al., 2014; Beck et al., 2013).
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Currently, several major mechanisms of pathogenesis for these C9orf72 repeat
expansions have been proposed: (1) gain of toxicity through a) formation of repeat RNA species
(Fratta et al., 2012; Gendron et al., 2013; Lee et al., 2013; Mizielinska et al., 2013; Chew et al.,
2015), or b) through dipeptide repeats that result from repeat-associated, non-ATG (RAN)
translation (Ash et al., 2013; Mizielinska et al., 2014; Mori et al., 2013), and (2) reduced
levels/loss of function of the normal C9orf72 protein, the function of which is yet unknown (Ciura
et al., 2013; O'Rourke et al., 2016; DeJesus-Hernandez et al., 2011; Gijselinck et al., 2008;
Renton et al., 2011; Therrien et al., 2013). It is certainly possible that all three contribute to
disease pathogenesis, and current efforts are underway to determine each mechanism’s
contribution in this process.
(1) Gain of toxicity – RNA species and dipeptide repeats
The C9orf72 repeat expansion has been proposed to result in toxic effects via formation
of RNA species as well as via toxic dipeptide protein repeats. It has been demonstrated that the
C9orf72 GGGGCC (G4C2) repeat transcript, as well as the antisense CCCCGG (C4G2) transcript,
accumulate in RNA foci; these RNA foci have been observed in the frontal cortex and spinal cord
of patients as well as in patient-derived iPSCs; additionally, the number of foci has been shown to
correlate with age-at-onset (DeJesus-Hernandez et al., 2011; Almeida et al., 2011; Donnelly et
al., 2013; Gendron et al., 2013; Mizielinska et al., 2013; Zu et al., 2013). At the same time, the
hexanucleotide repeat expansion in C9orf72 exhibits repeat-associated non-ATG dependent
translation (RAN translation). As the name implies, this RAN translation does not require an ATG
codon and results in the generation of dipeptide repeat proteins (DPRs) (Ash et al., 2013; Mori et
al., 2013). Interestingly, DPRs are generated from both the sense and antisense directions,
producing glycine-alanine (GA), glycine-proline (GP), proline-alanine (PA), glycine-arginine (GR),
and proline-arginine (PR) dipeptides, depending on reading frame. These DPRs have been found
to accumulate in affected regions of the brain (Mori et al., 2013; Zu et al., 2013), as well as
unaffected areas.
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In a recent significant development supporting a role for gain of function in disease
development, Chew et al. demonstrated that intracerebroventricular administration of an AAV
vector expressing 66 GGGGCC repeats ((G 4C2)66) in postnatal day 0 mice, resulted in formation
of nuclear RNA foci, ubiquitin-positive dipeptide repeat inclusions, and cortical neuron and
cerebellar Purkinje cell loss (Chew et al., 2015). In addition, this was the first model to
demonstrate significant TDP-43 aggregates, as these were seen in ~7-8% of cells in the cortex
and hippocampus. The cells containing TDP-43 aggregates also always contained RNA foci.
These pathological findings were accompanied by behavioral changes – specifically, at 6 months,
compared to mice with only two G4C2 repeats, the (G4C2)66 mice exhibited differences in the open
field assay and also decreased latency to fall in rotarod testing, suggesting both social and motor
impairment (Chew et al., 2015). Thus, this model is a significant step forward as it closely models
disease, exhibiting the prominent pathological hallmark of disease, TDP-43 aggregates, as well
as consistent behavioral changes. However, this model does not separate out the toxic effects of
the nuclear RNA foci versus the dipeptide repeats, and, notably, ~75% of cells harboring RNA
foci and TDP-43 aggregates also had dipeptide inclusions. Below I discuss additional evidence
for each, RNA foci and dipeptide repeat proteins, in the pathogenesis of disease and highlight
approaches that have been undertaken to try to separate out each of their pathogenic
contributions.
1a) Evidence for RNA foci in disease
Several reports have identified co-localization of the C9orf72-associated RNA foci with
RNA-binding proteins (RBPs), suggesting pathogenic sequestration of RBPs may be occurring
(Fratta et al., 2012; Gendron et al., 2013; Lee et al., 2013). This sequestration of RBPs may
disrupt RNA processing with downstream negative consequences for the cell. Intriguingly, one
study demonstrated that RNA foci burden within the frontal cortex correlates with disease severity
in patients with C9orf72-associated FTLD (Mizielinska et al., 2013). Another study demonstrated
that degradation of these foci via antisense oligonucleotides (ASOs) results in correction of
neurodegenerative characteristics in C9orf72-expansion ALS fibroblast lines from ALS patients
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and in patient-derived induced pluripotent stem cell-differentiated neurons (iPSNs) (Donnelly et
al., 2013). Specifically, these iPSNs exhibited intranuclear C9orf72-expansion RNA foci,
sequestration of the RNA binding protein ADARB2, dysregulated gene expression, and increased
susceptibility to glutamate-mediated excitotoxicity as compared to normal controls; these effects
were all mitigated upon treatment with novel ASOs that targeted the C9orf72 expansion
sequence (Donnelly et al., 2013).
1b) Evidence for toxic dipeptide repeats (DPRs) in disease
The major evidence for a role of DPRs in neurodegeneration is as follows. 1) Mizielinska
et al. reported that expression of DPRs, but not engineered repeat RNA incapable of translation
(288 repeats of G4C2), resulted in degeneration of the eye in a Drosophila model, (Mizielinska et
al., 2014), suggesting that the DPRs are the major contributors to disease. Arginine-rich
dipeptides specifically (GR and PR) were sufficient to cause toxicity within the eyes and nervous
systems of the flies; GA also resulted in mild toxicity at later stages, but the other DPRs did not
exhibit toxic effects (Mizielinska et al., 2014). 2) The toxicity of arginine-rich dipeptides was also
confirmed in non-neuronal mammalian cells by another group, as synthetic peptides were shown
to bind to nucleoli and to impede multiple steps in RNA biogenesis (Kwon et al., 2014). 3) Wen et
al. have recently shown that the arginine-rich dipeptide repeats, especially PR, are potently
neurotoxic when expressed in rat cortical and motor neurons. In addition, they reported that
induced motor neurons from C9orf72-associated ALS patients showed increased intranuclear PR
aggregates and decreased survival as compared to controls (Wen et al., 2014). However, some
have questioned the role of DPRs in disease as other investigators have found that DPRs rarely
co-localize with TDP-43 pathology and neurodegeneration (Gomez-Deza et al., 2015; Gendron et
al., 2013).
Overall, evidence is growing for toxic gain of function mechanisms for C9orf72, including
mechanisms associated with DPRs, but questions remain. For example, why does there seem to
be a disconnect between the brains areas that show regional vulnerability in human disease
cases versus areas in which DPRs are most likely to develop in model organisms? More globally,
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the relevance of cellular overexpression models to actual disease pathogenesis is a major
ongoing question; these studies highlight the importance of directly comparing models with
patient samples and fully characterizing the DPR-containing inclusions within patient samples.
1c) Evidence for RNA and DPRs in impaired nucleocytoplasmic transport
Finally, recent evidence has emerged associating the C9orf72 expansion with impaired
nucleocytoplasmic transport and should be discussed (Boeynaems et al., 2016; Freibaum et al.,
2015; Jovicic et al., 2015; Zhang et al., 2015). Whether this is due to DPRs (Jovicic et al., 2015;
Boeynaems et al., 2016), RNA (Zhang et al., 2015), or a combination of both (Freibaum et al.,
2015) is currently unclear. With regards to the evidence for DPRs, Jovicic et al. performed an
unbiased modifier screen in yeast that overexpressed PR, identifying genes that suppress or
enhance PR’s toxicity. This screen identified a striking enrichment in genes involved in
nucleocytoplasmic transport, such as nuclear import proteins karyopherins, components of the
nuclear pore, and regulators of the Ran GTPase cycle needed to power nuclear import (Jovicic et
al., 2015). Building upon these data, Boeynaems et al. performed a targeted genetic modifier
screen in a Drosophila model, assessing for suppression and enhancement of eye degeneration
in flies expressing a 25 PR repeat construct in the eye. Notably, this Drosophila screen found that
orthologs of the top yeast genes, including the gene encoding nuclear transport receptor
transportin 1, were significant modifiers of DPR toxicity (Boeynaems et al., 2016).
Freibaum et al. also screened for modifiers of eye degeneration in a C9orf72 expansion
Drosophila model which exhibits both RNA foci formation as well as DPR production. Strikingly,
this screen identified 18 genetic modifiers which also comprised components of the nuclear pore
complex and nucleocytoplasmic transport factors (Freibaum et al., 2015). In addition, they
identified a defect in RNA export in Drosophila cells containing the C9orf72 expansion, and found
similar RNA export deficits in aged iPSCs derived from patients with C9orf72-associated disease
(Freibaum et al., 2015).
Finally, Zhang et al. demonstrated that a dominant gain-of-function mutant of RanGAP,
an important regulator of nucleocytoplasmic transport, is one of the strongest suppressors of eye
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degeneration in a Drosophila model (Xu et al., 2013), building upon their prior work that showed
the C9orf72 expansion binds to the RanGAP1 protein (the human orthologue of Drosophila
RanGAP) (Donnelly et al., 2013). RanGAP1 was mislocalized in the presence of the C9orf72
repeat, both in Drosophila as well as in C9orf72 ALS patient brain tissue, appearing as puncta
rather than the smooth perinuclear appearance seen in controls. Additionally, treating C9orf72associated ALS iPSCs with antisense oligonucleotides targeted against the sense strand of
RanGAP1 reduced the RNA foci and mitigated the altered nuclear-cytoplasmic distribution of Ran
GTPase, implicating sense RanGAP1 RNA in nucleocytoplasmic transport defects.
Thus, these studies used a wide array of models and techniques, but all converged on
nucleocytoplasmic transport as a pathway implicated in C9orf72-associated FTLD and ALS.
Defects in nucleocytoplasmic transport may help explain why TDP-43, FUS, and other RNA
binding proteins accumulate and are pathognomonic features in disease. While it still must be
fully determined if it is the DPRs or the RNA that contribute primarily to the impairment in
nucleoctyoplasmic transport, it should be noted that DPR-expressing only models (Boeynaems et
al., 2016; Jovicic et al., 2015) identified the same pathway (nucleocytoplasmic transport) as
Freibaum’s and Zhang’s models, which harbor both RNA foci and DPRs (Freibaum et al., 2015;
Zhang et al., 2015). This suggests that DPRs may be the primary players implicated in
derangements in nucleocytoplasmic transport. In addition, Woerner et al. recently demonstrated
that targeting aggregate species such as TDP-43 to the cytoplasm, as opposed to the nucleus,
results in defects in nucleocytoplasmic transport, mislocalization of nuclear pore complex
components, and inhibition in nuclear mRNA export; these data may suggest that the cytoplasmic
DPR inclusions similarly are largely responsible for the impairments in nucleocytoplasmic
transport (Woerner et al., 2016).
(2) Reduced levels of C9orf72 protein
Another potential mechanism by which hexanucleotide repeat expansions in C9orf72
may contribute to disease pathogenesis – and one central to my hypothesis – is via decreased
levels of the C9orf72 protein. Indeed, decreased transcript levels of C9orf72 are seen in the brain
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tissues, lymphoblast cells, and induced pluripotent stem cell (iPSC)-derived neurons of patients
with C9orf72-associated FTLD and ALS (Ciura et al., 2013; DeJesus-Hernandez et al., 2011;
Gijselinck et al., 2012; Donnelly et al., 2013). Another study demonstrates decreased C9orf72
protein expression in disease-affected frontal cortex (Waite et al., 2014).
The function of C9orf72 is currently unknown, although it is predicted to be a DENN
protein through sensitive homology searches (Levine et al., 2011; Zhang et al., 2012). Members
of the DENN family (Differentially Expressed in Normal and Neoplastic cells) act as GDP-GTP
exchange factors (GEFs) for Rab GTPases. Rab GTPases are a family of regulatory GTPases
which act as molecular switches – cycling between a GTP-bound, membrane-bound active state,
and a GDP-bound, cytosolic inactive state. As GEFs, DENN proteins thus play important roles in
the regulation of membrane trafficking and autophagy (Zhang et al., 2012; Zerial and McBride,
2001). However, it has yet to be determined experimentally if C9orf72 demonstrates GEF activity,
and this protein's normal function and role in disease pathogenesis are open questions.
Current animal models have yielded conflicting data as to whether loss of C9orf72 protein
can result in disease-related phenotypes. First, knockdown of the zebrafish ortholog zC9orf72 in
zebrafish demonstrated axonal degeneration of motor neurons; this degeneration could be
rescued by expression of human C9orf72 mRNA (Ciura et al., 2013). In a similar vein, knockdown
of the C9orf72 orthologue in C. elegans also resulted in motility defects and degeneration of
GABAergic motor neurons (Therrien et al., 2013). In contrast, a neuron-specific C9orf72 knockout
mouse model did not exhibit disease-like pathology – specifically, the mice did not have motor
neuron degeneration, defects in motor function, or altered survival as compared to controls
(Koppers et al., 2015). However, a recent study describes that while C9orf72-/- mice showed no
evidence of neurodegeneration through 17 months, macrophages and microglia from these mice
exhibit evidence of impaired late endosomal to lysosomal trafficking, and this lysosomal
perturbation was associated with pro-inflammatory states, with increased IL-6 and IL-1b by qRTPCR (O'Rourke et al., 2016). This raises the possibility that C9orf72 plays a role in phagosomal
maturation and immune responses in microglia, the former consistent with its putative role as a
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GEF. O’Rourke et al. propose a model in which decreased C9orf72 results in diminished ability of
macrophages and microglia in clearing aggregated proteins, and suggest a dual-effect
mechanism whereby the RNA foci and DPRs caused by the C9orf72 expansion compounds with
C9orf72-deficient dysfunctional microglia to result in neurodegeneration (O'Rourke et al., 2016).
This provides evidence that disease pathogenesis may, and likely does, involve interplay
between both gain of toxicity and loss of function mechanisms. In normal brain, C9orf72
transcription levels are found to be high in neuronal subtypes known to be affected in disease
(Suzuki et al., 2013). Loss-of-function of the normal C9orf72, as a presumed DENN protein, could
result in alterations to vesicular trafficking and endolysosomal/autophagosomal disturbances.
This, coupled with the accumulation of ubiquitinated dipeptide aggregates and RNA-protein
aggregates could further challenge the degradative machinery of the post-mitotic neuron,
resulting in increased toxicity and neuronal cell death. Additionally, O’Rourke et al.’s data
highlights the importance of considering the microenvironment – not just neuron, but the microglia
and other cell types as well likely play a role in the development of disease.
1.1.6

Summary
In summary, mutations in MAPT, GRN, and C9orf72 comprise the most common

Mendelian causes of FTLD, with mutations in C9orf72 and GRN resulting in FTLD-TDP
pathology. However, there are other interesting, albeit rarer, causes of disease which give us
further insight into potential cellular pathways and processes that are dysregulated in FTLD and
lead us to postulate that TMEM106B could be involved in these processes. Below, I will introduce
the endolysosomal and autophagosomal pathways, highlighting potential roles of genes/proteins
in which rare genetic mutations can cause FTLD, and discuss the implications of dysregulation of
these pathways in FTLD.
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1.2 PART II: Introduction to the endolysosomal/autophagosomal network
As will be described in detail in Chapter 3, increased TMEM106B levels result in
alterations to the endolysosomal/autophagosomal pathways. Additionally, mutations in CHMP2B,
VCP, and GRN hint at disturbances within these pathways as a potential mechanism underlying
FTLD

pathogenesis.

In

the

following

pages,

I

will

provide

an

overview

of

endolysosomal/autophagosomal pathways and their relevance to neurodegenerative diseases
and to FTLD in particular.
The endosomal and autophagosomal pathways involve many converging steps and
share common players; indeed, the lysosome lies at the convergence of these pathways, linking
them

together

in

a

greater

connected

network

(hereinafter

referred

to

as

the

endolysosomal/autophagosomal network or pathway, as depicted in Figure 1.3). Endosomes,
lysosomes, and autophagosomes are constantly docking, exchanging material, fusing and
separating, working together to maintain homeostasis of the cell. Internalized cargo are targeted
to endosomes, where they are directed towards their final destination. Autophagosomes
sequester long-lived proteins and cellular organelles, targeting them for degradation; lysosomes
help degrade these and other substrates, recycling metabolites and basic building blocks.
Alterations in one subset of organelles often result in perturbations to the others, reflecting their
interdependence (Settembre et al., 2013).
The importance of the endolysosomal/autophagosomal network in normal cellular
function

is

highlighted

by

its

dysregulation

in

disease.

Indeed,

altered

endolysosomal/autophagosomal states have been shown to be associated with cancer,
neurodegenerative diseases, autoimmunity, and infectious diseases (Huang and Klionsky, 2007;
Levine et al., 2011; Shintani and Klionsky, 2004; Deretic et al., 2009). In neurodegeneration
specifically, endolysosomal/autophagosomal dysfunction has been previously described in many
adult-onset diseases, including Alzheimer’s disease and Parkinson’s disease (Nixon and Yang,
2011), as well as in primary lysosomal disorders. The endolysosomal/autolysosomal network and
its

dysregulation

in

neurodegeneration

will
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be

discussed

in

further

detail

below.

Figure 1.3:

Figure 1.3: A simplified schematic of the endolysosomal / autophagosomal pathway
Lysosomes, depicted in dark gray, fuse with endosomes and autophagosomes, thus receiving
incoming materials from both the endocytic and autophagic pathways. Endocytic substrates are
delivered to early endosomes and then to late endosomes. Cargo destined for degradation are
sorted into the intraluminal vesicles (ILVs) of late endosomes and are degraded upon lysosome
fusion. The fusion of endosomes and lysosomes form endolysosomes (ELs), which are hybrid
organelles that mediate much of degradation. Along the autophagic pathway, autophagosomes
bind to lysosomes to form autolysosomes (ALs) or to endosomes to form amphisomes (not
depicted). ALs and ELs themselves can exchange materials or fuse to form EL-AL hybrids. After
degradation, lipids and other materials can be released into the extracellular environment via
lysosomal exocytosis (LE). Following the completion of lysosomal degradation, autolysosomes
undergo extensive tubulation, and protolysosomes are budded off these tubular autolysosomes to
ultimately reform lysosomes during autophagic lysosomal reformation (ALR).
Adapted from (Tooze and Yoshimori, 2010).
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1.2.1

Endosomes
The endosomal pathway involves the internalization and sorting of extracellular moieties,

plasma membrane proteins, and membrane lipids. It is essential for cellular homeostasis, and is
involved in myriad cellular processes including nutrient uptake, cell migration, control of signaling
pathways, and establishment of cell polarity. Endocytic cargoes are internalized at the cell
surface by a variety of different mechanisms, and most are ultimately delivered to early sorting
endosomes. While clathrin-mediated endocytosis (Pearse and Robinson, 1990) is the best
understood mechanism of endocytosis, other forms such as caveolin-mediated endocytosis,
caveolin- and clathrin-independent endocytosis, macropinocytosis, and phagocytosis are
becoming increasingly elucidated (Conner and Schmid, 2003). Early sorting endosomes comprise
tubular and vacuolar domains and constitute the main site of cargo sorting – a highly complex
and regulated process in which cargo are sorted and sent to the trans-Golgi network, to
lysosomes for degradation, or are recycled back to the plasma membrane either directly or via
distinct tubulovesicular recycling endosomes (Huotari and Helenius, 2011). For example,
signaling receptors such as EGFR (Epidermal Growth Factor Receptor) can undergo endocytosis
via clathrin-mediated or clathrin-independent routes; after this internalization, receptors can be
recycled to the plasma membrane or, alternatively, targeted to the lysosome for degradation, thus
terminating the receptor signaling pathway (Katzmann et al., 2001; Raiborg and Stenmark, 2009).
Another important endosomal function is the sorting of ubiquitinated proteins by
endosomal sorting complexes required for transport (ESCRT complexes) (Katzmann et al., 2001).
In this pathway, proteins are conjugated with a polyubiquitin chain or multiple mono-ubiquitins.
The ESCRT complexes, of which there are four, ESCRT 0, I, II, and III, capture and sort the
ubiquitinated proteins into inwardly-budded intraluminal vesicles (ILVs). These ILVs accumulate
as early endosomes mature into late endosomes; the late endosomes ultimately fuse with
lysosomes for subsequent degradation of their contents, including the protein and lipid contents
of the ILVs (Raiborg and Stenmark, 2009).
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Early endosomes mature along a continuum to become late endosomes, and, in doing
so, accumulate an increased number of ILVs. Various features distinguish and indeed define
early vs. late endosomes. For example, while early endosomes are weakly acidic with pH 6.85.9, late endosomes have a pH ranging from 6.0-4.9 (Yamashiro and Maxfield, 1987). The
maturation process from early to late endosome also requires the switch from Rab5 GTPase to
Rab7 GTPase at the limiting membrane (Rink et al., 2005). Rab GTPases are molecular switches
that cycle between a GTP-bound, membrane-bound active state, and a GDP-bound, cytosolic
inactive state. In addition, a proportion of PtdIns(3)P are converted to PtdIns(3,5)P(2) during the
early endosome to late endosome maturation program (Schu et al., 1993; Behnia and Munro,
2005). Late endosomes are further characterized by a low buoyant density and a high negative
surface charge. In addition, late endosomes are enriched for lysosomal transmembrane proteins
such as LAMP1 as well as mannose-6-phosphate receptors (M6PRs) (Bayer et al., 1998;
Falguieres et al., 2008). M6PRs bind lysosomal enzymes in the trans-Golgi network (TGN) and
convey them to endosomes. Ultimately, fusion of endosomes with lysosomes results in the
delivery of these resident lysosomal enzymes to the lysosome (Ghosh et al., 2003).
Endosomal cargo can be delivered to lysosomes by direct fusion or by “kiss and run”
(Bright et al., 2005). “Kiss and run” involves a transient docking of late endosomes and
lysosomes, during which small amounts of material are exchanged and then degraded within the
lysosome. Alternatively, direct fusion between the endosomal and lysosomal membranes results
in transient organelles termed endolysosomes (ELs) or hybrid organelles (Tjelle et al., 1996;
Bright et al., 2005). The core machinery orchestrating the process of fusion between endosomes
and lysosomes was elucidated using cell-free assays, which demonstrate that fusion undergoes
three sequential steps: 1) tethering (the establishment of fine striations between the two
organelles), 2) the formation of a trans-SNARE complex (composed of Syntaxin7, Vti1b,
Syntaxin8 and VAMP7), and 3) membrane fusion. The presence of Rab7, N-ethylmaleimidesensitive factor (NSF) as well as NSF-attachment proteins are also required (Luzio et al., 2007).
Indeed, the Rab7 GTPase is a key regulator of the endolysosomal pathway, and is thought to
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help mediate late endosome maturation, late endosome-lysosomal fusion, autophagosomal
formation and autophagosomal-lysosomal fusion (Bucci et al., 2000; Vitelli et al., 1997).
Hybrid organelles formed from endosome-lysosomal fusion must subsequently
disassociate to reform lysosomes. Preliminary research into this process of fission has
demonstrated that this requires retrieval of membrane proteins and content condensation. In cellfree systems, it has been demonstrated that a proton-pumping ATPase and lumenal Ca+2 are
required for this lysosomal reformation (Luzio et al., 2007). Additionally, live-cell experiments
have demonstrated that vesicular tubular structures bud off of hybrid organelles, presumably
retrieving endosomal membrane proteins (Bright et al., 2005). A similar route of recovery may
occur with autolysosomes (organelles formed from autophagosome-lysosome fusion), as
autolysosomes have also been shown to extend tubular structures at sites concentrated with
lysosomal hydrolases and lysosomal membrane proteins (Tjelle et al., 1996; Pryor et al., 2000;
Yu et al., 2010; Bright et al., 2005). Further data on lysosomal reformation arising from
autolysosomes, a process termed autophagic lysosomal reformation (ALR) will be discussed
further below.
Along the various steps of the endolysosomal/autophagosomal pathway, Rab GTPases
regulate membrane trafficking and vesicular transport within the cell, with different Rab GTPases
localized to distinct organelles. This action of Rab GTPases helps to define and separate
membranes and control spatial-temporal membrane trafficking events within the cell (Seabra and
Wasmeier, 2004; Bock et al., 2001; Zerial and McBride, 2001). For example, Rab1 helps regulate
transport from the endoplasmic reticulum to the Golgi; Rab5 regulates the vesicular trafficking of
endocytosis (Zerial and McBride, 2001); Rab11 plays an important role in the regulation of
endocytic recycling and exocytosis (Takahashi et al., 2012). As described above, Rab7 plays a
major role at multiple steps of the pathway – late endosome-lysosome fusion, autophagosomelysosome fusion, and autophagosome formation (Bucci et al., 2000; Meresse et al., 1995;
Hyttinen et al., 2013). Control and proper regulation of Rab GTPase activity, and thus proper
regulation of the endolysosomal pathway, are vital for proper neuronal function. Indeed,
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mutations in RAB7A, which codes for Rab7, result in an autosomal dominant axonal neuropathy –
Charcot-Marie-Tooth disease (Verhoeven et al., 2003). The disease-associated mutations target
highly conserved residues on the surface of Rab7 and alter nucleotide exchange (BasuRay et al.,
2010; Verhoeven et al., 2003). Additionally, dysregulation of DENN proteins has been shown to
result in disturbed GEF activity linked to neurodegeneration (Azzedine et al., 2003; Del Villar and
Miller, 2004; Hadano et al., 2010). Moreover, in Huntington’s disease, an autosomal neurological
disease caused by the expansion of a trinucleotide repeat in the gene encoding huntingtin (htt),
mutant huntingtin has been shown to disrupt the association of Rab8 with the autophagy receptor
optineurin at the Golgi, resulting in reduced AP-1 and clathrin-mediated trafficking to lysosomes
(del Toro et al., 2009). These are a few examples that demonstrate that disruption of Rab
GTPase activity can have consequences on proper regulation of the endolysosomal pathway and
to the maintenance of neuronal health.
1.2.2

Lysosomes
Lysosomes are a central site of degradation for the cell, with cell and foreign material

destined for degradation reaching the lysosome via endocytosis, phagocytosis, autophagy, or
direct transport (Mijaljica et al., 2011; Mizushima et al., 2010). Lysosomes are acidic organelles
containing hydrolases that degrade a vast variety of biological substrates; these hydrolases
include proteases, glycosidases, phosphatases, lipases, nucleases, and sulfatases. Most soluble
lysosomal enzymes are modified in the Golgi to generate terminal mannose-6-phosphate
residues; these are recognized by mannose-6-phosphate receptors in the trans-Golgi network for
targeting to late endosomes and ultimately to lysosomes. These enzymes are most active within
the acidic environment of the lysosome, which is generated primarily by the vacuolar ATPase
(vATPase). The vATPase is a large protein complex on the lysosomal membrane that pumps H +
ions into the lysosome (Yamashiro and Maxfield, 1987). Compared to endosomes, lysosomes are
more electron-dense by electron microscopy, contain high levels of H + and Ca+2, and are highly
enriched in glycosylated transmembrane proteins such as LAMP1 and LAMP2 which help protect
the lysosome from self-digestion (Luzio et al., 2007; Saftig and Klumperman, 2009).
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In recent years, the lysosome has come to be appreciated beyond its role as a central
site of degradation; data has demonstrated that the lysosome has myriad roles in a broad range
of cellular processes, such as energy metabolism, the immune response, and cellular
homeostasis (Settembre et al., 2013). For example, the mammalian target of rapamycin complex
1 (mTORC1) has been shown to recruit to the lysosomal membrane, in response to specific
amino acid cues, where it encounters Rag GTPases that activate it (Sancak et al., 2010).
mTORC1 is a master regulator of cell growth, positively regulating processes such as lipid
biosynthesis and ATP production in response to factors such as growth factors, oxygen, and
stress (Laplante and Sabatini, 2012). Inhibition of mTORC1 by starvation or drugs results in the
activation of autophagy. Intriguingly, the binding of mTORC1 at the lysosomal membrane is
dependent on accurate sensing of the lumenal amino acid content, which is in turn dependent on
the presence of the lysosome’s vATPase, demonstrating the lysosome’s nutrient-sensing role
within the cell (Zoncu et al., 2011).
Further evidence for the interdependence of lysosomal and autophagy pathways comes
from the recent finding that mTORC1 activation regulates the translocation of a master
transcription factor, transcription factor EB (TFEB) (Roczniak-Ferguson et al., 2012). TFEB is a
master regulator of lysosomal biogenesis and autophagy which regulates >400 genes belonging
to the Coordinate Lysosomal Expression and Regulation (CLEAR) network (Settembre et al.,
2011; Settembre et al., 2013; Sardiello et al., 2009). Under normal non-starvation conditions,
mTORC1 inhibits the translocation of TFEB to the nucleus; however, when mTORC1 is inhibited
by amino acid or glucose deprivation, TFEB translocates to the nucleus and upregulates the
CLEAR network, increasing the transcription of genes involved in lysosomal biogenesis,
autophagosome formation, the immune response, and lipid catabolism (Settembre et al., 2011;
Palmieri et al., 2011). This results in the coordinated timing of autophagy activation and
lysosomal biogenesis.
1.2.3

Autophagosomes and autophagy
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Autophagy is the process by which cells sequester cytoplasmic cargo material into
double-membraned organelles called autophagosomes; these cargoes are ultimately degraded
upon fusion of the autophagosome with lysosomes (Mizushima et al., 2010). Autophagy is a
complex process and is governed by AuTophaGy-related (ATG) genes, the first of which were
discovered in 1988 (Xie and Klionsky, 2007; Itakura and Mizushima, 2010; Mizushima et al.,
1998). Autophagy functions within the cell to degrade material – cytoplasmic components, longlived proteins, excess or aberrant organelles and pathogens – to allow cells to adapt to changes
in the environment and external and internal stresses. Autophagy has also been shown to play
role in development, immunity, and defense from pathogens (Melendez et al., 2003).
There are three major forms of autophagy – microautophagy, chaperone-mediated
autophagy, and macroautophagy – all of which culminate in lysosomal degradation. In
microautophagy, the lysosomal membrane invaginates, allowing small amounts of the cytoplasm
into the lumen (Mijaljica et al., 2011). In chaperone-mediated autophagy, cytosolic proteins with
consensus motifs are recognized by LAMP2A, a lysosomal transmembrane protein, and directly
translocated across the lysosomal membrane (Cuervo and Dice, 2000). Macroautophagy, or
simply “autophagy” from hereafter, is the most studied form of autophagy, and involves the
formation of a double-membrane phagophore which elongates to completely surround
cytoplasmic cargo material, forming the autophagosome (Mizushima et al., 2010). Selective forms
of autophagy also exist, wherein specific substrates are targeted into the autophagosome by
selective autophagy receptors. For example, mitophagy involves selective autophagy of
dysfunctional mitochondria, whereas aggrephagy refers to the specific clearance of protein
aggregates or inclusion bodies within the cell (Kopito, 2000).
The steps of autophagy are as follows: 1) induction, 2) substrate cargo recognition, 3)
isolation membrane (aka. phagophore) formation, 4) double-membrane elongation, 5)
autophagosome maturation, 6) fusion of the autophagosome with lysosomes/late endosomes to
form autolysosomes/amphisomes respectively, 7) degradation of the engulfed material, 8) release
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of the resulting macromolecules, and finally 9) dissolution of the autolysosome/amphisome into its
component parts with reformation of lysosomes (Chen and Yu, 2013; Klionsky et al., 2012).
Autophagy is initiated through phosphorylation state changes of components of the
Atg1/Unc51-like kinase (ULK) complex (comprised of ULK1, ULK2, Atg13, FIP200 and Atg101)
(Chan et al., 2009; Mizushima et al., 2010). Phosphorylation of ULK1 is mainly regulated by
mTORC1, but can also be independently activated by the AMP-activated protein kinase (AMPK)
(Mizushima et al., 2010). Stressors such as starvation, accumulation of protein aggregates, or
hypoxia result in the inhibition of mTORC1 and its disassociation from the ULK complex; this
results in the downstream activation of autophagy (Lamb et al., 2013).
ULK1 in turn then recruits and phosphorylates the class III phosphoinositide 3-kinase
(PI3KC3) complex, resulting in its activation and relocation from the cytoskeleton to the isolation
membrane in the ER, a pre-autophagosomal structure (Di Bartolomeo et al., 2010; Fimia et al.,
2007; Suzuki et al., 2007). This PI3KC3 complex, consisting of, beclin-1, p150, and Atg14L,
generates phosphatidylinositol 3-phosphate (Lu et al., 2013). The generation of PI3P is essential
for autophagosome formation, as PI3P recruits PI3P-binding proteins called double FYVEcontaining protein (DFCP1) and members of the WD-repeat protein interacting with
phosphoinositides (WIPI) family, resulting in the formation of ER subdomains called omegasomes
(Axe et al., 2008). WIPI proteins function as PI3P-binding effectors, mediating the downstream
effects of PI3Ps, and bridging PI3P generation to the recruitment of microtubule-associated
protein 1A/1B-light chain 3 (LC3) (Lamb et al., 2013).
The subsequent elongation step requires two ubiquitination-like conjugation systems, the
LC3 and the Atg12-Atg5-Atg16L systems (He and Klionsky, 2009). The conjugation of
phosphatidylethanolamine (PE) to LC3 is mediated by an E1-like enzyme, Atg7, and an E2-like
enzyme, Atg3 (Shibutani and Yoshimori, 2014). Atg12 is covalently conjugated to Atg5 by Atg7
and the E2-like enzyme Atg10. Atg12-Atg5 then binds Atg16L (Fujita et al., 2009; Shibutani and
Yoshimori, 2014). This Atg12-Atg5-Atg16L complex is recruited to the initiation site, possibly by a
WIPI protein, and functions as an E3-like ligase on the LC3-PE conjugate to mediate the
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lipidation of LC3 (Hanada et al., 2007; Dooley et al., 2014). LC3 itself is thought to be important
for the closure of the autophagosome (Lamb et al., 2013). The full mechanism behind elongation
and complete closure of the autophagosome is still under investigation, but is thought to involve
several SNARE proteins, membrane components, and complexes containing ubiquitin-like
proteins (Lamb et al., 2013).
1.2.3.1 Autophagosome-lysosome fusion
Autophagosomes can fuse with lysosomes, creating autolysosomes, or they can also
fuse with endosomes, creating amphisomes which can also fuse with lysosomes downstream.
Within the cell, lysosomes are predominantly located in the perinuclear region (Lee et al., 2011b;
Roberts and Gorenstein, 1987). In neurons in particular, autophagosomes travel in a retrograde
fashion towards the cell body, fusing first with the late endosomes predominant in the neuritic
processes to create amphisomes (Hollenbeck, 1993; Larsen and Sulzer, 2002; Lee et al., 2011b).
These amphisomes then fuse with the perinuclear lysosomes.
The mechanism underlying autophagosome-lysosome fusion has yet to be fully
explicated, but multiple players have been shown to play a role in this process: Rab7, soluble Nethylmaleimide–sensitive factor attachment protein receptors (SNAREs), the HOPS complex, the
ESCRT-III complex, presenilin 1, UVRAG, p97VCP, LRRK2 and HSP70 to name a few (Lu et al.,
2013; Gutierrez et al., 2004). Syntaxin-17 (STX17) was recently identified as the autophagosomal
SNARE required for autophagosome-lysosome fusion (Itakura et al., 2012), as siRNA-mediated
knockdown of syntaxin-17 resulted in a block in autophagic flux and a loss of co-localization
between autophagosomal marker LC3 and late endosomal/lysosomal markers. Intriguingly,
amphisomal and autolysosomal formation require many of the same players involved in the
formation of late endosomes – the HOPS complex, and ESCRT components are involved in
amphisomal formation (Lee and Gao, 2009; Rusten and Stenmark, 2009).
Following fusion of the autophagosome with lysosomes, the limiting membrane of the
resulting autolysosome contains lysosomal membrane proteins and the vacuolar proton pump
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vATPase. The cellular cargo and the inner membrane of the autophagosome are subsequently
degraded by lysosomal hydrolases (Settembre et al., 2013).
1.2.3.2 Resolution of autophagy
The successful resolution of autophagy requires the lysosomal digestion of cargo and
release of metabolites for reuse. It also requires the dissolution of autolysosomes/amphisomes
and the reconstitution of the lysosomal pool. Recent evidence supports autophagic lysosomal
reformation (ALR) as one potential process by which the lysosomal pool is renewed. In ALR,
mTORC1, which is inhibited during autophagic induction, is reactivated after a delayed interval,
and this reactivation is associated with the formation of tubules and protolysosomes which bud off
of autolysosomes. These protolysosomes ultimately acidify and mature to become lysosomes (Yu
et al., 2010; Chen and Yu, 2013). Since one autophagosome can fuse with multiple lysosomes,
ALR is proposed to help maintain a pool of active lysosomes, as without a lysosomal “recycling”
mechanism, the cell would soon be depleted of lysosomes. Another potential mechanism
terminating the autolysosome is autolysosome exocytosis, whereby autolysosomal contents are
exocytosed by fusion of the autolysosome to the plasma membrane. Recent evidence has
demonstrated that if autophagosome-lysosome fusion or lysosomal acidification is impaired,
autophagosomal exocytosis increases (Spampanato et al., 2013). In addition, this process may
depend on TFEB, as increased expression of TFEB has been shown to result in increased
exocytosis of vesicles labeled with lysosomal and autophagosomal markers (Ejlerskov et al.,
2013; Martina et al., 2014; Medina et al., 2011; Spampanato et al., 2013).
Intriguingly, recent data indicates that ALR is dependent on the ability of the lysosome to
degrade, as inhibition of lysosomal protease activity with leupeptin impaired mTORC1
reactivation and abolished ALR, resulting in the persistence of giant autolysosomes in rat kidney
cells (Yu et al., 2010). Thus, it could be that the impairment in autolysosomal clearance seen in
some neurodegenerative processes can result in the loss of mTORC1 reactivation, thereby
impairing ALR and decreasing the number of available lysosomes. This could result in “stalled”

29

autolysosomes, as well as persistence of autophagosomes, as they have few lysosomes with
which to fuse.
1.2.4

The endolysosomal/autophagosomal pathway in neurons and neurodegenerative
diseases

1.2.4.1 Autophagy in neurons
Autophagic homeostasis is important for many cell types, but may be of the utmost
importance for neurons. These post-mitotic cells rely heavily on the clearance mechanisms of
autophagy and the degradative ability of the lysosome to help clear misfolded proteins,
aggregates, and dysfunctional organelles, as they cannot clear these through cell division. In
genetic murine models, knockout of essential autophagy Atg genes has been shown to result in
severe neurodegeneration (Komatsu et al., 2005; Hara et al., 2006; Komatsu et al., 2006).
Specifically, a knockout mouse model of Atg7 within the central nervous system (Atg7

flox/flox;

nestin-Cre) has been shown to result in dramatic neuronal loss in the cerebral and cerebellar
cortices by postnatal day 56 (P56) with earlier onset (P14) motor and behavioral defects such as
tremor and abnormal limb-clasping reflexes (Komatsu et al., 2005; Komatsu et al., 2006).
Similarly, suppression of basal autophagy by knockout of Atg5 in basal neural cells resulted in
profound neurodegeneration and cytoplasmic inclusion bodies in mice (Hara et al., 2006).
The importance of autophagy to neurons is also demonstrated by human lysosomal
storage diseases (LSDs). LSDs are rare inherited metabolic disorders wherein a defect in any
one of functionally distinct lysosomal enzymes produces a severe neurodegenerative and
multisystem phenotype with lysosomal/autophagosomal disruption evident by pathology (Pryor et
al., 2000). These disorders are characterized by accumulation of undegraded material such as
sphingolipids, glycoproteins, glycogen, and mucopolysaccharides within lysosomal structures,
reflecting the primary enzymatic defect. How accumulation of these substrates ultimately results
in cellular dysfunction and disease progression has yet to be fully understood. One possibility is
that the lysosomal defect initially results in the accumulation of the undegraded substrate within
the lysosome (primary storage); over time, this results in impaired overall lysosomal trafficking,

30

resulting in accumulation of additional lysosomal substrates (secondary storage), including
dysfunctional mitochondria and polyubiquitinated proteins (Settembre et al., 2013; Settembre et
al., 2008). These effects on lysosomal function feed forward to autophagy, as evidence
demonstrates that many LSDs also exhibit autophagic impairment as well (Lieberman et al.,
2012; Ballabio and Gieselmann, 2009). Examples of LSDs include neuronal ceroid lipofuscinoses
(NCL), Gaucher’s disease, and mucopolysaccharidosis IIA. In NCL, mutations in cathepsin D
(CTSD), a typically ubiquitously expressed lysosomal protein, result in severe mental retardation
or

juvenile

dementia

(Siintola

et

al.,

2006).

In

Gaucher’s

disease,

mutations

in

glucocerebrosidase (GBA) result in impaired lysosomal hydrolysis and accumulation of
sphingolipids (Sardi et al., 2011); patients with the neuronopathic type of Gaucher’s typically
present with progressive dementia at a young age. In mucopolysaccharidosis IIA, lysosomal
sulfamidase mutations (SGGH) result in impaired autophagosome-lysosome fusion and patients
often exhibit mental retardation (Settembre et al., 2008). Thus, these lysosomal storage diseases
highlight the importance of proper lysosomal and autophagosomal function in neuronal
populations.
1.2.4.2 Endolysosomal/autophagosomal dysfunction in adult neurodegenerative disease
These primary lysosomal disorders may be compared to adult onset neurodegenerative
diseases, as endolysosomal and autophagosomal dysfunction has been demonstrated in multiple
neurodegenerative diseases (Tresse et al., 2010; Urwin et al., 2010; Ginsberg et al., 2010; Harris
and Rubinsztein, 2011), including Alzheimer’s, Parkinson’s, Huntington’s, and FTLD.
In

Parkinson’s

disease,

mutations

in

genes

encoding

important

endolysosomal/autophagosomal proteins have been shown to result in disease, and mutations in
PD-associated

genes

with

unclear

functions

have

also

been

shown

to

result

in

endolysosomal/autophagosomal aberrations. For example, mutations in ATPase type 13A2
(ATP13A2), a component of the lysosomal acidification machinery, have been found in patients
with hereditary parkinsonism (Williams et al., 2005). Fibroblasts derived from these patients
exhibit defective clearance of autophagosomes and accumulation of α-synuclein (Usenovic et al.,
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2012; Ramirez et al., 2006); additionally, these mutations result in decreased activity of lysosomal
enzymes and reduced degradation of substrates (Dehay et al., 2012). Mutations in PINK (PTENinduced putative kinase) and PARK2 (which encodes a component of the ubiquitin ligase
complex) are also known Mendelian causes of Parkinson’s disease and are associated with
defective mitophagy (Geisler et al., 2010; Narendra et al., 2008; Valente et al., 2004).
Additionally, mutations in VPS35, which encodes an endosomal protein involved in retrograde
transport between endosomes and the trans-Golgi, have been shown to result in Parkinson’s
disease and result in decreased autophagosome biogenesis (Chartier-Harlin et al., 2011;
Zimprich et al., 2011). Finally, missense mutations in leucine-rich repeat kinase 2 (LRRK2), which
codes for a large protein called dardarin of uncertain function with functional GTPase and kinase
domains, are the most common known genetic cause of Parkinson’s disease (Hedrich et al.,
2006). Disease-associated mutations have been shown to affect vesicular trafficking, autophagy,
cytoskeletal function, and protein synthesis in both cell and animal models of Parkinson’s (Martin
et al., 2016; MacLeod et al., 2013).
In

Alzheimer’s

disease

(AD),

most

data

suggesting

a

link

to

endolysosomal/autophagosomal dysfunction is more correlative. For example, affected brains
from Alzheimer’s patients as well as from animal models exhibit dystrophic neurites which contain
accumulations of autophagosomes and autolysosomes (Lee et al., 2010; Nixon and Yang, 2011).
Beclin-1, the mammalian ortholog of yeast Atg6 (Liang et al., 1998), has been shown to be
decreased in AD patients and may be one of the initial signs of autophagic dysfunction in AD
(Pickford et al., 2008). Abnormal upregulation of Rab GTPases, including Rab5 and Rab7, has
been shown in cholinergic basal forebrain neurons microdissected from postmortem brains
(Ginsberg et al., 2010) and, additionally, a genome-wide analysis shows transcriptional
upregulation of autophagy-related genes in affected Alzheimer’s brain (Lipinski et al., 2010),
possibly indicating a compensatory mechanism in response to autophagic dysfunction. However,
perhaps the strongest link between AD and lysosomal dysfunction comes from work with
presenilin-1 (PS1). Mutations in PSEN1 (presenilin 1) are one of the most common causes of
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familial AD. It has been reported that loss of PS1 or AD-associated mutations in PSEN1 result in
impaired lysosomal acidification and degradative ability (Lee et al., 2010; Avrahami et al., 2013;
Dobrowolski et al., 2012). In presenilin-1 knockout mouse blastocysts, Lee et al. reported
defective clearance of autophagic vacuoles as well as defective lysosome acidification as
measured by LysoTracker fluorescence (a pH sensitive dye whose intensity correlates with
acidity). Lee et al. further provide evidence that loss of PS1 results in a failure of the V0a1 subunit
of the vATPase to be properly N-glycosylated in the ER, resulting in impaired delivery of PS1 to
autolysosomes and lysosomes (Lee et al., 2010).
In FTLD specifically, dysregulation of the endolysosomal/autophagosomal network has
also been linked to disease. For example, mutations in the charged multivesicular body protein
2B (CHMP2B) gene are a known cause of disease. CHMP2B is a subunit of the ESCRT-III
complex and plays a role in sorting ubiquitinated proteins into the intraluminal vesicles of late
endosomes for ultimate degradation upon lysosomal fusion (Urwin et al., 2010; Filimonenko et al.,
2007; Rusten and Stenmark, 2009; Katzmann et al., 2002). Disease-associated mutations in
CHMP2B result in the deletion of the C-terminus of the protein (Urwin et al., 2010) and
expression of these C-terminal deletion mutant CHMP2Bs in human neuroblastoma cells results
in the formation of enlarged late endosomes (van der Zee et al., 2008). Furthermore, patient
fibroblasts as well as cortical neurons also exhibit enlarged endosomes (Urwin et al., 2010). This
defect was attributed to impairments of endosome-lysosome fusion, as late endosomes in
CHMP2B mutant cells were defective in their ability to recruit the Rab7 GTPase, a key player in
the fusion of endosomes-lysosomes and lysosomes-autophagosomes (Bucci et al., 2000;
Hyttinen et al., 2013; Jager et al., 2004). Mutant CHMP2B thus disturbs endosomal and
autophagic trafficking (Urwin et al., 2010; Filimonenko et al., 2007; Lee et al., 2007), intimating at
a general role for endolysosomal/autophagosomal disturbances in the development of FTLD.
In addition, mutations in VCP, which encodes valosin-containing protein (VCP), also
cause a familial form of FTLD. Specifically, these VCP mutations cause a dominantly inherited,
multisystem degenerative disease that affects muscle, bone, and brain. VCP has been shown to
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have a multitude of activities within the cell including cell-cycle regulation, DNA repair, organelle
biogenesis, protein quality control, endolysosomal sorting, and autophagosome biogenesis and
maturation (Ritz et al., 2011; Tresse et al., 2010; Ju et al., 2009; Braun et al., 2002). VCP is
thought to be able to execute this variety of functions due to its N-terminal domain, which can
interact with many different adaptor proteins. The conformation of this N-terminal domain is
determined by the presence of ATP or ADP in the nucleotide binding pocket (Abramzon et al.,
2012; Tang et al., 2010). FTLD-associated mutations alter the shape of the binding pocket, and
this is thought to increase the interactions of VCP with some adaptors and decrease its
interactions with others (Fernandez-Saiz and Buchberger, 2010).
Among its many functions, VCP has been shown to be essential for maturation of
autophagosomes, as knockdown of VCP (or expression of dominant-negative VCP) results in the
accumulation of immature autophagic vesicles (Tresse et al., 2010). FTLD-associated mutations
in VCP have similarly been shown to interfere with and alter autophagosomal pathways, blocking
transport of ubiquitinated cargo to lysosomes and also impairing the maturation of
autophagosomes (Ju et al., 2009; Ritz et al., 2011). In addition, large LAMP1+/LAMP2+ vacuoles
with accumulated LC3 and TDP-43 are seen in myoblasts of patients with VCP mutations (Ju et
al., 2009; Tresse et al., 2010).
Mutations

in

CHMP2B

and

VCP

thus

intimate

that

dysregulation

of

endolysosomal/autophagosomal pathways may contribute to disease pathogenesis in FTLD.
1.2.5

Summary
Multiple

lines

of

evidence

are

converging

on

dysregulation

of

the

endolysosomal/autophagosomal network as a central common theme in neurodegenerative
processes. Many neurodegenerative diseases exhibit impaired neuronal autophagy and
accumulation of toxic proteins, with detrimental effects for cells. Proper lysosomal and
autophagosomal function is vital to clear aggregates and maintain cellular homeostasis. This is of
even more importance in the post-mitotic neuron, which cannot reduce the effects of damaged
organelles or protein aggregates through cell division and must maintain cellular clearance and
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recycling of proteins over long distances between the cell body and distal processes (Lee et al.,
2011b).
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1.3 PART III: TMEM106B
1.3.1

The discovery and initial characterization of TMEM106B
While the disease-associated mutations in GRN, MAPT, and C9orf72 as described above

account for most of the known Mendelian cases of FTLD, non-Mendelian patterns of inheritance
often occur within families, suggesting that more common genetic variants conferring risk for
FTLD exist (Sieben et al., 2012). In order to identify other risk factors for the most common
neuropathological subtype of disease, FTLD-TDP, a genome-wide associate study (GWAS) was
performed on 515 FTLD-TDP patients and 2,509 controls in 2010. Multiple SNPs within the
minimally characterized gene TMEM106B, which codes for Transmembrane Protein 106B, at
7p21 were found to significantly associate with FTLD-TDP with and without GRN mutations (odds
ratio 1.6, p=1.08x10-11 for top SNP rs1990622) (Van Deerlin et al., 2010). These SNPs are
located within a 36-kb haplotype block that contains no other genes (Gallagher et al., 2014). The
identification of the uncharacterized gene TMEM106B as a risk factor for FTLD-TDP has been
replicated several times, including in a clinically diagnosed cohort of patients (Finch et al., 2011;
van der Zee et al., 2011a). Interestingly, TMEM106B genotypes that increase risk for FTLD also
increase the risk of dementia in ALS patients (Vass et al., 2011).
Prior to the discovery of its link to FTLD-TDP, little was known about TMEM106B or the
274 amino acid TMEM106B protein that it encodes (predicted molecular weight of 32 kDa).
TMEM106B is conserved throughout vertebrates and has no yeast ortholog. It has 43% sequence
identity with family member TMEM106A and 47% sequence identity TMEM106C, the functions of
which are also both poorly understood. Since then, our laboratory and others have worked to
characterize this protein. TMEM106B has been shown to be a highly glycosylated, Type II
transmembrane protein which may exist as a homo- or hetero-dimer with TMEM106C (ChenPlotkin et al., 2012; Lang et al., 2012; Stagi et al., 2014; Brady et al., 2013). Initial work from our
laboratory

was

among

the

first

to

show

that

TMEM106B

co-localizes

with

late

endosomal/lysosomal marker LAMP1 as well as the pH-sensitive dyes LysoTracker and
LysoSensor (Chen-Plotkin et al., 2012). Multiple investigators have independently confirmed the
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late endosomal/lysosomal localization in multiple cell types with Brady et al. demonstrating that
TMEM106B co-localized with the late endosomal/lysosomal protein Rab7, and did not co-localize
with the early endosomal Rab GTPase, Rab5, or with recycling endosome marker Rab11 in N2a
(mouse neuroblastoma) cells (Brady et al., 2013). The late endosomal/lysosomal localization of
TMEM106B was subsequently also confirmed in mouse and rat primary cortical and hippocampal
neurons by antibody immunofluorescence and expression of fluorescently tagged TMEM106B
(Lang et al., 2012; Schwenk et al., 2014; Stagi et al., 2014). Furthermore, our laboratory and
others have shown that TMEM106B does not co-localize with Golgi marker GM130, TDP-43, or
synaptic vesicle markers (Schwenk et al., 2014; Brady et al., 2013; Chen-Plotkin et al., 2012).
Additionally, initial work in the laboratory demonstrated that increased expression of TMEM106B
by transient transfection in HEK293 and HeLa cells resulted in the striking appearance of
enlarged, >2μm LAMP1+ organelles (Chen-Plotkin et al., 2012), an effect that was also later
confirmed (Brady et al., 2013; Lang et al., 2012).
Building upon these initial discoveries by others within the laboratory, I undertook as my
thesis project to provide an initial characterization of TMEM106B within cell biological and
disease-associated contexts. In the following chapter, I provide the first report on the distribution
of TMEM106B in normal as well as FTLD-TDP human brain. In Chapter 3, I address the cell
biological sequelae of disease-relevant increased TMEM106B expression and the relationship of
TMEM106B

to

C9orf72.

Specifically,

I

will

describe

the

perturbations

to

endolysosomal/autophagosomal pathways that occur with increased TMEM106B expression and
discuss their implications for our understanding of disease development. Below I summarize
some of our laboratory’s initial data regarding TMEM106B, which formed the basis and rationale
for my own subsequent investigations of this protein detailed in the following chapters. In
particular, I will summarize data suggesting that increased TMEM106B expression may be linked
to FTLD, and data suggesting specific mechanistic connections between TMEM106B and the
FTLD-TDP-associated proteins progranulin and C9orf72.
1.3.2

Increased levels of TMEM106B are implicated in disease
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Variants in TMEM106B likely increase disease risk by increasing levels of TMEM106B
expression, suggesting that an underlying cis-acting genetic regulatory mechanism may explain
the GWAS results (Van Deerlin et al., 2010). Data to support this claim are as follows.
First, risk genotypes at the GWAS-implicated SNPs are associated with higher
expression levels in both lymphoblastoid cell lines and in human frontal cortex (Van Deerlin et al.,
2010; Chen-Plotkin et al., 2012; Dixon et al., 2007). Second, TMEM106B mRNA levels were also
found to be elevated >2.5x in FTLD-TDP cases versus controls, even after controlling for
genotype (Van Deerlin et al., 2010; Chen-Plotkin et al., 2012). In brain, the highest levels of
TMEM106B were displayed by FTLD-TDP cases harboring GRN mutations, the next highest in
FTLD-TDP without GRN mutations, and the lowest levels were found in normal brain. This trend
was found to be true in multiple areas of the brain, with the most striking differences seen in the
frontal cortex (Chen-Plotkin et al., 2012). Third, we previously identified microRNA-132 (miR-132)
in a global miRNA expression screen as the microRNA exhibiting the greatest difference between
FTLD-TDP and controls (p=0.0001), with a 50% decrease seen in diseased brains. Intriguingly,
we have shown that miR-132 targets the 3’UTR of TMEM106B, thus negatively regulating mRNA
expression (Chen-Plotkin et al., 2012). Since mir-132 negatively regulates TMEM106B, the
decreased levels of this miRNA seen in disease would be expected to result in overexpression of
TMEM106B, again linking increased TMEM106B expression to disease states. Fourth, evidence
also exists at the protein level for elevation of TMEM106B expression in disease, as we have
shown that TMEM106B is elevated ~1.5x in GRN-associated FTLD-TDP frontal cortex by
immunoblot (Chen-Plotkin et al., 2012). In addition, TMEM106B exhibits more intense
immunohistochemical staining and is more widely distributed in the cytoplasm of neurons from
FTLD-TDP brain, particularly in individuals with GRN-associated FTLD-TDP, than in normal or
disease controls, suggesting higher levels (Chen-Plotkin et al., 2012; Busch et al., 2013; Gotzl et
al., 2014). One report aimed at explaining these elevated levels of TMEM106B suggests that the
coding variant rs3173615 (p.T185S), which is in linkage disequilibrium with the top GWAS SNP,
exhibits differential degradation rates between the protective (S185) and risk (T185) isoforms
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(Nicholson et al., 2013). The risk (T185) isoform is associated with higher steady state levels due
to a slower protein degradation rate than the protective isoform. While this is at best a partial
explanation (since differential protein degradation rates cannot explain the robust correlation
observed between TMEM106B mRNA levels and TMEM106B genotypes in multiple expression
quantitative trait loci datasets), it does indicate a growing convergence in the field on increased
TMEM106B expression as a mechanism for increasing FTLD-TDP risk.
Given these data, which together suggest that elevated TMEM106B levels may play a
role in disease, I sought to characterize the effects of increased TMEM106B within the cell. The
results of this investigation will be reported in Chapter 3.
1.3.3

TMEM106B and progranulin
Multiple lines of evidence suggest a relationship between TMEM106B and progranulin.

First, the GWAS linking TMEM106B to FTLD-TDP demonstrated that the top disease-associated
SNP at the TMEM106B locus was more strongly associated with disease in the subset of GRNassociated FTLD-TDP cases than in cases without GRN mutations (Van Deerlin et al., 2010); this
association was subsequently replicated in an additional cohort of GRN mutation carriers (Finch
et al., 2011). Additionally, GRN-mutation bearing patients who were also homozygotes for the risk
allele of TMEM106B have a median age of onset thirteen years earlier than heterozygotes and
homozygotes for the protective allele (p=9.9x10-7) (Cruchaga et al., 2011), suggesting a genetic
modifier effect of TMEM106B on GRN. Finally, TMEM106B genotypes have also been found to
correlate with plasma progranulin levels. Specifically, the major (risk) allele of the top SNP
rs1990662 was associated with lower plasma progranulin levels in both normal controls and in
GRN-associated FTLD-TDP patients (Cruchaga et al., 2011; Finch et al., 2011).
Following up on this data, we and others have shown that TMEM106B and progranulin
proteins co-localize within lysosomes within neurons and, furthermore, that overexpression of
TMEM106B appears to increase intracellular levels of progranulin (Brady et al., 2013; ChenPlotkin et al., 2012; Nicholson et al., 2013). In addition, in Chapter 2, I demonstrate that cortical
neurons from GRN mutation-associated FTLD-TDP human brain exhibit an altered distribution of
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TMEM106B as compared to other subsets of FTLD pathology. Further investigation into a
potential link between TMEM106B and progranulin is an ongoing area of active research, and I
describe potential models on how these proteins may interact in the development of disease in
the Discussion.
1.3.4

TMEM106B and C9orf72
In addition to TMEM106B’s connection to progranulin, recent genetic evidence links

TMEM106B to C9orf72 as well (van Blitterswijk et al., 2014; Gallagher et al., 2014). Specifically,
we have demonstrated that TMEM106B also acts as a genetic modifier in C9orf72-associated
FTLD-TDP (Gallagher et al., 2014). Strikingly, the major allele of the SNP rs1990622, which
associated with increased risk of FTLD-TDP by genome-wide association (Van Deerlin et al.,
2010; van der Zee et al., 2011a; Finch et al., 2011) and with earlier age at disease onset in GRNassociated FTLD-TDP, also modulates the age at onset and age at death in C9orf72-associated
FTLD cases from an international consortium. Building upon these genetic data, in Chapter 3, I
present the first cell biological evidence that C9orf72 and TMEM106B proteins may
mechanistically interact within the cell, as the lysosomal effects induced by increased TMEM106B
expression appear to be dependent on the presence of C9orf72 protein, functionally implicating
both players within the same pathway for the first time.
1.3.5

Summary
Finally, in the Discussion, I will frame my work in the context of the current understanding

of FTLD and propose how risk genotypes in TMEM106B may contribute to disease pathogenesis.
I will also propose potential models of how levels of TMEM106B could influence progranulin
pathways; furthermore, I discuss the implications of our C9orf72 data and what this suggests for
C9orf72’s normal function within the cell as well as within disease.
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CHAPTER 2: EXPRESSION OF TMEM106B IN NORMAL AND DISEASED HUMAN
BRAIN
This chapter has been adapted from the following manuscript: “Expression of TMEM106B, the
frontotemporal lobar degeneration-associated protein, in normal and diseased human brain” by
Busch, J.I., Martinez-Lage, M.M., Ashbridge, E., Grossman, M., Van Deerlin, V.M., Hu, F., Lee,
V.M.-Y., Trojanowski, J.Q., and Chen-Plotkin, A.S. in Acta Neuropathologica Communications.
SUMMARY:
A recent genome-wide association study (GWAS) identified multiple SNPs within the
TMEM106B gene that significantly associated with FTLD-TDP, suggesting that TMEM106B
genotype confers risk for FTLD-TDP (Van Deerlin et al., 2010). TMEM106B expression levels,
which correlate with TMEM106B genotype, may play a role in the pathogenesis of disease.
Given that little is known about TMEM106B and its expression in human brain, we
performed immunohistochemical studies of TMEM106B in postmortem human brain samples
from normal individuals, FTLD-TDP individuals with and without GRN mutations, and individuals
with other neurodegenerative diseases. We find that TMEM106B protein is cytoplasmically
expressed in both histopathologically affected and unaffected areas of the brain by neurons, glia,
and perivascular cells (endothelial cells or pericytes). Furthermore, we demonstrate that
TMEM106B expression may differ among neuronal subtypes. Finally, we show that TMEM106B
neuronal expression is significantly more disorganized in FTLD-TDP cases with GRN mutations
(GRN-associated FTLD-TDP) compared to normal and disease controls, including FTLD-TDP
cases without GRN mutations (GRN-negative FTLD-TDP). Our data thus provide an initial
neuropathological characterization of this newly discovered FTLD-TDP-associated protein and
add to evidence that TMEM106B and progranulin are pathophysiologically linked in FTLD-TDP.
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2.1 INTRODUCTION
Frontotemporal lobar degeneration (FTLD) is a fatal neurodegenerative disease
characterized by selective degeneration of the frontal and temporal lobes (Neary et al., 2005;
Ratnavalli et al., 2002). FTLD is neuropathologically classified into two major subtypes: FTLD-tau
and FTLD-TDP (Chen-Plotkin et al., 2010; Mackenzie et al., 2009). FTLD-tau cases are
characterized by abnormal accumulations of the microtubule-associated protein tau in neurons
and glia (Mackenzie et al., 2009). In contrast, FTLD-TDP, the largest neuropathological subset of
FTLD (45-60% of FTLD), is characterized by inclusions of hyperphosphorylated, ubiquitinated
TAR DNA-binding protein 43 (TDP-43) (Neumann et al., 2006; Arai et al., 2006; Ling et al., 2013).
Mutations in the gene GRN, which codes for a growth factor progranulin with neuroprotective
effects (Van Damme et al., 2008; Gao et al., 2010) account for ~10% of FTLD-TDP (Gass et al.,
2006; Baker et al., 2006; Cruts et al., 2006). The majority of these autosomal dominant mutations
result in premature termination codons and thus progranulin haploinsufficiency (Cruts et al., 2006;
Shankaran et al., 2008). In addition, expansions in the C9orf72 gene have recently been shown
to be an important Mendelian cause of FTLD-TDP (DeJesus-Hernandez et al., 2011; Renton et
al., 2011). However, the majority of FTLD-TDP cases do not show clear Mendelian patterns of
inheritance.
In order to identify additional genetic risk factors, we previously performed a genomewide association study (GWAS) and identified multiple SNPs within the uncharacterized gene
TMEM106B that significantly associated with FTLD-TDP (odds ratio 1.6, p=1.08x10-11 for top
SNP rs1990622) (Van Deerlin et al., 2010). This association has been replicated in a clinically
diagnosed cohort of patients (van der Zee et al., 2011b) and in a cohort of FTLD-TDP patients
carrying GRN mutations (Nicholson et al., 2013). We and others have investigated the
physiological (Lang et al., 2012; Brady et al., 2013; Chen-Plotkin et al., 2012) and
pathophysiological (Finch et al., 2011; Cruchaga et al., 2011; Rutherford et al., 2012; Vass et al.,
2011) function of TMEM106B. TMEM106B genetic variants may confer increased disease risk by
increasing levels of TMEM106B expression, since mRNA expression levels of TMEM106B are
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>2.5-fold higher in FTLD-TDP cases vs. controls (Van Deerlin et al., 2010), and are particularly
increased in FTLD-TDP cases with GRN mutations (Chen-Plotkin et al., 2012). Moreover,
TMEM106B risk genotypes have been associated with higher levels of TMEM106B expression in
lymphoblastoid cell lines (Dixon et al., 2007) and in human brain tissue (Chen-Plotkin et al., 2012;
Van Deerlin et al., 2010), suggesting that the variants found by GWAS tag a cis-acting
mechanism for regulating TMEM106B expression. One possible mechanism was recently
identified by Nicholson et al. (Nicholson et al., 2013), who demonstrated that differential isoforms
at the coding SNP rs3173615 (p.T185S), which is in linkage disequilibrium with the GWAS SNP
rs1990622, result in different rates of protein degradation. The risk (T185) isoform of TMEM106B
is degraded less quickly than the protective (S185) form of TMEM106B. Together, these data
suggest that TMEM106B variants resulting in higher levels of TMEM106B protein may increase
disease risk.
Evidence further suggests that TMEM106B risk genotypes/increased TMEM106B
expression may modulate disease risk by affecting progranulin pathways. For example,
TMEM106B risk genotypes have been associated with decreased plasma progranulin levels
(Finch et al., 2011), and significantly earlier onset of disease in GRN mutation carriers (Cruchaga
et al., 2011). Moreover, TMEM106B has recently been described as localizing to late endosomes
/ lysosomes in multiple cell lines and in mouse primary cortical and hippocampal neurons where it
co-localizes with progranulin (Chen-Plotkin et al., 2012; Nicholson et al., 2013; Brady et al., 2013;
Lang et al., 2012). Intriguingly, expression of TMEM106B as compared to control results in
increased intracellular progranulin (Chen-Plotkin et al., 2012; Brady et al., 2013; Nicholson et al.,
2013), and changes progranulin’s apparent subcellular compartmentalization as visualized by
immunofluorescence microscopy (Chen-Plotkin et al., 2012).
While studies to date have established TMEM106B as an important risk factor for FTLDTDP and implicated TMEM106B in progranulin pathways, many basic features of this protein -including its expression patterns in human brain -- are largely unknown. To further characterize
this novel disease-related protein, we investigate here the distribution and appearance of
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TMEM106B in postmortem human brain samples from normal and disease controls, FTLD-TDP
individuals with GRN mutations (hereinafter GRN-associated FTLD-TDP), and FTLD-TDP
individuals without GRN mutations (GRN-negative FTLD-TDP). Table 1 further details the cases
and brain regions evaluated.
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Table 1:
Case

Brain
Evaluated

Regions

1

frontal, hippocampal

2

GRN
mutation

Diagnosis

Other
mutation

Age

Gender

AD

65

f

frontal

AD

87

m

3

frontal

AD

87

m

4

frontal

AD

70

f

5

frontal

AD

63

f

6

frontal

FTLD-tau

66

m

7

frontal

FTLD-tau

66

m

8

frontal

FTLD-tau

82

f

9

frontal

FTLD-tau

78

m

10

frontal

FTLD-tau

87

m

11

frontal

FTLD-tau

76

m

12

frontal,
occipital,
cerebellar,
hippocampal, lentiform

FTLD-TDP GRN (-)

49

f

13

frontal

FTLD-TDP GRN (-)

48

m

14

frontal

FTLD-TDP GRN (-)

53

m

15

frontal

FTLD-TDP GRN (-)

77

f

16

frontal

FTLD-TDP GRN (-)

73

f

17

frontal,
occipital,
cerebellar,
hippocampal, lentiform

FTLD-TDP GRN (+)

c.1252C>T

62

f

18

frontal

FTLD-TDP GRN (+)

c.1477C>T

65

m

19

frontal

FTLD-TDP GRN (+)

c.348A>C

78

m

20

frontal

FTLD-TDP GRN (+)

c.1179+2T>C

61

m

21

frontal

FTLD-TDP GRN (+)

c.911G>A

78

f
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C9ORF72

22

frontal

FTLD-TDP GRN (+)

23

frontal

24

c.1252C>T

68

f

Normal

56

f

frontal

Normal

83

m

25

frontal

Normal

82

f

26

frontal

Normal

>90

f

27

frontal

Normal

55

f

28

frontal,
occipital,
cerebellar,
hippocampal, lentiform

Normal

68

f

29

frontal,
occipital,
cerebellar,
hippocampal, lentiform

Normal

85

f

Table 1: Characteristics of cases and brain regions evaluated for TMEM106B expression
GRN mutations were present in cases 17-22, as designated “FTLD-TDP GRN (+)” here.
Nomenclature follows cDNA sequence NM_002087.2; all mutations are believed to be pathogenic
(http://www.molgen.ua.ac.be/admutations/). Case 16 carries a C9orf72 expansion -- this case
was rated a "2" by both scorers for TMEM106B staining pattern. No cases had MAPT mutations.
All FTLD-TDP cases were FTLD-TDP Type A cases.
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2.2 RESULTS
2.2.1

TMEM106B expression by cell type in normal human brain tissue
We began by characterizing TMEM106B expression in normal human brain tissue. As

shown in Figure 2.10, we found that TMEM106B is expressed in neurons, glia, and in cells
surrounding blood vessels in frontal and occipital cortical samples from normal controls.
Specifically, TMEM106B appears to be a cytoplasmic protein that assumes a polarized, perikaryal
distribution in neurons (Figure 2.1a). Glial cells also demonstrate TMEM106B in an asymmetric,
polarized pattern within the cytoplasm (Figure 2.1b). Finally, occasional robust TMEM106B
immunoreactivity was observed perivascularly in endothelial cells or pericytes (Figure 2.1c).
TMEM106B immunoreactivity in neurons and glia was observed throughout all layers of
neocortex, with prominent expression in the pyramidal neurons of layers 3-5 (Figure 2.2a).
2.2.2

TMEM106B expression by brain region in normal human brain tissue
We next evaluated whether TMEM106B expression and appearance varies by brain

region. In occipital cortex, a region of the brain relatively spared from TDP-43 pathology, neurons
and glia had a similar perikaryal, cytoplasmic pattern of TMEM106B expression when compared
to neurons and glia of frontal cortex, a brain region which typically displays a heavy burden of
TDP-43 pathology (Figure 2.2b and 2.2c) (Geser et al., 2009).
In the hippocampus, however, whereas TMEM106B expression was clearly seen in the
pyramidal neurons of Ammon’s horn (Figure 2.2d), no significant staining of the dentate gyrus
was observed (Figure 2.2e), suggesting neuronal subtype specificity of TMEM106B expression.
Lentiform nucleus sections from normal controls showed minimal TMEM106B expression (Figure
2.2f); additionally, neurons of the nucleus basalis of Meynert had little to no staining (not
pictured). In cerebellar sections, Purkinje cells demonstrated little TMEM106B expression (Figure
2.2g), and neurons of the granular layer did not stain for TMEM106B. In contrast, neurons of the
deep cerebellar nuclei showed diffuse TMEM106B immunoreactivity with varying degrees of
granularity (Figure 2.2h).
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In summary, we observed variability in TMEM106B expression by neuronal subtype.
However, TMEM106B expression did not demonstrate obvious differences in neocortical regions
vulnerable to neurodegeneration, compared to those relatively resilient to neurodegeneration, in
FTLD-TDP.

Figure 2.1:

Figure 2.1: TMEM106B expression in neurons, glial and endothelial cells or pericytes in
cortical specimens from normal controls
(a) Neuronal staining in cortices from normal human controls demonstrated a perikaryal,
polarized cytoplasmic distribution mainly in the cell body and variably extending into processes.
(b) Glial distribution of TMEM106B similarly demonstrated an asymmetric cytoplasmic
distribution.
(c) A subset of endothelial cells or pericytes demonstrated intense cytoplasmic expression of
TMEM106B. Sections were stained with the anti-TMEM106B polyclonal antibody N2077.
Scale bar = 50μm.
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Figure 2.2:

Figure 2.2: TMEM106B protein expression in brain tissue from normal controls
(a) TMEM106B protein expression in frontal cortex. TMEM106B protein expression is found
throughout all layers of neocortex.
(b,c) TMEM106B neuronal and glial staining pattern is similar in both histopathologically affected
areas of the brain (b, frontal cortex) and in areas of the brain that are relatively spared of TDP-43
pathology (c, occipital cortex).
(d, e) In the hippocampus, the pyramidal neurons of Ammon’s horn show positive TMEM106B
immunoreactivity (d), whereas those of the dentate gyrus do not (e).
(f) Lentiform nucleus sections demonstrated very rare neuronal staining.
(g) There was minimal staining of the Purkinje cells of the cerebellum; rarely, cells demonstrated
a cytoplasmic, granular staining, as highlighted in the inset.
(h) Neurons of the deep cerebellar nuclei demonstrated diffuse cytoplasmic TMEM106B. Sections
were stained with the anti-TMEM106B polyclonal antibody N2077.
Scale bar = 50 μm.
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2.2.3

TMEM106B expression in FTLD-TDP brain
Given the putative role of TMEM106B in FTLD-TDP, we stained frontal cortex, occipital

cortex, cerebellar, hippocampal, and lentiform nucleus sections from individuals with GRNassociated FLTD-TDP, GRN-negative FTLD-TDP, and normal controls. In addition, we included
FTLD-tau, and Alzheimer’s disease (AD) brain samples as non-FTLD-TDP disease controls.
While FTLD-TDP is characterized by neuronal cytoplasmic inclusions (NCI) and
(depending on histological subtype) neuronal intranuclear inclusions (NII) of TDP-43, these TDP43-containing pathological inclusions did not contain TMEM106B. Furthermore, TMEM106B did
not appear to form pathological inclusions of any type in the eleven FTLD-TDP cases investigated
here. Comparing normal and disease-affected specimens, however, we noted greater variability
in the appearance of TMEM106B cytoplasmic staining among the disease cases. Specifically, in
neurons, cytoplasmic TMEM106B ranged from an organized perikaryal distribution to a
disordered phenotype in which TMEM106B was expressed diffusely throughout the cell body and
even extended into neuronal processes.
To further characterize these differences, we semi-quantitatively rated specimens based
on their degree of apparent TMEM106B disorganization and loss of subcellular localization using
an ordinal scale ranging from 0 (most polarized/organized) to 3 (most diffuse/disorganized).
Specifically, two individuals blinded to disease status rated 29 frontal cortex samples for patterns
of TMEM106B staining, as described in Figure 2.3a (normal controls n=7; AD n=5; FTLD-tau
n=6, GRN-associated FTLD-TDP n=6, GRN-negative FTLD-TDP n=5).
Inter-rater reliability was moderately high (weighted kappa = 0.44). Moreover, as shown
in Figure 2.3b, GRN-associated FTLD-TDP cases showed the most disorganized patterns of
TMEM106B staining, with an average score (2.125) that was significantly greater when compared
to all other cases (Mann-Whitney test, p=0.005). Moreover, while TMEM106B expression rarely
extended into neuronal processes for normal controls, FTLD-tau, AD, or GRN-negative FTLDTDP cases, in every GRN-associated FTLD-TDP case, we observed TMEM106B expression
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extending into neuronal processes even in otherwise healthy-appearing neurons. Staining
sections with a second TMEM106B antibody demonstrated similar results (Figure 2.4).
Furthermore, TDP-43 pathology did not differ significantly between GRN-associated FTLD-TDP
and GRN-negative FTLD-TDP cases (Figure 2.4). Of note, GRN-negative FTLD-TDP cases used
in this study were matched by histopathological subtype to GRN-associated FTLD-TDP cases; all
were FTLD-TDP Type A cases (Mackenzie et al., 2011).
Thus, TMEM106B expression differs significantly in frontal cortex neurons of GRNassociated FTLD-TDP brain. Specifically, in this genetic subtype, TMEM106B is diffusely
expressed throughout the neuronal cytoplasm, with frequent extension into neuronal processes.
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Figure 2.3:

Figure 2.3: Scoring of neuronal TMEM106B protein expression
(a) Scoring schema used to grade severity of disorganization of neuronal TMEM106B expression.
Scores of 0 were assigned to sections in which almost all neurons displayed cytoplasmic
TMEM106B expression with a vesicular pattern exhibiting a polarized quality. Nuclear boundaries
were clear. Scores of 1 were assigned to sections in which a sizeable number of neurons
displayed more diffuse TMEM106B staining dispersed more widely in the cytoplasm, but still
delimited to the soma. Polarity was still usually maintained. Scores of 2 were assigned to
sections in which most neurons recapitulated the characteristics of a score of 1. However, these
sections also contained rare, non-degenerating neurons which displayed highly disorganized and
diffuse TMEM106B staining throughout the cytoplasm with extension into processes. Scores of 3
were assigned to sections in which numerous neurons displayed highly disorganized and diffuse
TMEM106B staining, with extension into processes.
(b) Shown is the average scoring of the degree of diffuse neuronal TMEM106B expression by two
independent, blinded scorers for N2077-stained human frontal cortical samples. Normal cases
n=7; Alzheimer’s disease n=5; FTLD-tau n=6, GRN-negative FTLD-TDP n=5, GRN-associated
FTLD-TDP n=6. The colors in the dot plot correspond to the groups delineated in the bar graph.
Weighted kappa = 0.44. GRN-associated FTLD-TDP cases demonstrated more disorganized
patterns of TMEM106B expression (p=0.005 for Mann-Whitney test).
Scale bar = 30 μm.
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Figure 2.4:

Figure 2.4: TMEM106B expression is more disorganized in neurons from GRN-associated
FTLD-TDP cases, despite comparable levels of TDP-43 pathology
Representative frontal cortical sections from a normal control (a), GRN-negative FTLD-TDP (b),
and GRN-associated FTLD-TDP (c). Both the N2077 antibody (top row) and a different polyclonal
antibody (middle row) raised against the N-terminus (amino acids 1-96) of TMEM106B show
similar patterns of immunoreactivity on serial sections from the same cases. GRN-associated
FTLD-TDP cases showed more disorganized TMEM106B expression than GRN-negative FTLDTDP cases, despite similar degrees of TDP-43 pathology, as indicated by staining against
pathological, phosphorylated forms of TDP-43 (bottom row).
Scale bar = 50 μm.
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2.3 DISCUSSION
We have provided an initial characterization of TMEM106B protein expression in normal,
GRN-negative FTLD-TDP, and GRN-associated FTLD-TDP human brain, as well as other
neurodegenerative disease controls. We find that TMEM106B is normally expressed in the
cytoplasm of neurons, glia, and perivascular endothelial cells or pericytes, although there may be
differences based on neuronal subtype. Unlike many neurodegenerative disease-related proteins,
TMEM106B does not form pathological inclusions in diseased brain. Instead, we show that
neurons in GRN-associated FTLD-TDP cases exhibit more disorganized cytoplasmic TMEM106B
expression than normal or disease controls. Specifically, TMEM106B expression in these cases
demonstrates loss of polarity as well as subcellular compartmentalization.
We have recently shown that TMEM106B is localized to endosomes or lysosomes in
immortalized cell lines and primary cortical neurons, with other investigators corroborating this
finding (Brady et al., 2013; Chen-Plotkin et al., 2012; Lang et al., 2012; Nicholson et al., 2013).
We note that the pattern of TMEM106B staining in normal human brain tissue is compatible with
this

subcellular

localization

as

well,

although

further

studies

using

double-label

immunofluorescence would be needed to definitively demonstrate this.
The present finding that GRN-associated FTLD-TDP cases exhibit significantly different
patterns of TMEM106B expression is intriguing. It is unlikely that this finding is due to
neurodegeneration

alone,

since

disease

controls

(FTLD-tau,

AD)

showed

the

least

disorganization. Moreover, GRN-negative FTLD-TDP cases with similar patterns of TDP-43
pathology did not demonstrate TMEM106B expression extending into neuronal processes,
suggesting that this effect is specific to the GRN-associated FTLD-TDP genetic subtype. We
have previously shown that GRN-associated FTLD-TDP has a distinct global mRNA expression
profile (Chen-Plotkin et al., 2008), suggesting that distinct pathophysiological mechanisms may
exist in this molecularly defined subgroup. Moreover, recent evidence implicates TMEM106B in
GRN-associated FTLD-TDP pathways. First, we have previously shown that TMEM106B may be
expressed at higher levels in GRN-associated FTLD-TDP brain (Chen-Plotkin et al., 2012), which
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is consistent with the histopathological pattern described here of TMEM106B expression
throughout the neuronal cytoplasm in these genetic cases. Secondly, TMEM106B may act as a
genetic modifier among GRN mutation carriers, influencing age at disease onset and levels of
circulating progranulin (Cruchaga et al., 2011; Finch et al., 2011). Finally, we and others have
recently demonstrated that overexpression of TMEM106B affects endolysosomal appearance
and function as well as the distribution of progranulin in intracellular and extracellular
compartments (Brady et al., 2013; Chen-Plotkin et al., 2012; Nicholson et al., 2013).
In this context, the current study provides further evidence of a relationship between
TMEM106B and progranulin, although the directionality of this relationship is unclear. The
observation that GRN mutation carriers exhibit disordered TMEM106B expression suggests that
abnormalities in progranulin can influence TMEM106B expression patterns, whereas the
TMEM106B overexpression studies suggest that TMEM106B levels affect progranulin. One
possibility to reconcile these findings is that a feedback loop exists between TMEM106B and
progranulin in the pathogenesis of FTLD-TDP. Additional studies to investigate this possibility
would be a valuable addition to the data presented here.
Our current study has several limitations. First, our sample size of 29 cases may not
adequately represent the full range of TMEM106B expression that might exist in a larger sample
size. However, even with this small sample size, we were able to detect a significant difference in
TMEM106B expression in GRN-associated FTLD-TDP. Second, the use of postmortem brain
samples limits our ability to interpret the current finding, since non-specific effects due to
postmortem interval, disease duration, cell loss and gliosis could confound our results. Finally,
samples used here were not strictly age- and gender-matched among groups. However, the
GRN-associated FTLD-TDP group did not differ significantly from the other groups in these
respects (t-test p=0.612 for age comparison, chi-square p=0.775 for sex comparison), decreasing
the possibility that these demographic variables may account for the observed effect.
In conclusion, we have provided the first histological characterization of TMEM106B
expression in multiple regions of pathological and normal human brain. Our data add to the
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growing body of evidence that TMEM106B and progranulin may be linked mechanistically in the
pathogenesis of FTLD-TDP. Further characterization of this new FTLD-TDP risk factor, as well as
its interactions with progranulin, may open up new avenues for the development of diseasemodifying therapies.
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2.4 MATERIALS AND METHODS
Brain samples:
Human postmortem brain samples were obtained from the University of Pennsylvania
Center for Neurodegenerative Disease Brain Bank under IRB approval. These comprised
samples from normal individuals (n=7), as well as individuals with FTLD-TDP (n=11), FTLD-tau
(n=6), and Alzheimer's disease (AD, n=5). Regions sampled included midfrontal cortex, occipital
cortex, cerebellum, lentiform nucleus, and hippocampus. See Table 1 for full list of cases.
Histopathological subtyping for FTLD-TDP was performed according to established criteria
(Mackenzie et al., 2011). Genetic testing for C9orf72 expansions, GRN mutations, and MAPT
mutations was performed as previously described (Brettschneider et al., 2012; Van Deerlin et al.,
2003). One FTLD-TDP case was found to harbor a C9orf72 expansion – TMEM106B expression
in this case did not appear atypical for the GRN-associated FTLD-TDP group. In addition, 6
FTLD-TDP cases had GRN mutations, and no cases had MAPT mutations.

Immunohistochemistry:
Formalin-fixed, paraffin-embedded 6 μm sections from various brain regions were cleared
in a descending ethanol series then blocked with 3% H2O2/MeOH for 30 minutes. After washing,
sections were immersed in Antigen Unmasking Solution (Vectashield) and microwaved 1x10
minutes at 50% power, then 2x6 minutes at 50% power. Slides were allowed to cool to room
temperature, then washed with 0.1 M Tris buffer, pH 7.6 (Tris) for five minutes. Sections were
blocked in Tris+ 2% FBS, pH 7.6 (Tris/FBS) for five minutes, before overnight incubation at 4°C
with primary antibody. Specimens were immersed in Tris buffer x 5 minutes, followed by Tris/FBS
x 5 minutes. Biotinylated goat anti-rabbit secondary antibody (Vectashield) was applied, and
samples were incubated at room temperature in a humidified chamber for one hour. Samples
were washed briefly in Tris. VECTASTAIN AB solution (Vector Labs) made up in Tris/FBS was
applied to the samples and incubated for one hour at room temperature. Slides were then
incubated with ImmPACT DAB solution (Vector Labs) for 2-8 minutes until desired stain intensity
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was achieved. Specimens were rinsed briefly with Tris, followed by dH2O and then
counterstained with Harris’ hematoxylin (Thermo-Shandon) for 10-30 seconds. Slides were
washed in running tap water for 5 minutes. Coverslips were sealed with Cytoseal (Thermo
Scientific) and slides were allowed to dry for at least one hour.
TMEM106B antibodies used in this manuscript included N2077, a previously validated
(Chen-Plotkin et al., 2012) polyclonal rabbit antibody directed at amino acids 4–19 of TMEM106B
(a peptide sequence specific to TMEM106B), used at 1ug/ml. A second polyclonal rabbit antibody
raised against amino acids 1–96 of TMEM106B was also used at 1:750 to verify results; this
second antibody has been previously validated as well (Brady et al., 2013). In addition, p409/410
anti-TDP-43 (phosphorylated at 409/410) was used at 1:500.

Semi-quantitative scoring of TMEM106B expression pattern in frontal cortical neurons:
Two independent, blinded observers (MML and ACP) scored stained specimens from
normal controls (n=7), as well as from patients with Alzheimer’s disease (n=5), FTLD-tau (n=6),
GRN-associated FTLD-TDP (n=6), and GRN-negative FTLD-TDP (n=5), assessing for the nature
and degree of neuronal staining. Specimens were assigned scores of 0-3 based on an ordinal
scale representing increasing disorganization of staining pattern.
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CHAPTER 3: INCREASED EXPRESSION OF THE FRONTOTEMPORAL DEMENTIA
RISK FACTOR TMEM106B CAUSES C9ORF72-DEPENDENT ALTERATIONS IN
LYSOSOMES
Portions of this chapter have been adapted from the following manuscript (submitted): “Increased
expression of the frontotemporal dementia risk factor TMEM106B causes C9orf72-dependent
alterations in lysosomes” by Busch, J.I., Unger, T.L., Jain, N., Skrinak, R.T., Charan, R.A., and
Chen-Plotkin, A.S.

SUMMARY:
Frontotemporal lobar degeneration with TDP-43 inclusions (FTLD-TDP) is an important
cause of dementia in individuals under age 65. Common variants in the TMEM106B gene were
previously discovered by genome-wide association to confer genetic risk for FTLD-TDP (p=1x1011,

OR=1.6). Furthermore, TMEM106B may act as a genetic modifier affecting age at onset and

age at death in the Mendelian subgoup of FTLD-TDP due to expansions of the C9orf72 gene.
Evidence suggests that TMEM106B variants increase risk for developing FTLD-TDP by
increasing expression of Transmembrane Protein 106B (TMEM106B), a lysosomal protein. To
further understand the functional role of TMEM106B in disease pathogenesis, we investigated the
cell biological effects of increased TMEM106B expression. Here, we report that increased
TMEM106B expression results in the appearance of a vacuolar phenotype in multiple cell types,
including neurons. Concomitant with the development of this vacuolar phenotype, cells overexpressing TMEM106B exhibit impaired lysosomal acidification and degradative function, as well
as increased cytotoxicity. We further identify a potential lysosomal sorting motif for TMEM106B
and demonstrate that abrogation of sorting to lysosomes rescues TMEM106B-induced defects.
Finally, we show that TMEM106B-induced defects are dependent on the presence of C9orf72, as
knockdown of C9orf72 also rescues these defects. In sum, our results suggest that TMEM106B
exerts its effects on FTLD-TDP disease risk through alterations in lysosomal pathways.
Furthermore, TMEM106B and C9orf72 may interact in FTLD-TDP pathophysiology.
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3.1 INTRODUCTION
Frontotemporal lobar degeneration (FTLD) is a leading cause of presenile dementia
(Neary et al., 2005; Ratnavalli et al., 2002). The most common neuropathological subtype of
disease, FTLD-TDP, is characterized by inclusions of TAR DNA-binding protein of 43 kDa (TDP43) (Baborie et al., 2011). Two of the major Mendelian causes of FTLD-TDP have been identified
as 1) non-coding hexanucleotide repeat expansions in C9orf72 (DeJesus-Hernandez et al., 2011;
Renton et al., 2011) and 2) haploinsufficiency mutations in GRN, which encodes the growth factor
progranulin (Baker et al., 2006; Gass et al., 2006; Cruts et al., 2006). In addition, a recent
genome-wide association study (GWAS)(Van Deerlin et al., 2010) revealed multiple common
variants in the largely uncharacterized gene TMEM106B that significantly associated with FTLDTDP (p=1x10-11, OR=1.6).
In addition to acting as a genetic risk factor for FTLD-TDP, TMEM106B has also been
shown to act as a genetic modifier in both GRN mutation-associated FTLD-TDP (Cruchaga et al.,
2011) and C9orf72 expansion-associated FTLD-TDP (van Blitterswijk et al., 2014; Gallagher et
al., 2014), affecting age at onset of disease and age at death. Moreover, while genotypes at
TMEM106B do not appear to confer risk for development of amyotrophic lateral sclerosis (ALS),
another disease defined by TDP-43 proteinopathy (Chen-Plotkin et al., 2010), TMEM106B
variants associated with increased FTLD-TDP risk correlate with development of dementia in ALS
(Vass et al., 2011). Most recently, TMEM106B variants associated with increased FTLD-TDP risk
have been reported to correlate with increased burden of TDP-43 proteinopathy in aged
individuals without overt clinical FTLD (Yu et al., 2015).
Since its initial discovery as an FTLD-TDP risk factor, TMEM106B has been
characterized as a Type II transmembrane protein localized to late endosomes/lysosomes (Stagi
et al., 2014; Schwenk et al., 2007; Lang et al., 2012), with widespread expression in human brain
(Busch et al., 2013). Recent data suggests that TMEM106B regulates lysosomal transport in
neurons, with knockdown of TMEM106B resulting in increased retrograde lysosomal transport in
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one report (Schwenk et al., 2007) and increased bidirectional transport in another report (Stagi et
al., 2014). TMEM106B has also been demonstrated to affect lysosomal size, acidification, and
degradative capacity in immortalized cell lines (Stagi et al., 2014; Brady et al., 2013; Chen-Plotkin
et al., 2012), and lysosomal size and number in neurons (Stagi et al., 2014).
While

functional

characterization

of

FTLD-TDP-associated

genetic

variants

at

TMEM106B remains incomplete, we and others have demonstrated that TMEM106B genotypes
associated with disease also correlate with increased TMEM106B expression (Chen-Plotkin et
al., 2012; Van Deerlin et al., 2010; Nicholson et al., 2013; Yu et al., 2015). To further understand
the contribution of TMEM106B to FTLD-TDP disease pathogenesis, we investigated the cell
biological effects of disease-associated increases in TMEM106B expression.
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3.2 RESULTS
3.2.1

Increased expression of TMEM106B in results in altered endolysosomal
morphology
We (Chen-Plotkin et al., 2012) and others (Brady et al., 2013) have previously shown that

increased expression of TMEM106B results in enlargement of organelles positive for the
lysosomal marker LAMP1 in immortalized cells. By live cell imaging, we confirmed this effect of
increased TMEM106B expression, using a GFP-tagged TMEM106B construct (Brady et al.,
2013). These enlarged organelles were readily visible by brightfield imaging and did not occur
with increased expression of another lysosomal protein, LAMP1 (Figure 3.1a).
We next extended our investigations of TMEM106B overexpression to neurons. As
shown in Figure 3.1b, primary mouse hippocampal neurons overexpressing TMEM106B also
exhibited multiple, enlarged vacuolar structures >2-3μm in size in the cell body and extending into
processes. In contrast, overexpression of LAMP1 in neurons did not result in the appearance of
these enlarged vacuolar structures (Figure 3.1c). These enlarged vacuoles appeared within a
day post-nucleofection and were observed in both hippocampal and cortical neurons (data not
shown). Mirroring our prior results in immortalized cell lines (Chen-Plotkin et al., 2012), these
vacuoles were positive for both TMEM106B itself and for LAMP1, which co-localized with
TMEM106B at the limiting membrane of these vacuoles. Indeed, the average size of LAMP1+
organelles in neurons overexpressing TMEM106B was ~50% larger than a control nonoverexpressing condition (Figure 3.1d). Moreover, vacuoles were also negative for EEA-1, a
marker of early endosomes, and SV2, a marker of synaptic vesicles; neither of these markers
demonstrated strong co-localization with TMEM106B (Figure 3.2a, b).
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Figure 3.1:

Figure 3.1: Increased expression of TMEM106B alters endolysosomal morphology
(a) Live image of HeLa cells transfected with GFP-TMEM106B or GFP-LAMP1. Expression of
TMEM106B resulted in the appearance of enlarged vacuolar structures (left) visible by
fluorescence or brightfield microscopy. This phenotype was not observed upon expression of
GFP-LAMP1, another transmembrane lysosomal protein (right).
(b) In primary mouse hippocampal neurons nucleofected with GFP-TMEM106B, the enlarged
vacuolar structures demonstrate co-localization of TMEM106B (green) and the lysosomal marker
LAMP1 (red). The two right panels show the merged images, which are shown in monochrome in
the first and second panels. Scale bar for images excluding magnified right panel = 10 μm.
(c) Primary mouse hippocampal neurons nucleofected with GFP-TMEM106B exhibited enlarged
>2-3 μm vacuolar structures (left), whereas GFP-LAMP1-expressing neurons did not (right).

63

(d) The diameter of LAMP1+ organelles in TMEM106B overexpressing neurons is significantly
larger than that of neighboring neurons not overexpressing TMEM106B. p < 0.001 for four
replicate experiments.
Scale bar = 10 μm.
***p<0.001.
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Figure 3.2:

Figure 3.2: TMEM106B does not co-localize with EEA-1 and SV-2
(a) Primary mouse hippocampal neurons nucleofected with FLAG-TMEM106B and
immunofluorescently labeled with N2077 (green) and early endosomal marker EEA-1 (red);
individual channels are shown in monochrome in left and middle panels with the merged
channels shown on the right. Little co-localization was seen between TMEM106B and EEA-1.
(b) Primary mouse hippocampal neurons nucleofected with GFP-TMEM106B (green) and labeled
with synaptic vesicle marker SV-2 (red). Minimal co-localization was noted between TMEM106B+
organelles and SV-2 in GFP-TMEM106B+ neurons. In the top and bottom panels, GFPTMEM106B (green) is shown in monochrome in the left panel, while SV-2 (red) is shown in the
middle panel; merged channels are shown on the right. The bottom panel provides a higher
magnification view of TMEM106B+ organelles along the axon.
Scale bar = 10 μm.
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To better characterize these enlarged LAMP1+ TMEM106B+ organelles, we performed
ultrastructural analyses by electron microscopy. Exogenous expression of empty vector, GFP, or
LAMP1 resulted in no notable changes in ultrastructure (data not shown). However, in HeLa cells
(Figure 3.3a, b), COS-7 cells (Figure 3.3c), HEK293 cells (Figure 3.3d), and DIV7 mouse
hippocampal neurons (Figure 3.3e, f), expression of TMEM106B resulted in the appearance of a
striking vacuolar phenotype. Specifically, TMEM106B overexpressing cells contained multiple
enlarged, electron-lucent, single-membrane-delimited cytoplasmic organelles >2μm in diameter.
These enlarged organelles often appeared largely empty, although at times they contained
multilamellar structures and cytoplasmic material or organelles in varying states of degradation. In
addition, smaller organelles resembling intraluminal vesicles (ILVs) were also observed within a
subset of the enlarged vacuoles (arrows), as seen in late autophagic vacuoles (amphisomes and
autolysosomes) and late endosomes. Because of the “empty” appearance of some of these
vacuoles, we investigated the possibility that they could be lipid droplets. However,
immunofluorescence microscopy in HeLa cells demonstrated that these enlarged vacuoles were
negative for BODIPY 493/503, which labels neutral lipids (Figure 3.3g).
We next quantified this ultrastructural phenotype in both HeLas and primary neurons.
Because TMEM106B was overexpressed in cells by transient transfection or nucleofection, not all
cells overexpressed TMEM106B. Thus, we enriched for TMEM106B-expressing cells by
expressing GFP-TMEM106B and sorting into GFP-positive and GFP-negative populations using
flow cytometry (Figure 3.4). In GFP-positive TMEM106B-transfected HeLa cells, 26% (26/100)
exhibited enlarged vacuoles >1 µm in diameter. In the corresponding GFP-negative population
(cells which presumably express little or no TMEM106B), only 4% (4/100) displayed this
phenotype (p<0.001, Fisher exact test). As GFP sorting of nucleofected neurons was complicated
by cell death, we could not similarly confine our quantitative analyses to neurons with confirmed
GFP-TMEM106B expression. However, 22% (11/50) of the total primary hippocampal neurons
nucleofected with TMEM106B exhibited the enlarged organelles, whereas only 2% (1/50) of GFPLAMP1-nucleofected

neurons

did

(p=0.004,
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Fisher

exact

test).

Figure 3.3:
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Figure 3.3: Ultrastructural characterization of TMEM106B-induced vacuolar phenotype
(a, b) HeLa cells transfected with TMEM106B exhibit multiple large electron-lucent, singlemembraned organelles. These organelles often contain cytosolic components in varying states of
degradation and multilamellar structures (see insets), an ultrastructural phenotype consistent with
late autophagic vacuoles (autolysosomes or amphisomes).
(c) COS-7 cells transfected with TMEM106B also display a similar phenotype, with intraluminal
vesicles (ILVs, arrow) and multilamellar structures within the enlarged vacuoles (see insets).
(d) HEK293 cells transfected with TMEM106B also display the enlarged vacuoles, some
containing components in varying states of degradation (see inset).
(e, f) Primary mouse hippocampal neurons nucleofected with TMEM106B display the same
ultrastructural phenotype. The organelle depicted in the middle panel of (e) demonstrates a small
area of still visible double membrane (arrowhead), consistent with identification as a late
autophagic vacuole (double membrane-autophagosome fusing with a lysosome, resulting in
degradation of the inner membrane). Occasional internal ILVs are similarly noted as well (arrow in
top inset for (f)).
(g) HeLa cells transfected with TMEM106B demonstrate the same vacuolar appearance
(arrowhead) seen by electron microscopy when visualized by fluorescence microscopy. Vacuoles
do not stain with BODIPY 493/503, as would be expected with lipid droplets.
Scale bar = 2μm for the lower-power view, and 0.5μm for the insets in electron microscopy. Scale
bar = 10 μm for BODIPY panel.
e, f imaged by R. Tyler Skrinak.
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Figure 3.4: Flow cytometry of GFP-TMEM106B-transfected HeLa cells

Figure 3.4: Flow cytometry of GFP-TMEM106B-transfected HeLa cells
(a) Flow cytometry of HeLa cells transfected with GFP-TMEM106B. Forward scatter is shown on
the x-axis, and side-scatter is shown on the y-axis, with the cell population gated as delimited in
red.
(b) A spectrum of GFP expression levels was present in the cell population. GFP fluorescence is
shown at a log scale on the x-axis and side scatter is shown on the y-axis. The GFP-low
population (Neg) was defined as indicated in blue, whereas the GFP-high population (Pos) was
defined as indicated in orange.
(c) Histogram of the GFP-low (Neg) and GFP-high (Pos) populations.
Experiments conducted with R. Tyler Skrinak.
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3.2.2

Increased expression of TMEM106B results in multiple lysosomal abnormalities
Having observed that TMEM106B overexpression results in a striking vacuolar

phenotype, we next asked what the functional consequences of this phenotype might be.
Previous data in immortalized cell lines has also demonstrated that TMEM106B overexpression
results in impaired acidification of the lysosomal compartment as well as compromised lysosomal
degradative capability (Brady et al., 2013; Chen-Plotkin et al., 2012). To expand this to more
disease-relevant cell types, we overexpressed TMEM106B in primary mouse hippocampal
neurons and assessed lysosomal acidification with the pH-sensitive dye, LysoTracker. As shown
in Figure 3.5a, TMEM106B overexpressing neurons showed visibly decreased mean
fluorescence intensity (MFI) of LysoTracker compared with non-overexpressing neurons,
suggesting that elevated levels of TMEM106B impaired acidification. Indeed, quantification of the
LysoTracker MFI for TMEM106B overexpressing neurons revealed a significant decrease
compared to neighboring non-overexpressing neurons (14.23 ± 2.75% decrease, p=0.002). In
contrast, LAMP1 overexpression did not result in significant changes in Lysotracker MFI
comparing LAMP1 overexpressing cells to neighboring non-overexpressers (Figure 3.5b).
The loss of lysosomal acidification observed here in neurons and previously described in
other cell types has consequences for lysosomal degradative function. Corroborating the reports
of others (Brady et al., 2013), we found that overexpression of TMEM106B results in impaired
lysosomal degradation of the epidermal growth factor receptor (EGFR) (Figure 3.5c). Under
normal conditions, EGFR rapidly targets to the lysosome for degradation upon internalization via
endocytosis of its ligand epidermal growth factor, (EGF) (Eden et al., 2009; Katzmann et al.,
2002). Quantification of EGFR degradation demonstrated a significant delay in EGFR
degradation in the context of increased TMEM106B expression vs. vector-expressing control
(two-way ANOVA p=0.011, Figure 3.5d).
The delay in EGFR degradation upon conditions of increased TMEM106B expression
could be solely due to inefficient lysosomal degradation. Alternatively, trafficking defects induced
by increasing TMEM106B expression could also be playing a role. To assess these possibilities,
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we evaluated the trafficking of fluorescently-labeled EGF from introduction into the cell culture
medium to internalization in a LAMP1+ vesicle. As shown in Figure 3.5e and 3.5f, TMEM106B
overexpression resulted in delayed delivery of EGF to LAMP1+ vesicles at both higher and lower
concentrations of EGF (two-way ANOVA p=0.001 for 50 ng/ml EGF, p<0.001 for 400 ng/ml EGF).
Quantification of EGF-488’s co-localization with LAMP1 over time demonstrates that EGF
reaches its peak level of co-localization with LAMP1 (i.e. time to reach the lysosome) at 90
minutes in control cells (Figure 3.5e). In contrast, in cells transfected with TMEM106B, EGF-488
was significantly delayed in reaching the lysosome (two-way ANOVA p=0.001). EGF delivery to
LAMP1+ vesicles was also delayed when using a higher concentration of EGF, 400ng/ml (Figure
3.5f). This concentration may utilize other internalization mechanisms in addition to receptormediated endocytosis (Sorkin and Duex, 2010; Mineo et al., 1999). Thus, both trafficking of EGF
to the lysosome as well as lysosomal degradation of EGFR may be impaired upon increased
expression of TMEM106B.
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Figure 3.5:

Figure 3.5: TMEM106B overexpression alters lysosomal acidification and function
(a) Expression of GFP-TMEM106B (top three panels) in DIV4 primary mouse hippocampal
neurons results in an apparent decrease in intensity of LysoTracker, a pH-sensitive dye that
fluoresces intensely at low pH and weakly at higher pH. Expression of GFP-LAMP1 (bottom three
panels) does not affect LysoTracker intensity. In each set of three panels, the right-most panel
shows the merged images, with LysoTracker in red, and TMEM106B or LAMP1 in green. Cells
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overexpressing TMEM106B or LAMP1 fluoresce brightly in green compared to nonoverexpressing neighbors.
(b) Quantification of lysosomal acidification combined from four independent experiments.
TMEM106B-overexpressing neurons demonstrate a significant decrease in mean fluorescence
intensity (MFI) of LysoTracker, compared to neighboring non-overexpressers. Overexpression of
LAMP1 does not affect LysoTracker MFI.
(c) A representative immunoblot is depicted of the EGFR degradation assay. Addition of EGF in
the presence of cycloheximide results in rapid EGFR lysosomal degradation in vector-transfected
cells (right immunoblot). EGFR degradation in TMEM106B-transfected cells, however, was
impaired, as EGFR was still present in high quantities at 120 minutes (left immunoblot). EGFR is
as indicated; other bands are non-specific.
(d), Quantification of four replicates of the EGFR degradation assays demonstrated a significant
delay in EGFR degradation in TMEM106B-transfected versus vector-transfected control cells
(mean ± SEM; p=0.011).
(e,f) The endolysosomal trafficking of EGF to lysosomes (LAMP1+ organelles) is significantly
delayed in TMEM106B overexpressing cells, as demonstrated by decreased co-localization
between EGF and LAMP1, as compared to control cells (mean ± SEM; p=0.001). Two different
concentrations of EGF were tested, as the lower concentration is internalized via EGFR-mediated
endocytosis, and the higher concentration may also utilize other internalization mechanisms. In
both cases, TMEM106B overexpression delayed the delivery of EGF to lysosomes. Colocalization was quantified by Mander’s overlap; quantification with Pearson’s coefficient
demonstrated similar results (data not shown).
Scale bars = 10 µm. FLAG-TMEM106B is detected by FLAG antibody in the bottom row.
*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001.
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3.2.3

Increased TMEM106B alters autophagosomal and lysosomal populations
Our ultrastructural analyses suggested that a proportion of the enlarged organelles seen

on TMEM106B overexpression could be late autophagic vacuoles. Thus, we evaluated cells
overexpressing TMEM106B for subcellular localization of TMEM106B, LAMP1, and the
autophagosome/autolysosome marker LC3, using triple-label immunofluorescence microscopy.
While LC3 staining was minimal and did not co-localize well with TMEM106B under endogenous
conditions, upon TMEM106B overexpression, many enlarged LAMP1+ organelles also expressed
LC3, with TMEM106B, LAMP1, and LC3 demonstrating co-localization (Figure 3.6a). In addition,
cells overexpressing TMEM106B displayed a marked increase in the number of LC3+ organelles
(Figure 3.6b), compared to neighboring non-overexpressers. Quantification of the number of
LC3+ organelles demonstrated that TMEM106B-expressing cells had a significant increase in the
average number of LC3+ organelles per cell compared with controls expressing GFP or vector
(Figure 3.6c). This suggested that increased TMEM106B expression increases the number of
autophagosomes (APs), potentially through increased autophagosomal formation or via blocking
downstream autophagic flux, possibly through the previously described impairment of lysosomal
acidification.
However, in contrast to the increase seen in LC3+ organelles, we observed a decrease in
the number of LAMP1+ organelles (late endosomes/lysosomes) with TMEM106B overexpression
(Figure 3.6d). Specifically, we found a significant decrease in the average number of LAMP1+
organelles in cells with increased expression of TMEM106B compared to controls (71.56 ± 4.29
LAMP1+ organelles for TMEM106B-overexpressing cells vs. 97.2 ± 5.56 for GFP-overexpressing
cells vs. 92.3 ± 8.41 for non-overexpressing cells).
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Figure 3.6:

Figure 3.6: TMEM106B co-localizes with LC3 and overexpression of TMEM106B alters
autophagosome and lysosome populations
(a) Immunofluorescence microscopy demonstrates co-localization of the autophagosomal marker
LC3 (red) with TMEM106B+ (green) and LAMP1+ (blue) organelles in HeLa cells overexpressing
TMEM106B. Right-most panel merges channels, which are shown individually in monochrome in
left three panels. Two cells are shown, with the bottom one demonstrating increased TMEM106B
expression.
(b) Expression of TMEM106B results in a visible increase in the number of LC3+ organelles/cell
(arrows), compared to neighboring cells in which TMEM106B expression is not increased. Rightmost panel shows merged TMEM106B (green) and LC3 (red) channels, which are shown
individually in monochrome in the left panels. Four HeLa cells are shown in the field, with the two
on the right demonstrating increased TMEM106B expression.
(c) Quantification of the average number of LC3+ puncta per cell shows a significant increase in
LC3+ puncta in TMEM106B-transfected HeLa cells, compared to GFP- or vector-transfected
controls.
(d) The number of LAMP1+ organelles decreased significantly in TMEM106B-overexpressing
HeLa cells, compared to GFP-overexpressing HeLa cells or non-overexpressing (control) HeLa
cells (mean ± SEM; p=0.000642 for TMEM106B vs. GFP, p=0.00271 for TMEM106B vs. nonoverexpressing cells; quantifications performed for three experiments).
Scale bars = 10 μm. **p<0.01, ***p<0.001. TMEM106B is detected by N2077 in (a) and by the
FLAG tag in panel (b).
b, c imaged and quantified by Robert Arauz Perez
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3.2.4

Increased TMEM106B levels may decrease cell survival
Notably, the endolysosomal disturbances associated with TMEM106B overexpression

appear to be associated with decreased cell survival, since we observed that HeLa cells
expressing TMEM106B “disappeared” from culture approximately forty-eight hours posttransfection, whereas LAMP1-expressing cells remained readily apparent (Figure 3.7a). To
further quantify these observations, we assessed cytotoxicity in several ways. First, we measured
LDH release from cultured cells, which occurs when cell membranes are compromised. After
transient transfection with TMEM106B or control constructs, we assessed cytotoxicity at multiple
timepoints. Compared with both vector control and LAMP1-overexpressing cells, cells
overexpressing TMEM106B exhibited significantly higher cytotoxicity at 48 hours post-transection
(two-way ANOVA p=0.026 compared to vector control, p=0.010 compared to LAMP1, Figure
3.7b), suggesting that TMEM106B overexpression is toxic to cells. Second, because we were
concerned that LDH result could also result from our transfection methods, we also quantified the
proportion of Trypan Blue (+) cells in HeLa cells expressing TMEM106B or controls GFP or
LAMP1 to quantitated non-viable cells in each condition. These studies corroborated the cytotoxic
effect of increased TMEM106B expression (Figure 3.7c). Finally, in order to investigate the
contribution of apoptotic cell death mechanisms to the cytotoxicity observed with TMEM106B
expression, we performed TUNEL staining. Corroborating the results of others (Brady et al.,
2013), we did not see a difference in numbers of cells undergoing apoptosis in conditions with vs.
without TMEM106B overexpression, with very few TUNEL+ cells in both conditions (Figure 3.7d).
Taken together, our findings suggest that increased expression of TMEM106B in multiple
cell types, including neurons, results in prominent morphological alterations in LAMP1+
organelles such as late endosomes, lysosomes, or autolysosomes. Moroever, these alterations
affect trafficking to lysosomes, lysosomal acidification and degradative function, ultimately
resulting in cytotoxicity.
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Figure 3.7:

Figure 3.7: Increased levels of TMEM106B are cytotoxic to cells
(a) Growth and survival of HeLa cells transfected with FLAG-TMEM106B, LAMP1, and GFP. The
proportion of TMEM106B-overexpressing cells to total number of cells decreases over time
compared with overexpression controls (mean ± SEM; ****p<0.0001 for two independent
experiments). Overexpressing cells were identified by immunofluorescent labeling with N2077,
LAMP1, and GFP antibodies; the total number of cells was enumerated by counting the number
of DAPI+ nuclei. Results are normalized to the 24 hour timepoint.
(b) Increased expression of TMEM106B results in cytotoxicity. Cytotoxicity was quantified in HeLa
cells overexpressing TMEM106B or controls (LAMP1, vector) using measurements of LDH
release (which accompanies loss of cell membrane integrity); data is combined for eighteen
replicates performed on three days. Over a 48h time-course, TMEM106B overexpression (green)
resulted in significantly greater cytotoxicity than overexpression of LAMP1 (blue, two way ANOVA
p<0.001) or vector control (red, two-way ANOVA p=0.026).
(c) Trypan Blue labeling demonstrates that TMEM106B overexpression decreases cell viability.
HeLa cells were transfected with controls (GFP and LAMP1) or myc-TMEM106B and analyzed
for uptake of Trypan Blue. The proportion of blue cells normalized to the GFP-expressing
condition is shown (mean ± SEM; **p<0.01, ***p<0.001 for nine replicates performed on three
separate days).
(d) HeLa cells treated with 1 µM of the positive control staurosporine exhibit TUNEL staining (top
row), while TMEM106B overexpressing HeLa cells (arrowhead, bottom row) do not. For the top
row, the right panel shows the merged channels of LAMP1 (red), TUNEL (green), and DAPI
(blue). Individual channels are shown in monochrome in the left three columns. For the bottom
row, the right panel demonstrates the merged channels of TMEM106B (red), TUNEL (green), and
DAPI (blue).
Scale bars = 10 µm. FLAG-TMEM106B is detected by FLAG antibody in the bottom row.
**p<0.01, ***p<0.001 b, c conducted with Travis L. Unger
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3.2.5

The cell biological effects of increased TMEM106B expression are dependent on
localization of TMEM106B to lysosomes
The preceding experiments demonstrate that increased expression of TMEM106B results

in changes in lysosomes, autophagosomes, and autolysosomes, with concomitant cytotoxic
effects. Furthermore, these effects are relatively specific to TMEM106B, since they are not seen
upon overexpression of another lysosomal protein, LAMP1, or a control protein, GFP. We next
asked whether the localization of TMEM106B to lysosomes is necessary for these changes to
occur.
To answer this question, we first had to determine, and then abrogate, potential
lysosomal sorting motifs for TMEM106B. Inspection of the cytosolic, N-terminal domain of
TMEM106B revealed three potential canonical lysosomal sorting motifs (Figure 3.8a) – two
tyrosine-based (YDGV, YVEF) and one extended dileucine-based motif (ENQLVALI), fitting the
tyrosine consensus sequence YXXØ and dileucine motif [DE]XXXL[LI], respectively(Bonifacino
and Traub, 2003). We therefore used site-directed mutagenesis to individually mutate each
potential motif. The potential lysosomal sorting motifs are identified in Figure 3.8b along with the
mutations introduced: YDGV  ADGV, YVEF  AVEF, and ENQLVALI  ENQLVAAA. We
assessed the subcellular localization of each of these motif mutants by immunofluorescence
microscopy.
While the constructs containing mutated tyrosine-based motifs (YDGV  ADGV, YVEF
 AVEF) continued to localize to lysosomes, mutation of the leucine and isoleucine residues
within the extended dileucine-based motif abrogated lysosomal localization of TMEM106B, as
demonstrated by decreased co-localization with LAMP1 (Figure 3.8c). Instead, in the
ENQLVAAA TMEM106B mutant, TMEM106B expression appeared more diffusely cytoplasmic. In
addition, we verified that the ENQLVAAA TMEM106B mutant was not retained in the
endoplasmic reticulum (ER) by confirming cell surface expression under non-permeabilized
immunofluorescence microscopy conditions (Figure 3.9a) and by Endoglycosidase H (EndoH)
and

Peptide-N-Glycosidase

F

(PNGaseF)

deglycosylation
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experiments

(Figure

3.9b).

Specifically, both wild-type TMEM106B and ENQLVAAA TMEM106B showed similar EndoHresistant bands ~35kDa by immunoblot, demonstrating that ENQLVAAA TMEM106B achieves
complex glycosylation in the Golgi and is not retained in the ER. This 35kDa band fully collapsed
down to TMEM106B’s predicted 31 kDa size when deglycosylated with PNGaseF for both
ENQLVAAA TMEM106B and wild-type TMEM106B.
Accompanying the abrogation of lysosomal localization, ENQLVAAA TMEM106B also
demonstrated a striking loss of the vacuolar phenotype (Figure 3.8c, 3.10a). In fact, on brightfield
microscopy, cells expressing ENQLVAAA TMEM106B showed virtually no vacuoles (Figure
3.10a). We considered the possibility that the loss of phenotype might be due to lower expression
levels of this construct. We found, however, that, whereas our wild-type TMEM106B construct
demonstrated overexpression levels 2-10X over baseline, the ENQLVAAA TMEM106B mutant
construct showed much higher expression (Figure 3.10b, c).
Given the loss of the vacuolar phenotype in cells overexpressing ENQLVAAA
TMEM106B, we asked if the other cell biological effects of TMEM106B overexpression were also
abrogated upon mutation of this motif. Indeed, ENQLVAAA TMEM106B expressing cells did not
exhibit decreased lysosomal acidification as seen with wild-type TMEM106B (Figure 3.11a, b). In
addition, ENQLVAAA TMEM106B-expressing cells showed only a modest increase in the number
of LC3 puncta, compared to the >1.5X-increase in LC3 puncta observed with increased wild-type
TMEM106B expression (Figure 3.11c, d). Finally, the cytotoxicity effects exerted by wild-type
TMEM106B were also rescued in this point mutant, since expression of ENQLVAAA TMEM106B
caused no more toxicity than controls (Figure 3.11e, f).
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Figure 3.8:

Figure 3.8: ENQLVALI is a potential lysosomal sorting motif for TMEM106B
(a) Three potential classical lysosomal targeting motifs – two tyrosine motifs and one
isoleucine/dileucine motif – were identified in the N-terminal domain of TMEM106B.
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(b) The primary amino acid sequence of TMEM106B is shown, with lysosomal targeting motifs
depicted in green. These motifs were individually mutated to alanine residues, with mutated
residues indicated in red.
(c) SDS-PAGE and immunoblotting of the lysosomal motif mutants demonstrates that expression
levels in HeLa cells are comparable to wild-type TMEM106B; overexpression levels of all
TMEM106B constructs are only moderately increased over endogenous levels.
Endo=endogenous TMEM106B, WT=wild-type TMEM106B, ENQ=ENQLVAAA TMEM106B,
AVEF=AVEF-TMEM106B, and ADGV=ADGV-TMEM106B. Two bands (arrows) for TMEM106B
at 70kDa (dimer) and 40kDa (monomer) are detected by the N2077 antibody.
Scale bars = 10 µm. FLAG-TMEM106B is detected by FLAG antibody.
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Figure 3.9:

Figure 3.9: ENQLVAAA TMEM106B is not retained in the endoplasmic reticulum
(a) Mutation of a dileucine-based motif in TMEM106B abrogates lysosomal localization but does
not prevent the mutated protein from leaving the endoplasmic reticulum (ER). HeLa cells were
transfected with either wild-type TMEM106B (top panel) or the ENQLVAAA TMEM106B mutant
(bottom panel), and expression was visualized on the cell surface by staining under nonpermeabilized conditions. Antibodies directed at a FLAG-tag on the TMEM106B construct were
used to ensure that staining was specific for the expressed construct. Both wild-type and
ENQLVAAA TMEM106B demonstrated surface expression of TMEM106B. Scale bar = 10 μm.
(b) Immunoblot patterns for wild-type TMEM106B (five lanes on left) and ENQLVAAA TMEM106B
(five lanes on right) expressed in HeLa cells are similar under conditions of Endo H digestion and
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PNGase F digestion. The presence of Endo H-resistant bands by immunoblot demonstrates that
the ENQLVAAA TMEM106B mutant achieves complex glycosylation in the Golgi and is not
retained within the ER. The top arrow indicates the 40 kDa band of monomeric TMEM106B which
collapses down to TMEM106B’s predicted molecular weight of 31 kDa upon complete
deglycosylation with PNGase F (bottom arrow). Digestion with Endo H reveals Endo H-resistant
complex glycosylation, with a resulting intermediate molecular weight of ~35 kDa. The blot is
developed with a long exposure so as to show the 40 kDa species of TMEM106B.
(c) Trypan Blue staining confirms LDH assay results suggesting that HeLa cells transfected with
ENQLVAAA-TMEM106B (ENQLVAAA) do not have increased cell death over controls (LAMP1
and GFP over-expressing conditions), whereas wild-type TMEM106B-transfected cells do show
increased toxicity (mean ± SEM; **p<0.01 for nine replicates performed on three independent
days). GFP, LAMP1, and TMEM106B data are the same as shown in Supplementary Fig. 4b,
with ENQLVAAA-TMEM106B results added for comparison.
Scale bar = 10 μm.
c conducted with Travis L. Unger.
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Figure 3.10:

Figure 3.10: Characterization of lysosomal motif mutants
(a) Live imaging of HeLas overexpressing either wild-type TMEM106B or lysosomal motif mutants
by bright-field microscopy demonstrates loss of the vacuolar phenotype in cells expressing the
ENQLVAAA TMEM106B mutant. In contrast, cytoplasmic vacuoles ranging in size were readily
seen in cells expressing wild-type, ADGV-, or AVEF-TMEM106B.
(b, c) Lysosomal motif mutants all exhibit expression levels that are comparable to, or higher
than, wild-type TMEM106B, with the ENQLVAAA TMEM106B construct expressing at the highest
levels in HeLa cells. Endo=endogenous TMEM106B, WT=wild-type TMEM106B,
ENQ=ENQLVAAA TMEM106B, AVEF=AVEF-TMEM106B, and ADGV=ADGV-TMEM106B. In the
example immunoblot (b), two bands (arrows) for TMEM106B at 70kDa (dimer) and 40kDa
(monomer) are detected (N2077 antibody). Quantification for four replicate experiments is shown
in (c), normalized to the endogenous condition (mean ± SEM).
Scale bar = 100 µm.
b conducted by R. Tyler Skrinak.
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Figure 3.11:

Figure 3.11: The effects of increased TMEM106B expression depend on proper localization
of TMEM106B to lysosomes
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(a,b) While expression of wild-type TMEM106B impairs lysosomal acidification (as demonstrated
by decreased LysoTracker mean fluorescence intensity), expression of ENQLVAAA TMEM106B
does not significantly alter organelle acidification. Representative images are shown in (a), and
quantification is shown in (b) (mean ± SEM; p=8.44 x 10-5 for wild-type TMEM106B
overexpressing cells (oe) vs. neighboring non-overexpressing (nonoe) cells; no significant
difference in ENQLVAAA TMEM106B overexpressing cells vs. neighboring non-overexpressing
cells).
(c,d) ENQLVAAA TMEM106B-expressing HeLa cells demonstrate a modest increase in the
number of LC3+ puncta, whereas wild-type TMEM106B-expressing cells exhibit a >1.5x increase
compared to neighboring non-over-expressers. Representative images are depicted in (c),
whereas quantification from two independent experiments is depicted in (d) (mean ± SEM;
p=4.85 x 10-2 for wild-type vs. non-expressers, p=0.0288 for ENQLVAAA TMEM106B vs. nonexpressers).
(e) Cytotoxicity is quantitated by measurement of LDH in the cell culture medium, as LDH release
accompanies compromise of the plasma membrane. While wild-type TMEM106B expression in
HeLa cells induces cytotoxicity by 48 hours (TMEM106B, green line), the loss of lysosomal
localization (ENQ TMEM106B, pink) rescues this cytotoxicity to levels seen with transfection of
vector only (Control, red line, almost entirely overlapped by pink line). Cytotoxicity seen with
expression of LAMP1 (blue line) is also shown for comparison purposes. Beyond the 48 hour time
point, wild-type TMEM106B-expressing cells are largely lost from the culture medium due to cell
death. % cytotoxicity is calculated in comparison to the maximal LDH release induced by
treatment with Triton X as described in Materials and Methods.
(f) Trypan Blue staining confirms LDH assay results suggesting that HeLa cells transfected with
ENQLVAAA TMEM106B (ENQ) do not have increased cell death over controls (LAMP1 and GFP
overexpressing conditions) (mean ± SEM; **p<0.01 for nine replicates performed on three
independent days).
Scale bars = 10 μm.
*p<0.05, **p<0.01, ****p<0.0001. Wild-type TMEM106B and ENQLVAAA TMEM106B are
detected by their FLAG tags in panels a and c.
d, e, f conducted with R. Tyler Skrinak and Travis L. Unger.
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3.2.6

Lysosomal acidification and cytotoxicity effects
expression are dependent on C9orf72

of

increased

TMEM106B

We have previously demonstrated that TMEM106B is a genetic modifier affecting age at
death in C9orf72-associated FTLD-TDP (Gallagher et al., 2014), suggesting that TMEM106B and
C9orf72 may interact in the pathophysiology of FTLD-TDP (Cooper-Knock et al., 2014; Deming
and Cruchaga, 2014; van Blitterswijk et al., 2014). The protein product of the C9orf72 gene, in
which hexanucleotide repeat expansions are the most common Mendelian cause of both FTLDTDP and ALS (Renton et al., 2011; DeJesus-Hernandez et al., 2011), is predicted to be a DENN
protein by structural analysis (Levine et al., 2013a). As DENN proteins are guanine exchange
factors (GEFs) regulating Rab GTPases, which in turn regulate cell biological events such as
vesicular trafficking and fusion (Zhang et al., 2012), we asked whether TMEM106B's cell
biological effects might be dependent on C9ORF72.
Strikingly, siRNA-mediated knockdown of C9ORF72 expression abrogated the vacuolar
phenotype seen upon overexpression of TMEM106B. This effect was found in multiple cell types,
and did not occur with control siRNA knockdown (Figure 3.12a, b). Moreover, quantification of
LAMP1+ organelle size demonstrated that siRNA knockdown of C9orf72, but not control siRNA
knockdown, rescued the LAMP1+ organelle diameter size in TMEM106B over-expressing cells to
levels near that of cells with endogenous levels of C9orf72 and TMEM106B (Figure 3.12c, d).
Intriguingly, in HEK293 cells but not in HeLa cells, concomitant overexpression of both C9orf72
and TMEM106B resulted in the most dramatic increases in vacuolar size (Figure 3.12d).
Moreover, in both cell types, knockdown of C9orf72 without overexpression of TMEM106B
resulted in a small, but significant, decrease in the LAMP1+ organelle diameter size, compared to
cells without knockdown of C9orf72 (Figure 3.12c, d, right graph).
We then asked if other cell biological phenotypes observed with TMEM106B
overexpression are similarly dependent on the presence of C9orf72 protein. Specifically, we
evaluated cytotoxicity as well as the lysosomal acidification defect induced by TMEM106B
overexpression. As shown in Figure 3.13a and b, the difference in LysoTracker MFI typically
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seen in TMEM106B overexpressing HeLa cells as compared to non-overexpressing cells is
abrogated in the context of C9orf72 knockdown, but maintained in the context of control siRNA
knockdown. In addition, knockdown of C9orf72 abrogated the cytotoxic effects of TMEM106B
overexpression (Figure 3.13c).
To ensure that the reversal of TMEM106B overexpression effects by C9orf72 knockdown
were not due to off-target effects of the siRNA used, we repeated our experiments with an shRNA
targeting C9orf72. As shown in Figure 3.14a, knockdown of C9orf72 by this second method in
TMEM106B overexpressing cells again rescued LAMP1+ organelle diameter sizes to baseline.
Additionally, knockdown of C9orf72 by shRNA also rescued the cytotoxicity of TMEM106B
overexpression (Figure 3.14b).
Of note, immunoblots were run in parallel to confirm C9orf72 knockdown for all
experiments and demonstrated nearly complete disappearance of the endogenous C9orf72 band;
validation of the specificity for the C9orf72 antibody used was demonstrated with C9orf72
knockdown and overexpression in immortalized cells (Figure 3.14c). Additionally, quantitative
PCR experiments demonstrated efficient knockdown and overexpression of C9orf72 in our siRNA
experiments (Figure 3.14d). Finally, we considered the possibility that C9orf72 knockdown and
overexpression might secondarily affect TMEM106B expression levels, thus rescuing TMEM106B
overexpression phenotypes. However, manipulation of C9orf72 levels minimally affected
TMEM106B expression (Figure 3.14e, f).
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Figure 3.12:
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Figure 3.12: Knockdown of C9ORF72 rescues TMEM106B-induced vacuolar phenotype
(a,b) In HeLa cells (a) and in HEK293 cells (b), treatment with control siRNA does not affect the
LAMP1+ vacuolar phenotype seen in TMEM106B over-expressing cells (arrows, top row), but
siRNA knockdown of C9orf72 mitigates the phenotype (bottom row). For all panels, the right
panel shows the merged channels for TMEM106B (green) and LAMP1 (red); individual channels
are shown in monochrome in the left and middle panels. Scale bars = 10 μm. TMEM106B
detected by N2077 antibody.
(c,d) The diameter of LAMP1+ organelles was quantified in HeLa (c) and HEK293 (d) cells. In the
left graph for both cell types, LAMP1+ diameter was assessed under endogenous conditions (first
column), TMEM106B overexpression (second column), TMEM106B overexpression with C9orf72
knockdown (third column), and TMEM106B overexpression with control siRNA knockdown (fourth
column). In the right graph, LAMP1+ diameter is quantified under endogenous conditions (first
column), C9orf72 overexpression (second column), C9orf72 knockdown alone (third column),
TMEM106B overexpression alone (fourth column), and TMEM106B and C9orf72 concomitant
overexpression (fifth column). All values are normalized to the endogenous condition (first
column) and means +/- SEM from nine replicates performed on three separate days are shown.
In both HeLa (c) and HEK293 (d) cells, TMEM106B overexpression significantly increased
LAMP1+ organelle size (p<0.0001, left graph, compare first and second columns). In both cell
types, however, knockdown of C9orf72 abrogated the effects of TMEM106B overexpression,
resulting in a return of LAMP1+ organelle size towards that of the endogenous baseline (p<0.001,
left graph, comparing second and third columns).
***p<0.001, ****p<0.0001.TMEM106B is detected by N2077 (Ck). Scale bars = 10µm.
Experiments conducted with Travis L. Unger and Nimansha Jain.
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Figure 3.13:

Figure 3.13: Knockdown of C9orf72 mitigates TMEM106B-induced acidification defects and
cytotoxicity
(a, b) Knockdown of C9orf72 abrogates the acidification defect seen with TMEM106B
overexpression. (c) HeLa cells were transfected with control siRNA + TMEM106B or with C9orf72
siRNA + TMEM106B and incubated with Lysotracker. (b) In each of these transfection conditions,
the MFI was quantified for cells over-expressing TMEM106B and neighboring non-expressing
cells. TMEM106B overexpression in the context of control siRNA yielded the previously described
impairment in acidification in TMEM106B over-expressers compared to neighboring non-overexpressers. However, TMEM106B overexpression in the context of C9orf72 knockdown resulted
in no significant difference in MFI between TMEM106B over-expressers and non-overexpressers.
(c) TMEM106B overexpression induces cytotoxicity in HeLa cells, as quantified by LDH release
over a 48 hour time-course. Concomitant siRNA knockdown of C9orf72 abrogates cytotoxicity,
whereas treatment with control siRNA does not. Means +/- SEM for >12 replicates performed on
three days shown, and cytotoxicity compared by two-way ANOVA.
*p<0.05, ****p<0.0001.TMEM106B is detected by N2077 (Ck). Scale bars = 10µm.
Experiments conducted with Travis L. Unger and Nimansha Jain.
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Figure 3.14:
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Figure 3.14: Overexpression and knockdown of C9orf72
(a) Knockdown of C9orf72 with shRNA (fourth column) demonstrates abrogation of the vacuolar
phenotype associated with TMEM106B overexpression, relative to what is seen with control
shRNA knockdown (third column). Results are quantified from nine replicates performed on three
different days in HEK293 cells (mean ± SEM; ****p<0.0001), corroborating results seen with
siRNA-mediated knockdown of C9orf72. Additionally, shRNA knockdown of C9orf72 in the
context of endogenous levels of TMEM106B also led to a smaller LAMP1+ vesicle diameter size,
similar to results from siRNA experiments (first and second columns). Data is normalized to the
TMEM106B endogenous condition (shControl RNA and endogenous TMEM106B).
(b) Trypan Blue dye exclusion assay demonstrates that shRNA-mediated knockdown of C9orf72
rescues TMEM106B-overexpression-induced cell toxicity by ~50% in HEK293 cells. Data from
nine replicates performed on three different days are depicted (mean ± SEM; ****p<0.0001); data
are normalized to the shControl plus TMEM106B overexpression condition.
(c) Immunoblot with anti-C9orf72 (Sigma #HPA023873) demonstrates nearly complete
knockdown of the endogenous C9orf72 band in HEK293 cells transfected with C9orf72 siRNA as
compared to control siRNA (compare first and second columns, endogenous C9orf72 band
indicated by double arrowhead). In contrast, HEK293 cells transiently transfected with FLAGC9orf72 demonstrated a dark band slightly above the endogenous band, reflecting the slight
increase in size introduced by the tag (fourth column, single arrowhead).
(d) Quantitative PCR corroborates the efficient knockdown (~70% knockdown, note that a base 2
logarithmic scale is used) and level of overexpression of C9orf72 at the mRNA level.
(e, f) Knockdown and overexpression of C9orf72 does not significantly alter protein levels of
TMEM106B. Representative immunoblot (e) for TMEM106B demonstrates that TMEM106B
protein levels are not altered by C9orf72 knockdown (compare left two columns) or
overexpression (compare right two columns) in transiently transfected HEK293 cells. Both the 40
kDa and 70 kDa TMEM106B bands, probed with the N2077 TMEM106B antibody, are indicated
by the double arrowheads. Quantification of nine replicates performed on three different days (f)
demonstrates that knockdown (compare left two columns) or overexpression of C9orf72
(compare right two columns) does not significantly alter TMEM106B protein levels relative to
control knockdown, or to overexpression of a control GFP construct.
****p<0.0001
c-f conducted by Travis L. Unger.
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3.3 DISCUSSION
Genotypes at TMEM106B linked to increased risk for FTLD-TDP are associated with
increased expression of TMEM106B (Chen-Plotkin et al., 2012). Moreover, in human FTLD-TDP
brain, TMEM106B expression is also increased (Chen-Plotkin et al., 2012), with an altered
subcellular distribution (Busch et al., 2013). Here we explore the cell biological consequences of
this disease-associated increase in TMEM106B expression, demonstrating that it results in
multiple perturbations to endolysosomal and autophagosomal pathways, and that these changes
are dependent on the presence of C9orf72.
We and others have previously shown that TMEM106B overexpression results in
enlargement of LAMP1+ organelles (Chen-Plotkin et al., 2012; Stagi et al., 2014; Schwenk et al.,
2014). We corroborate and expand this result here with ultrastructural characterization in
neurons, as well as demonstrate that the lysosomal acidification defect extends to neurons. We
note that the ultrastructural characteristics of these organelles – single-membrane-bound,
electron-lucent, containing possible degradation products – suggests that they may be late
autophagic vacuoles (amphisomes and autolysosomes). Indeed, many LAMP1+ organelles colocalize with the autophagosomal marker LC3 in immunofluorescent labeling. Notably,
overexpression of ENQLVAAA TMEM106B, a mutant version of TMEM106B that exhibits
decreased LAMP1+ co-localization, results in only a minimal increase in the number of LC3+
organelles despite expressing at much higher levels than wild-type TMEM106B. This suggests a
specific effect that is dependent on both the identity of TMEM106B and its localization to the
lysosomal membrane.
Notably, the observed increase in the number of LC3+ organelles upon TMEM106B
overexpression is also accompanied by a significant decrease in the number of LAMP1+
organelles. Moreover, the LAMP1+ organelles that remain are poorly acidified and demonstrate
impairment in lysosomal degradation. Taken together, these results suggest that elevated
TMEM106B levels skew the endolysosomal pathway towards an increase in downstream fusion
products such as ALs, at the expense of maintaining a normal, functional lysosomal pool. This
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phenomenon of lysosomal exhaustion and consumption has been previously described in
starvation- as well as rapamycin-induced autophagy (Settembre et al., 2011; Yu et al., 2010). As
such, further investigation of the role of TMEM106B in autophagy pathways may be a valuable
addition to the data presented here. In support of an impact of TMEM106B on autophagy, it has
been recently reported that increased expression of TMEM106B results in increased nuclear
translocation of Transcription Factor EB (TFEB) (Stagi et al., 2014). Because TFEB has been
proposed as a master regulator of lysosomal and autophagosomal gene expression (Settembre
et al., 2011; Sardiello et al., 2009), our current findings may also support a potential interaction
between TMEM106B and TFEB, although how direct this interaction might be remains to be
seen. However, we note that the relationship is likely not straightforward, as while increased
TFEB translocation would be expected to increase the number of autophagosomes and promote
lysosome-autophagosome fusion, it would also be expected to increase lysosomal biogenesis
and enhance the cell’s ability to degrade (Sardiello et al., 2009; Ma et al., 2012).
Additionally, we identify for the first time here a possible lysosomal sorting motif for
TMEM106B, demonstrating that point mutations to a potential extended dileucine motif
(Letourneur and Klausner, 1992; Pond et al., 1995) abrogate lysosomal localization. The
elucidation of this lysosomal sorting motif is important for two reasons. First, it provides domainlevel detail for a protein that was virtually uncharacterized prior to 2010. Second, it provides a
valuable tool for mechanistic exploration of TMEM106B function. We exploit the latter use in the
current study as an important control, demonstrating that the effects seen with overexpression of
TMEM106B depend on both the identity of the overexpressed protein (since they are not seen
with LAMP1 or GFP overexpression) and on the proper subcellular localization of TMEM106B.
The abrogation of TMEM106B-induced effects by concomitant knockdown of C9orf72
also supports the assumption that the vacuolar phenotype, lysosomal acidification defect, and
cytotoxicity described here are disease-relevant effects of TMEM106B overexpression. Indeed,
these findings provide the first mechanistic evidence for a link between the two FTLD-TDP
associated genes TMEM106B and C9orf72. Hexanucleotide repeat expansions in C9orf72 are

95

the most common Mendelian cause of both FTD and ALS (DeJesus-Hernandez et al., 2011;
Renton et al., 2011; Beck et al., 2013). C9orf72-associated FTD and ALS cases demonstrate
large expansions (800-4,400 repeats), while healthy controls have <33 repeats (van Blitterswijk et
al., 2013; Beck et al., 2013). The effects of the C9orf72 repeat expansion are an area of active
research, with evidence for multiple mechanisms playing a role in disease. In particular, proposed
pathophysiological mechanisms for C9orf72 repeat expansions include toxic repeat RNA species
(Fratta et al., 2012; Gendron et al., 2013; Lee et al., 2013; Mizielinska et al., 2013), toxic
dipeptide repeats resulting from repeat-associated, non-ATG (RAN) translation (Ash et al., 2013;
Mizielinska et al., 2014; Mori et al., 2013), and reduced levels/loss of function of the normal
C9orf72 protein (Ciura et al., 2013; DeJesus-Hernandez et al., 2011; Gijselinck et al., 2012;
Renton et al., 2011).
We and others have previously demonstrated a genetic interaction between TMEM106B
and C9orf72 (Gallagher et al., 2014; van Blitterswijk et al., 2014), with TMEM106B genotypes
associated with increased risk for FTLD-TDP in non-C9orf72-expansion cases paradoxically
correlating with later age at death and age at onset in C9orf72-expansion-associated FTLD. This
sign epistatic effect has been described in other contexts before, and in these other contexts, the
protein products of the two genes involved have been shown to mechanistically interact (Schenk
et al., 2013; Silva et al., 2011). Our present study implicates TMEM106B and C9orf72 in the
same mechanistic pathways as well, since knockdown of C9orf72 mitigates most lysosomal
effects of TMEM106B overexpression.
While the normal function of C9orf72 protein is yet unknown, it is predicted by structural
analysis to be a DENN protein (Zhang et al., 2010; Levine et al., 2013a). DENN proteins function
as GDP-GTP exchange factors (GEFs) for Rab GTPases and, as such, they play a role in
regulating autophagy, vesicular trafficking and fusion, and membrane trafficking events. Proper
regulation of Rab GTPase activity is known to be important for neuronal function; furthermore,
dysregulation of Rabs by DENN proteins or other protein families with similar GEF activity has
previously been linked to neurodegeneration (Azzedine et al., 2003; Del Villar and Miller, 2004;
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Hadano et al., 2010). Thus, it is possible that many of the effects of increased TMEM106B
expression are mediated through alterations to one or more Rab GTPases, which are in turn
regulated by C9orf72. Such a model of pathogenesis implies that C9orf72 loss-of-function
mechanisms may play a role in development of disease.
We note that C9orf72 knockdown in the context of TMEM106B overexpression here has
a phenotype rescue effect. While this result may be counter-intuitive to straightforward
assumptions about loss-of-function mechanisms in disease, it is congruent with the sign epistatic
genetic modifier effect we previously reported for TMEM106B and C9orf72 in a 30-site
international cohort of C9orf72 expansion-associated FTLD-TDP cases (Gallagher et al., 2014).
That is, in human FTLD-TDP and in cell culture, increased TMEM106B expression (proxied by
TMEM106B risk genotype or manipulated by transient transfection) appears deleterious in most
cases, but is rescued in the specific context of reduced C9orf72 (proxied by C9orf72 expansion
carrier state or manipulated by C9orf72 knockdown). We further note that C9orf72 knockdown,
without concomitant TMEM106B overexpression, results in a small, but significant, decrease in
the size of LAMP1+ organelles. These data also support the notion that C9orf72 and TMEM106B
may function in the same cell biological pathways regulating the biogenesis, size, trafficking, or
turnover of these organelles.
Several limitations of our study deserve consideration. First, because many common
variant correlates of disease risk may act through cis-regulatory effects on expression of specific
genes (Gilad et al., 2008), we modeled these effects in our specific FTLD-TDP case by
overexpression of TMEM106B. Such a strategy is not without its dangers, since overexpression
may cause cellular artifacts. We guarded against such a possibility in several important ways.
First, we evaluated levels of TMEM106B overexpression by immunoblot in all experiments,
allowing us to verify that the observed cellular phenotypes occurred reliably at TMEM106B
overexpression levels ranging from ~2-10X (Figure 3.7b, c). In addition, we employed as controls
both overexpression of a different lysosomal protein (LAMP1) and overexpression ENQLVAAA
TMEM106B, in each case confirming that expression levels of control were equivalent to or
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greater than wild-type TMEM106B overexpression levels. Finally, we demonstrated that effects of
TMEM106B overexpression on organelle morphology, acidification, and toxicity could be rescued
by manipulation of a second disease-relevant protein, C9orf72. Taken together, these control
measures greatly decrease the possibility that the observed effects of increased TMEM106B
expression are non-specific overexpression artifacts.
A second limitation of our study is that we have modeled effects of TMEM106B
overexpression by transient transfection. While the advantage of such an approach is that it
allows for comparisons of cells overexpressing vs. not overexpressing TMEM106B within the
same field, longer-term effects of alterations in expression might not be captured.
Third, our study focused on the effects of disease-relevant increases in TMEM106B
expression on lysosomes, finding, in the process, that observed phenomena are dependent on
the presence of C9orf72. We note here that previous work by our group (Chen-Plotkin et al.,
2012) and others (Cruchaga et al., 2011; Brady et al., 2013; Lang et al., 2012) also suggests a
potential connection between TMEM106B and progranulin based on genetic and cell-based
analyses. Since progranulin localizes to lysosomes (Brady et al., 2013), and humans without
functional progranulin manifest with a lysosomal storage disorder (Smith et al., 2012), the
potential for TMEM106B-induced effects on lysosomes to affect progranulin pathways as well,
either in neurons themselves or in other support cells in which progranulin expression is very high
(e.g. microglia), is also an area worthy of further investigation.
In summary, since the discovery of the TMEM106B locus as a genetic risk factor for
FTLD-TDP in 2010 (Van Deerlin et al., 2010), multiple groups have worked to understand the
significance of TMEM106B in disease pathophysiology (Brady et al., 2013; Chen-Plotkin et al.,
2012; Lang et al., 2012; Nicholson et al., 2013; Stagi et al., 2014; Schwenk et al., 2014). Here we
dissect at a cell biological level the effects of disease-associated increases in TMEM106B
expression, demonstrating significant effects on lysosomal morphology and impairment in
lysosomal acidification, with associated cytotoxicity. We moreover demonstrate that these effects
may depend on the presence of a second FTLD-TDP-associated protein, C9orf72. Our study thus
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establishes the importance of lysosomal pathways to the development of FTLD-TDP and
suggests a mechanistic interaction between TMEM106B and C9orf72.
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3.4 MATERIALS AND METHODS
Constructs:
C9orf72 constructs – FLAG-C9orf72: open reading frame of human C9orf72 (transcript variant 2
NM_018325.3) in pCMV6 vector (Origene); this construct is dual-tagged with myc-FLAG inserted
after the C-terminus; however, because only the FLAG was used for antibody detection, we
hereinafter refer to this construct as FLAG-C9orf72.
Control constructs – 5TO: pcDNA/5TO backbone vector (Invitrogen). GFP: GFP was cloned into
the pcDNA/5TO vector (Invitrogen). GFP-LAMP1: gift from L. Volpicelli-Daley (University of
Alabama, Birmingham, AL). LAMP1: human LAMP1 in pCMV6-XL5 (Origene).
TMEM106B constructs – (1) FLAG-TMEM106B: the 5’ untranslated region and open reading
frame of TMEM106B and a C-terminal FLAG tag were cloned into pcDNA 3.0 vector (Life
Technologies). (2) GFP-TMEM106B: cloned into pEGFP-C3 vector (Clontech) by F. Hu (Cornell
University, Ithaca, NY) as previously described (Brady et al., 2013). (3) myc-TMEM106B: the 5’
untranslated region and open reading frame of TMEM106B and an N-terminal myc tag were
cloned into pcDNA 3.0 (Life Technologies).

Lysosomal motif mutants
Point mutations were introduced to putative lysosomal sorting motifs in the parent FLAGTMEM106B construct (see previous section). Mutations to the tyrosine and dileucine-based
motifs were created using the QuikChange II Site-Directed Mutagenesis Kit and primer design
software (Agilent Technologies). The primer used to mutate YVEF
tcctgtaaattccacagctggaaactgagagacatctccatttcttcc,

YDGV

gatgtgactccatcagcagcatcttctttgcttgaatgcaaagg,

ENQLVALI

and

tctctgatcactatatggagccgctgccaccagttggttttcttgccccc.

Cell culture, transfection, and nucleofection:
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 AVEF

was

ADGV

was

ENQLVAAA

was

Primary cortical and hippocampal mouse neurons were prepared from embryonic day 18
(E18) to E20 C57BL/6 mice. For each nucleofection, 5 million neurons in suspension were spun
down at 80xg and resuspended in 100 µl Mirus BioIngenio Electroporation Solution (Mirus
#50111). To introduce expression constructs into neurons, neurons were then transferred to an
Eppendorf containing 10 µg of the construct in question, gently mixed, and transferred to an
Amaxa aluminum electrode cuvette (Lonza). Mouse cortical and hippocampal neurons were
nucleofected on program O-005 on a Nucleofector 2b machine (Lonza). After nucleofection, 500
µl RPMI media (Corning #1040-CM) was gently added to the cuvette; media and cells were
transferred to an Eppendorf tube and incubated in a tissue culture incubator at 37°C for 5-10
minutes to allow cells to recover. Neurons were then aliquoted at 80-100 µl per well of a 12-well
plate containing poly-L-lysine coated coverslips and 1 ml of Neurobasal media (Gibco #21103031) supplemented with B27 (Gibco #17504-010) and Glutamax (Gibco #35050-061) per well.
The following day, half of the volume of media was exchanged with fresh media.
Cos7, HEK293, HeLa, and U2OS cells were also used for experiments and maintained in
complete DMEM medium (supplemented with 10% FBS (Gemini #900-108), 1% Pen-Strep
(Gibco #15410), and 1% L-Glutamine (Gibco #25030)). U2OS cells stably expressing mCherryGFP-LC3 were a gift from C. Coyne (University of Pittsburgh, Pittsburgh, PA) and have been
previously described (Moy et al, 2014). For transient transfections, cells were plated the day prior
to transfection; cells were transfected at 60-90% confluency using Lipofectamine 2000
(Invitrogen). Transfections were conducted in serum-free DMEM media (Gibco #19965)
according to manufacturer’s instructions; after 5-6 hours, serum-free medium was replaced with
complete DMEM medium.

Immunoblotting:
Immunoblots were performed as previously described (Neumann et al., 2006). The
following antibodies and conditions were used: N2077 rabbit TMEM106B antibody at 1ug/ml
(Chen-Plotkin et al., 2012); EGFR (Cell Signaling #2232) at 1:1000; LC3: rabbit anti-human
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(MBL) at 1:750; LAMP1 H4A3 at 0.5 ug/ml; alpha tubulin: mouse monoclonal DM1A (abcam
#ab7291) at 0.1333 ug/ml (1:7500); ); C9orf72: rabbit anti-human at 1:500 (Sigma #023873).

Live and immunofluorescence microscopy:
Live images were taken with the EVOS FL Cell Imaging System (Life Technologies) at
40x or 60x magnification.
Double- and triple-label immunofluorescence labeling experiments were performed as
previously described (Chen-Plotkin et al., 2012). The following primary antibodies and conditions
were used: C9orf72: anti-human rabbit C9orf72 (Sigma #HPA023873) at 0.8 µg/ml (1:250); EEA1: rat anti-mouse EEA-1 (BD #610456) at 1:100; GFP: goat polyclonal anti-GFP (abcam #6673)
at 0.98 µg/ml (1:1000); LAMP1 1D4B: rat anti-mouse 1D4B (DSHB) at 1 µg/mL; LAMP1 H4A3:
mouse anti-human H4A3 (DSHB) at 1 µg/ml; SV-2 mouse anti-mouse SV-2 (DSHB #SV2) at
1:3000. TMEM106B: custom rabbit anti-human, anti-mouse N2077 polyclonal antibody raised
against amino acids 4-19 of TMEM106B at 1 µg/ml; custom chicken anti-human N2077 serum
raised against the same peptide at 1:2000. TMEM106B antibody characterization has been
previously reported(Chen-Plotkin et al., 2012). Secondary antibodies: goat anti-rabbit Alexa Fluor
488 (Life Technologies #A-11008); goat anti-rabbit Alexa Fluor 594 (Life Technologies #A11037); goat anti-chicken Alexa Fluor 488 (Life Technologies #A-11039) all used at 1:1000.
AMCA anti-mouse (Vector Laboratories #CI-2000) at 1:100. LysoTracker DND-99 (Life
Technologies #L-7528) was used as previously described(Chen-Plotkin et al., 2012). Images
were taken on a Nikon 80i upright fluorescence microscope and analyzed with Nikon NISElements AR Imaging Software.
BODIPY 493/503 (Life #D-3922) was used per manufacturer’s instructions. Briefly, cells
grown on coverslips were washed with PBS and fixed with 2% paraformaldehyde. BODIPY stock
(1 mg/ml in 100% EtOH) was freshly diluted at 1:500 in DPBS and incubated on the coverslips in
the dark at room temperature for 15 minutes. Coverslips were then rinsed with DPBS three times,
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then counterstained with DAPI and mounted with ProLong Gold mounting medium (Life
#P36930).

Quantification of LAMP1+ organelle diameter:
The maximum diameter of the ten largest LAMP1+ organelles (by visual inspection)
within each cell analyzed was measured using the Nikon NIS-Elements AR Imaging Software,
with >150 LAMP1+ organelles (>15 cells) measured for each condition from images captured at
40X.
In the C9orf72 knockdown experiments, HeLa and HEK293 cells were transiently
transfected with TMEM106B plus one other transfectant, which could be: (1) siRNA targeting
C9orf72, (2) nontargeting siRNA control, (3) C9orf72 construct, for overexpression, or (4) nothing,
as indicated in the text. Within each transiently transfected well, there are cells that over-express
TMEM106B as well as neighboring cells that do not. These are readily distinguishable by staining
with antibodies against the TMEM106B construct. Raw data were scored for TMEM106B overexpressing cells vs. TMEM106B non-over-expressing cells, in these various transientlytransfected conditions. These raw data were then normalized to the control condition (cells that
have no additional transfectant – condition #4 above -- and are deemed not to over-express
TMEM106B by immunofluorescence microscopy).

Quantification of LC3 puncta, LAMP1 organelles, LysoTracker mean fluorescence
intensity:
LC3 puncta quantification: LC3 puncta were quantified in HeLa cells as well as U2OS cells stably
expressing mCherry-GFP-LC3. For HeLas, cells were transfected with TMEM106B or GFP
control constructs and stained with N2077 or anti-GFP antibodies to identify the cells expressing
each construct. Anti-LC3 antibody was used to stain autophagosomes. 20 fields were captured at
40x magnification using Nikon NIS-Elements AR Imaging Software. LC3+ puncta were then
counted in >75 cells for each condition – GFP-expressing, TMEM106B-expressing and no-
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construct-expressing cells for two independent experiments. mCherry-GFP-LC3 U2OS cells were
similarly transfected with TMEM106B or LAMP1 (Origene) and stained with N2077 and antiLAMP1 H4A3 antibody, respectively. 50 fields were imaged at 60x magnification for each
condition. The number of red and yellow LC3 puncta per cell was then counted for >50 cells for
each condition. The average number of yellow dots (autophagosomes) and red dots
(autolysosomes) per cell was calculated (± SEM). The % autophagosomes was calculated as
yellow dot/total red dot x 100 (Lu 2013). Data from two identical replicates were combined and
graphed.
LAMP1 quantification: Cells transfected with GFP or TMEM106B were stained for GFP or
TMEM106B respectively, as well as LAMP1. For each transfection condition, 12 fields were
captured at 60x magnification. The total number of LAMP1+ organelles per cell was then counted
for 25 GFP- and TMEM106B-overexpressing cells and 10 no-construct-expressing cells, and the
average number per cell was calculated (± SEM). Graph displays data from three replicate
experiments performed by two independent operators.
LysoTracker mean fluorescence intensity (MFI): Primary mouse hippocampal neurons were
nucleofected with either GFP-TMEM106B or GFP-LAMP1. At DIV4, LysoTracker Red DND-99
(Life Technologies) was administered according to manufacturer’s instructions and coverslips
were stained for DAPI and mounted onto slides. The average cytosolic MFI was determined as
previously described (Chen-Plotkin et al., 2012) for GFP-LAMP1-expressing, GFP-TMEM106Bexpressing and no-construct-expressing cells. >180 neurons were counted for each condition.
Data from four identical experiments were compiled and graphed.

EGF-R degradation and EGF trafficking assays:
EGF-R degradation assays: HeLa cells were transfected with FLAG-TMEM106B, GFP or 5TO
(vector) constructs. The next day, media was replaced with serum-free DMEM media. After 24h
starvation, 25 mg/ml cycloheximide (Sigma #C1988) was added to the wells; cells were then
stimulated with 100 ng/ml recombinant EGF (Invitrogen # PHG0311). At each timepoint, cells
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were lysed and harvested into 1x RIPA on ice and immunoblots were performed with anti-EGFR
antibody at 1:1000. Densitometry was used to quantify the amount of EGFR as normalized to
alpha tubulin for four replicate experiments.
EGF trafficking assays: A previously published protocol was adapted (Urwin et al., 2010). In
brief, HeLa cells were transfected with TMEM106B; 24-hours later, media was changed to serumfree media containing 1 µM leupeptin in DMSO (Sigma #L2023) and 1 µM pepstatin in DMSO
(Sigma #P4265). EGF-488 (Invitrogen #E-13345) was then added at 50 ng/ml or 400 ng/ml. The
0h timepoint was immediately fixed and immunofluorescently labeled with anti-LAMP1 H4A3 and
N2077. For subsequent timepoints, after 20 minutes of pulsing with EGF-488, media was
removed, cells were washed, and media containing unlabeled recombinant EGF, leupeptin, and
pepstatin

was

added

to

the

cells.

Coverslips

were

fixed

at

each

timepoint

and

immunofluorescently labeled. Z-stack images were taken at 100x and deconvolved using Nikon
NIS-Elements AR Imaging Software. For each timepoint, ~8 fields were taken; non-overexpressing and over-expressing cells (>12 each) were outlined using the region-of-interest tool
and Mander’s overlap was determined between the LAMP1- and EGF channels with the Nikon
NIS-Elements AR Imaging Software, comparing neighboring cells with vs. without TMEM106B
overexpression.

Cytotoxicity (LDH) assays:
The Clontech lactate dehydrogenase (LDH) assay #630117, an LDH-based colorimetric
kit, was used for quantitation of cytotoxicity. LDH release is indicative of compromise of cell
membrane integrity. HeLa cells were transfected as described above with FLAG-TMEM106B,
LAMP1, ENQLVAAA TMEM106B or 5TO vector backbone constructs. At 0 hours, 24 hours, and
48 hours after transfection, 150 µl media was removed from each condition and centrifuged at
800xg for 5 minutes. 100 µl of supernatant was then gently transferred into a clear 96-well plate;
100 µl of LDH Reaction Mixture (Clontech LDH assay #630117) was then added to each well.
The plate was incubated at room temperature in the dark for ten minutes, then read at 492 nm
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with a 620 nm reference wavelength. The percent cytotoxicity was calculated as indicated by the
manufacturer: (Absorbance – Low control) / (High control – low control), with “low control” being
media collected from untransfected cells and “high control” being media collected from cells
treated with Triton-X to release maximal LDH.

Trypan Blue assays were also used to assess

cytotoxicity. 48 hours after transfection, media was collected, adherent cells were trypsinized and
added to the collected media, and cells were spun down at 800xg for 5 minutes. Media was then
removed and a 50/50 mix of DMEM and 0.4% Trypan Blue were used to resuspend the cells. The
number of blue and total cells were counted using a hemacytometer.
Terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assays were
used to assess for cells with apoptosis-induced DNA damage. HeLa cells were transfected with
FLAG-TMEM106B or control empty vector. At 24 hours after transfection, staurosporine (Sigma
#S6942-200) was added to a final concentration of 1 µM to positive control wells and cells were
returned to the incubator for an additional 4 hours. Coverslips were then removed from the wells
for immunofluorescent labelling, with TMEM106B over-expressing cells identified by staining
against the FLAG tag. The TUNEL assay was then performed according to manufacturer’s
protocol (Roche #11 684 795 910), with the TUNEL fluorescein reaction mixture incorporated into
the secondary antibody step of immunofluorescent labelling. Images were taken on a Nikon 80i
upright fluorescence microscope and analyzed with Nikon NIS-Elements AR Imaging Software.

Electron microscopy:
Tissues for electron microscopic examination were fixed with 2.5% glutaraldehyde, 2.0%
paraformaldehyde in 0.1M sodium cacodylate buffer, pH 7.4, overnight at 4°C. After subsequent
buffer washes, the samples were post-fixed in 2.0% osmium tetroxide for 1 hour at room
temperature, and rinsed in dH2O. After dehydration through a graded ethanol series, the samples
were infiltrated and embedded in EMbed-812 (Electron Microscopy Sciences, Fort Washington,
PA). The glass cover slips were dissolved with hydrofluoric acid, and thin sections were taken
and stained with uranyl acetate and lead citrate prior to examination with a JEOL 1010 electron
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microscope fitted with a Hamamatsu digital camera and AMT Advantage image capture software.
For analysis, grids with cells or neurons nucleofected with either control or TMEM106B
expression constructs were then scanned systematically; non-dividing, non-apoptotic cells were
imaged in an unbiased manner

C9orf72 knockdown:
Two rounds of knockdown with 120 pg of siRNA against C9orf72 (GE Healthcare ONTARGETplus SMARTpool #L-013341-01 Human C9orf72) or 120 pg of siControl (GE Healthcare
ON-TARGETplus Non-targeting Pool #D-001810-10-05) were performed at 24 hours and 48
hours after cell plating. For experiments that required concomitant overexpression of another
construct, the overexpression construct was transfected in parallel with the siRNA during the
second round of knockdown.
As a second method to confirm specificity of C9orf72 knockdown effects, we used 4 μg of
shRNA against C9orf72 (Origene pRS construct # TR305711 construct C) or 4 μg of an shRNA to
GFP as a negative control (Origene pRS construct # TR30003). Transfections were performed 24
hours and 48 hours after plating, with overexpression of TMEM106B occurring at the same time
as the 48-hour knockdown transfection.

Statistical tests:
Two-tailed nonparametric (Mann-Whitney) tests were used except for time-course
experiments, for which two-way ANOVAs were used instead. Fisher exact tests were used for
electron microscopy analysis given low event counts in some control categories. Calculations
were performed using GraphPad Prism 5.

Quantitative PCR:
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qPCR was performed per standard protocols. Relative quantification was performed
(delta–delta method) using the geomean of ACTB and PPIA as our reference housekeeping
genes.
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CHAPTER 4: DISCUSSION
PREFACE:
In this work, I have focused on the role of TMEM106B, a previously uncharacterized
gene/protein implicated in risk for FTLD-TDP through genome-wide association of SNPs at this
locus (Van Deerlin et al., 2003). I have demonstrated that TMEM106B is an endolysosomal
protein in multiple cell types, including neurons, and that changing expression levels of
TMEM106B perturbs endolysosomal/autophagosomal pathways. The latter result is significant
because we and others (Van Deerlin et al., 2010; Yu et al., 2015; Nicholson et al., 2013; ChenPlotkin et al., 2012) have shown that SNPs associated with increased risk for FTLD-TDP at the
TMEM106B locus also correlate with increased expression of TMEM106B. My work adds to the
growing body of evidence implicating dysfunction in the endolysosomal/autophagosomal pathway
in the pathogenesis of FTLD.
In Chapter 2, I provide the first characterization of TMEM106B expression in human
brain, demonstrating that in neurologically normal controls, TMEM106B is expressed in the
cytoplasm of neurons, glia, and perivascular cells (endothelial cells or pericytes) and is found in a
polarized, perikaryal distribution in neurons through all layers of the neocortex. In addition, I also
find that TMEM106B exhibits a much more disorganized pattern in frontal cortical neurons from
GRN-associated FTLD-TDP brain as compared to FTLD-tau, FTLD-TDP cases lacking GRN
mutations, Alzheimer’s disease, and neurologically normal controls. This is likely indicative of
underlying endolysosomal dysfunction in GRN-associated FTLD-TDP, as subsequent LAMP1+
immunostaining recapitulated the TMEM106B immunostaining results with increased LAMP1+
disorganization seen primarily in GRN-associated FLTD-TDP specimens (Gotzl et al., 2014). As
discussed below, whether this perturbation in endolysosomal pathways is due to progranulin
deficiency, increased levels of TMEM106B, or a combination of both remains to be determined.
In Chapter 3, I investigate the cellular effects of disease-relevant, increased levels of
TMEM106B. I find that increased TMEM106B expression decreases cell viability and results in

109

major perturbations of the endolysosomal/autophagosomal pathway. Increased TMEM106B
levels also result in strikingly enlarged organelles positive for late endosomal/lysosomal markers,
marked impairment of lysosomal acidification and degradation, and increased cellular toxicity.
These biological effects of TMEM106B are dependent on its lysosomal localization, as point
mutations in a potential lysosomal sorting motif abrogated these effects. Lastly, knockdown of
C9orf72 mitigated the effects of elevated TMEM106B expression. Coupled with our previous
finding that TMEM106B acts as a genetic modifier affecting age at death in C9orf72-associated
FTLD-TDP, this suggests that TMEM106B and C9orf72 may interact, contributing to the
pathophysiology of FTLD-TDP.
In the following sections, I will discuss important implications of these results in the
context of existing literature on TMEM106B and on FTLD. I will highlight themes emerging from
my own findings, as well as those of others, considering them in aggregate. Specifically, I will
discuss the cell biological effects of TMEM106B overexpression and suggest two potential
models that might underlie these effects. I then will discuss the relationship between TMEM106B
and progranulin as well as C9orf72. Progranulin and C9orf72 have two things in common which
are pertinent here. First, genetic changes in each (GRN and C9orf72) are major autosomal
dominant causes of FLTD-TDP. Second, both progranulin (Ghoshal et al., 2012; Petkau et al.,
2010; Wils et al., 2012; Ahmed et al., 2007; Smith et al., 2012) and C9orf72 (Farg et al., 2014;
Levine et al., 2013b; O'Rourke et al., 2016) have been linked to endolysosomal/autophagosomal
pathways in previous literature. Finally, I will consider the role of endolysosomal/autophagosomal
dysfunction as a major disease mechanism underlying FTLD, pointing to specific roles that
TMEM106B, C9orf72, progranulin may play in this over-arching pathophysiological cascade.
4.1 Changes in TMEM106B expression levels result in alterations to the
endolysosomal/autophagosomal pathway
4.1.1

Increased levels of TMEM106B result in enlarged LAMP1 organelle size
Our laboratory and multiple investigators have shown that endogenous TMEM106B co-

localizes with late endosomal/lysosomal markers, such as LAMP1, LAMP2, and Rab7 in a variety
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of immortalized cell lines as well as mouse and rat primary cortical and hippocampal neurons
(Lang et al., 2012; Schwenk et al., 2014; Stagi et al., 2014; Brady et al., 2013). Furthermore,
TMEM106B does not appear to co-localize with synaptic vesicle markers or early or recycling
endosomal markers (Schwenk et al., 2014; Brady et al., 2013; Chen-Plotkin et al., 2012).
Additionally, we and others demonstrate that increased TMEM106B levels result in a striking
phenotype

of

enlarged

organelles,

which

maintain

late

endosomal/lysosomal

marker

immunoreactivity (Stagi et al., 2014; Brady et al., 2013; Lang et al., 2012), with my work
extending this to primary murine neurons as well.
A question that remains is what are these enlarged organelles? They appear to be
lysosome derived – N2A cells preloaded with dextran and transfected with TMEM106B
demonstrate that many of these enlarged organelles are positive for dextran. In this experiment,
cells are incubated with dextran, washed, then chased with growth medium such that dextran
accumulates in and marks lysosomes (Ohkuma, 1989; Brady et al., 2013). The enlarged
TMEM106B+ organelles were positive for dextran, suggesting they are likely derived from
lysosomes. In addition, in a parallel experiment, TMEM106B was first transfected, then
subsequently loaded with dextran and chased; these pre-existing TMEM106B overexpressioninduced organelles were found to be accessible to administered dextran, suggesting no
significant blockades between these organelles and incoming endosomes (Brady et al., 2013).
My data also suggests that many of the enlarged organelles demonstrate immunoreactivity, and
at times co-localization, for TMEM106B, LC3 and LAMP1 by immunofluorescence, suggesting
that these organelles are additionally capable of fusing with LC3+ autophagosomes. The
ultrastructure of these organelles also reveals them to be primarily single-membrane organelles
which appear empty or contain cytoplasmic debris, multilamellar structures, and organelles in
varying states of degradation. In some instances, we visualized a second membrane, suggestive
of the inner membrane of an autophagosome being degraded following the fusion of a lysosome.
Taken together, the morphological and immunofluorescence labeling data suggest that these
enlarged organelles may be an aberrant entity with characteristics of late endosomes/lysosomes
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or autolysosomes/amphisomes that demonstrate intact fusion capabilities but may fail to degrade
effectively.

4.1.2

Increased levels of TMEM106B results in lysosomal acidification and degradative
defects
In line with this, we also found that increased expression of TMEM106B, but not LAMP1

as a control, decreases the fluorescence of LysoTracker, as well as LysoSensor, in immortalized
cells (Chen-Plotkin et al., 2012) as well as in primary neurons, indicative of an increase in
intraluminal pH. This acidification defect was accompanied by delayed degradation of endocytic
cargo; specifically, the lysosomal degradation of EGFR was impaired. Similar results were
reported by Brady and colleagues – expression of GFP-TMEM106B in T98G cells, a glioblastoma
cell line, resulted in impaired lysosomal degradation of EGFR compared to vector control (Brady
et al., 2013). Additionally, I found that cells in which TMEM106B overexpression is established
exhibit delayed targeting of endocytosed EGF to LAMP1+ organelles. However, whether this is a
primary effect of TMEM106B overexpression itself or a secondary effect has yet to be determined
– for example, TMEM106B levels could directly affect mechanisms of internalization or
membrane trafficking to lysosomes; alternatively, the delay in EGF internalization itself may be a
downstream consequence of TMEM106B’s primary effect on another aspect of endolysosomal
function, such as lysosomal acidification itself – accumulation of undigested material can slow
down membrane trafficking and sorting (Parkinson-Lawrence et al., 2010; Luzio et al., 2007).
Impaired lysosomal acidification has previously been shown to play a role in other
neurodegenerative diseases – for example, Alzheimer’s-associated mutations in PSEN1 may
impair lysosomal acidification by impairing the trafficking of a vATPase subunit (Lee et al., 2010).
Additionally, mutations in ATPase type 13A2 (ATP13A2), a component of the lysosomal
acidification machinery, have been found in patients with hereditary parkinsonism (Williams et al.,
2005; Dehay et al., 2012). Moreover, mutations in LRRK2 are the most common known genetic
cause of Parkinson’s disease (Hedrich et al., 2006) and LRRK2 kinase activity has been
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proposed to activate a Ca+2-dependent pathway that results in alkalization of lysosomes as well
as increased autophagosome formation (Gomez-Suaga et al., 2012).
Late endosomal/lysosomal acidification is maintained primarily by the vATPase, with ClC
transporters (which mediate Cl- transport) and Na+/K+ channels providing the counter-ions to
uphold this 100-1000x H+ gradient. Maintenance of this gradient is vital to lysosomal trafficking,
maintenance, and generation of the membrane potential, as well as content condensation during
membrane fusion (Luzio et al., 2007). The vATPase consists of V o and V1 domains and operates
through an incompletely understood mechanism in which each cycle of ATP hydrolysis by the V 1
domain results in rotation of the Vo rotor domain (Forgac, 2007). This coordinated rotation results
in the translocation of H+ ions into the lysosomal lumen.
I note in this context our preliminary data from an initial immunoprecipitation-mass
spectrometry experiment. I expressed FLAG-TMEM106B in HEK293 cells, immunoprecipitated
against the FLAG tag, and subjected the immunoprecipitated material for peptide identification of
potential TMEM106B binding partners by mass spectrometry. Intriguingly, my initial data
demonstrate that TMEM106B may interact with several vacuolar ATPase (vATPase) subunits: 1)
subunit a, part of the integral domain Vo which is involved in fusion between lysosomes and
phagosomes as well as in the acidification of synaptic vesicles in neurons as well (Nishi and
Forgac, 2000; Hiesinger et al., 2005); 2) subunit A, part of the cytosolic domain V1 which plays a
role in ATP binding and hydrolysis (Forgac, 1998); and 3) subunit B2 (brain isoform), part of
the V1 domain, shown to bind to actin and aid in vATPase recycling (Bernasconi et al., 1990).
The interaction of TMEM106B and the vATPase was also found in a repetition of this experiment
by others in the lab.
It is possible that our preliminary findings are artifactual, as the vATPase can appear as a
non-specific hit in immunoprecipitation-mass spectrometry experiments; we minimized this
possibility as much as possible by comparing TMEM106B overexpression hits to hits from a GFP
overexpression control, subtracting non-specific hits and hits obtained from a TMEM106B
knockdown condition control, to enrich for true interactions. I will next attempt to confirm these
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interactions through co-immunoprecipitation or pulldown experiments between TMEM106B and
individual subunits. If confirmed, a direct interaction between TMEM106B and elements of the
vATPase raises the possibility that increased TMEM106B may disrupt the assembly or function of
the vATPase, perhaps by binding to and sequestering critical subunits, ultimately resulting in
downstream failure to acidify organelles. Additionally, future experiments should be aimed at
further elucidating the acidification defect on lysosomal function, such as assessing if it impairs
the maturation and thus activation of lysosomal enzymes, such as Cathepsin D. This would
further support my hypothesis that increased levels of TMEM106B result in significant lysosomal
dysfunction.
4.1.3

Increased levels of TMEM106B may impact autophagy pathways
As discussed above, our LC3 immunofluorescent experiments and ultrastructural

analysis suggested the increased TMEM106B levels may impact autophagy pathways. As
preliminary experiments, we enumerated the number of LC3+ organelles/cell, and found that they
significantly increased upon TMEM106B overexpression, but not with GFP overexpression
control. Additionally, expression of ENQLVAAA TMEM106B resulted in only a minimal increase in
LC3 puncta, despite much higher expression levels than wild-type TMEM106B. This suggests
that the significant increase in LC3+ organelles seen upon TMEM106B expression is dependent
on the localization of TMEM106B to the lysosomal membrane.
The observed apparent increase in LC3 may be the result of 1) an increase in
autophagosome formation 2) a block in downstream autophagic flux, such as due to the
lysosomal acidification defect or 3) a combination of both (Mizushima et al., 2010; Klionsky et al.,
2012). The third scenario is seen in a subset of lysosomal storage diseases – primary defects in
lysosomal function as seen in murine models of Niemann-Pick type C disease as well as
Gaucher’s are also associated with a maladaptive increase in basal autophagy (Lieberman et al.,
2012). Indeed, my preliminary data, discussed below, suggest mTORC1 is inhibited upon
TMEM106B expression, linking TMEM106B expression to autophagic induction. Consistent with
this, Stagi et al. report that TMEM106B overexpression results in increased TFEB translocation to

114

the nucleus (Stagi et al., 2014); TFEB translocates to the nucleus upon mTORC1 inhibition, as
mTORC1 inhibition releases TFEB from mTORC1-mediated phosophorylation and inactivation
(Zhou et al., 2013). To help clarify the effect of TMEM106B on autophagic flux, future
experiments will include monitoring the degradation of long-lived proteins, autophagic substrates
such as p62, and TDP-43 itself (which has been shown to be degraded by autophagy as well as
the ubiquitin proteasome system (Brady et al., 2011) over extended periods of carefully controlled
levels of TMEM106B expression.
4.1.4

TMEM106B overexpression may skew the endolysosomal/autophagosomal
pathway towards a net increase in fusion products
While the effects of TMEM106B overexpression on autophagy pathways await further

clarification, I note that the increase in the number of LC3+ structures upon wild-type TMEM106B
expression was accompanied by a significant decrease in the number of LAMP1+ organelles in
HeLa cells and primary mouse hippocampal neurons. Non-overexpressing cells display many
small, punctate LAMP1+, LysoTracker-bright organelles, while TMEM106B overexpressing cells
display a marked absence of this punctate population and instead are predominated by fewer,
enlarged LAMP1+ LysoTracker-dim organelles. Taken together, I hypothesize these data suggest
that elevated TMEM106B levels bias the endolysosomal/autophagosomal pathway towards a net
increase in secondary lysosomes (such as endolysosomes, amphisomes, and autolysosomes)
and that this is accompanied by depletion of the normal lysosomal pool.
In response to physiologic changes in cellular status, membrane fusion/fission events
trigger short-lived increases in lysosomal size and the genesis of larger (>0.5μm) LAMP1+
secondary lysosomes (such as endolysosomes (ELs), autolysosomes (ALs), and amphisomes).
(Yu et al., 2010). These secondary lysosomes are usually transient species which return to
normal-sized primary lysosomes via lysosomal reformation or fission (Luzio et al., 2007; Xu and
Ren, 2015; Yu et al., 2010). However, changes in trafficking flux, or the accumulation of
undegraded material such as seen in lysosomal storage diseases may result in vesicle
enlargement (Walkley and Vanier, 2009). For instance, defective lysosomal reformation (leading
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to persistent ALs), or, impaired autophagosome-lysosome fusion (leading to ELs via increased
endosome-lysosome fusion), can increase the lifespan of these typically transient enlarged
species. This increase in the lifespan of these secondary lysosomes results in disequilibrium
between input and output along the endolysosomal/autophagosomal pathway (Lieberman et al.,
2012). Moreover, the incompletely digested materials within these enlarged species can result in
their

further

enlargement,

ultimately

causing

escalating

disruption

of

the

endolysosomal/autophagosomal pathway (Xu and Ren, 2015; Walkley and Vanier, 2009).
What then is the mechanism by which TMEM106B overexpression results in the
observed skew towards the predominance and persistence of secondary lysosomes? A number
of possibilities exist, but they may be considered in the form of two general models: TMEM106B
overexpression may skew the endolysosomal/autophagosomal pathway towards secondary
lysosomes (autolysosomes, amphisomes, endolysosomes), either by (1) decreasing their
dissolution, or (2) increasing their formation.

116

Figure 4.1: Model 1

Model 1: TMEM106B overexpression results in persistent secondary lysosomes through
inhibition of autophagic lysosomal reformation.
ALR = autophagic lysosomal reformation. LE= lysosomal exocytosis.
Adapted from (Tooze and Yoshimori, 2010).

Our data suggests elevated levels of TMEM106B may result in a defect in the resolution
of secondary lysosomes; given the observed co-localization with LC3, I posit these secondary
lysosomes

may

comprise

primarily

amphisomes/autolysosomes.

Persistent

amphisomes/autolysosomes can result from impairment in several major processes, including: 1)
autolysosomal exocytosis or 2) autophagic lysosomal reformation. In autolysosomal exocytosis,
autolysosomes fuse with the plasma membrane, and their contents are expelled (Reddy et al.,
2001; Samie and Xu, 2014). However, impaired lysosomal acidification and TFEB overexpression
are typically associated with increased autolysosomal exocytosis (Ejlerskov et al., 2013; Martina
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et al., 2014; Medina et al., 2011; Spampanato et al., 2013). Thus, although it is possible that
increased TMEM106B overexpression may interfere with the autolysosomal exocytic machinery
(Heuser, 1989; Pryor et al., 2000) or impair the Ca+2 influx required for lysosomal fusion with the
plasma membrane (Jahn and Scheller, 2006), decreased autolysosomal exocytosis seems less
likely given that TMEM106B overexpression is associated with lysosomal acidification defects
and potentially increased TFEB translocation to the nucleus (Stagi et al., 2014).
It is more likely that the persistent amphisomes/autolysosomes represent impairment in
the process of autophagic lysosomal reformation (ALR). This hypothesis is consistent with: 1) the
enlarged persistent LC3+ organelles we see by immunofluorescence 2) the lysosomal
acidification and degradation defects observed and 3) the associated loss in lysosomal number
seen with TMEM106B overexpression.
ALR was first characterized as an evolutionarily conserved mechanism that coordinates
nutrient sensing and lysosomal homeostasis in starvation-induced autophagy (Yu et al., 2010).
Starvation typically results in the inhibition of mTORC1 and the induction of autophagy. However,
after this initial period of inhibition, mTORC1 is reactivated and ALR commences. This
reactivation

is

associated

with

the

budding

off

of

protolysosomes

from

autolysosomes/amphisomes, resulting in the restoration of the lysosomal population and the
disappearance of autolysosomes/amphisomes (Yu et al., 2010; Chen and Yu, 2013; Rong et al.,
2012). An impairment in ALR results in “stalled” autolysosomes which continue to fuse with
existing lysosomes but do not resolve, depleting the lysosomal pool.
Importantly, ALR and the reactivation of mTORC1 have been shown to be dependent on
the ability of the lysosome to degrade (Rong et al., 2012), suggesting that the impaired lysosomal
acidification and degradation defects associated with increased TMEM106B may have significant
consequences on ALR and exhibit sustained mTORC1 inhibition. Indeed, my preliminary
experiments assessing mTORC1 activity via phosphoS6K immunoblots (active mTORC1
phosphorylates S6K) show that while normal HEK293s reactivate mTORC1 9 hours after an initial
starvation-induced inhibition, cells expressing TMEM106B at expression levels ranging from 2-5x
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over endogenous levels do not reactivate mTORC1 and remain in a state of mTORC1 inhibition
even 24h later (data not shown).
Notably, starvation-induced mTORC1 inhibition increases autophagosome formation; it
also increases intracellular pH, clustering of lysosomes near the microtubule organizing center,
autophagosome-lysosome fusion (Korolchuk et al., 2011), and TFEB translocation (Settembre et
al., 2012; Roczniak-Ferguson et al., 2012; Martina et al., 2014). TMEM106B overexpression is
similarly associated with increased autophagosome formation, increased intracellular pH, and the
appearance of enlarged LC3+ LAMP1+ organelles, alterations in lysosomal trafficking and
positioning, and TFEB translocation (Chen-Plotkin et al., 2012; Schwenk et al., 2014; Stagi et al.,
2014), possibly representing a state of sustained impaired ALR. TMEM106B overexpression
would thus be expected to result in impaired autolysosomal clearance accompanied by a
decrease in the number of available lysosomes.
An important next step would be to confirm the dynamics and efficiency of autolysosomal
clearance. As one example, the fluorescent lysosomal substrate DQ-BSA can be monitored in
control versus TMEM106B overexpressing cells over time to assess for defects in lysosomal
degradation. DQ-BSA is a self-quenched dye conjugated to BSA which, when digested by
lysosomal proteases, is dequenched releasing highly fluorescent protein fragments (Voss et al.,
1996). In addition, to assess if the formation of the enlarged LAMP1+ organelles is indeed
autophagy dependent (as would be expected in ALR), we have begun experiments knocking
down essential autophagy genes in the context of TMEM106B overexpression. We can also
assess if restoring mTORC1 activity, in the context of TMEM106B overexpression, such as with
3-benzyl-5-((2-nitrophenoxy) methyl)-dihydrofuran-2(3H)-one (Ge et al., 2014), abrogates the
vacuolar phenotype.
One possible mechanism as to why increased TMEM106B may impair ALR is via
perturbation of the vATPase/mTOR/Ragulator axis, which is important for coordinating lysosomal
responses to cellular stressors and nutrient states (Settembre et al., 2013). The effect of
TMEM106B overexpression on the vATPase/mTORC1/Ragulator axis could be indirect, such as
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by altering lysosomal membrane integrity or lysosomal size (via changes in ion content,
osmolarity (Bandyopadhyay et al., 2014), decreases or increases in trafficking and membrane
fusion and fission events (Settembre et al., 2013), or impaired lysosomal degradative capacity
(Lieberman et al., 2012). Another possibility is via TMEM106B’s proposed interaction with the
vATPase subunits. ATP hydrolysis by the vATPase is necessary for the vATPase to mediate
amino-acid sensitive interactions between Ragulator and RAG GTPases which recruit mTORC1
to and, together with RHEB (Ras homologue enriched in brain), activate it at the lysosomal
membrane (Zoncu et al., 2011; Settembre et al., 2012). Elevated levels of TMEM106B may
interfere with the proper assembly and function of the vATPase at the lysosomal membrane,
thereby impairing the ability of vATPase to interact with Ragulator and Rag GTPases to recruit
mTORC1 to the lysosomal membrane. In any case, we could assess the effect of TMEM106B
levels on the localization of these players to the lysosomal membrane, especially mTORC1
localization, expecting that TMEM106B overexpression will correlate with decreased localization
of mTORC1 at the lysosomal membrane.
One potentially puzzling observation is that TMEM106B overexpression has been shown
by one group to result in increased TFEB translocation to the nucleus (Stagi et al., 2014), which
might be expected at face value to activate lysosomal function through transcription of the
CLEAR lysosomal and autophagosomal gene network. However, I note that TFEB translocation
to the nucleus 1) is necessary but not sufficient to coordinate transcription of the CLEAR network
(Zhou et al., 2013) and 2) increased expression of autophagosomal and lysosomal genes does
not necessarily translate to enhanced lysosomal function – for example, in many lysosomal
storage diseases, expression levels of lysosomal genes are increased in what is proposed to be
compensatory response to reduced degradative capacity (Gotzl et al., 2014; Ballabio and
Gieselmann, 2009; Lieberman et al., 2012). Confirmation of the TFEB translocation, as well as
further identification of specific lysosomal and autophagosomal genes affected by TMEM106B
overexpression, will be needed to further investigate these data.
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Figure 4.2: Model 2

Model 2: TMEM106B overexpression results increases the production of secondary
lysosomes via modulation of endolysosomal/autophagosomal Rab GTPase activity.
ALR = autophagic lysosomal reformation. LE = lysosomal exocytosis.
Adapted from (Tooze and Yoshimori, 2010).

As a second model, I propose that TMEM106B overexpression may primarily increase
the production and enlargement of secondary lysosomes, primarily amphisomes/autolysosomes,
via modulation of endolysosomal/autophagosomal Rab GTPase activity. This hypothesis stems
from 1) my data demonstrating that TMEM106B overexpression effects are abrogated by C9orf72
knockdown 2) growing evidence that C9orf72 may function, potentially as a GEF as predicted,
within the endolysosomal pathway (O'Rourke et al., 2016; Farg et al., 2014; Zhang et al., 2012).
Taken together this would implicate TMEM106B in Rab GTPase-modulated pathways. Thus, I
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hypothesize that TMEM106B modulates Rab GTPase activity to exert its effects on the
endolysosomal pathway.
To assess this hypothesis, I would determine if TMEM106B modulates Rab GTPase
activity by acting as an effector by using a panel of dominant negative and constitutively active
forms of candidate Rab GTPases. While there are >60 mammalian Rabs, I would prioritize Rab
GTPases that are known to be involved in endocytic and lysosomal trafficking as well as those
shown to co-localize with C9orf72 (Farg et al., 2014). These would include Rab5, Rab7, Rab 11,
as well as Rab38, noting the recent GWAS demonstrating it may be a genetic risk factor for
frontotemporal dementia and its role in trafficking to lysosomal-related organelles and maturation
of phagosomes (Ferrari et al., 2014; Bultema et al., 2012). Notably, constitutively active Rab7 has
been reported to impair ALR, resulting in the accumulation of enlarged autolysosomes, with the
dissociation of Rab7 a requirement for ALR to proceed (Yu et al., 2010). If TMEM106B is a Rab
effector, we would also expect it to reverse or prevent the effects of dominant negative forms of
Rabs when co-expressed with them. Additionally, I would assess the ability of TMEM106B to bind
efficiently to GTP-bound constitutively active forms of Rabs and weakly if at all to dominant
negative forms.
It is also possible that TMEM106B may not function as a Rab effector directly, but may
modulate Rab GTPases via other avenues. For example, rather than exhibit effector activity itself,
TMEM106B might interact with specific Rab effectors or alter the recruitment of a GEF or
GTPase-activating protein (GAP) (GAPs are the counterparts to GEFs, and activate hydrolysis of
GTP (Bos et al., 2007)). Alternatively, increased TMEM106B could impact Rab recruitment in
general, increasing or decreasing recruitment to target membranes. This would follow a similar
paradigm as one proposed to explain CHMP2B-associated FTLD, in which CHMP2B-associated
FTLD mutant cells were defective in their ability to recruit Rab7 to late endosomal membranes,
resulting in enlarged late endosomes and amphisomes (Urwin et al., 2010). If TMEM106B
expression levels affect Rab recruitment, we would expect TMEM106B overexpression and
knockdown to result in reciprocal changes in the candidate Rab’s colocalization with its
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associated endosomal/lysosomal membranes. This could be assessed by co-transfection of
labeled Rab7, for example, with either TMEM106B overexpression or knockdown constructs
followed by immunofluorescent staining for LAMP1+ and subsequent quantification of the level of
co-localization between Rab7 and LAMP1.
4.1.5

Point mutations in an extended dileucine lysosomal sorting motif abrogates
TMEM106B overexpression phenotypes
Our data demonstrate the effects of increased TMEM106B expression (the appearance

of enlarged organelles, acidification defect, and cytotoxicity) are abrogated by point mutations to
a potential extended dileucine lysosomal sorting motif in TMEM106B (ENQLVALI 
ENQLVAAA). This provided a valuable overexpression control to my experiments and suggested
that it is unlikely that the observed cell biological effects of TMEM106B overexpression are nonspecific artifacts of protein overexpression, since they are not seen with the even higher levels of
expression of ENQLVAAA TMEM106B, and are dependent on TMEM106B targeting to the
lysosome. In addition, this provides domain-level detail for a protein that was uncharacterized
prior to 2010.
The ENQLVAAA TMEM106B mutant will be useful in the future to identify and
investigate the adaptor protein(s) and other proteins with which wild-type TMEM106B interacts.
ENQLVALI may be an extended classical dileucine lysosomal targeting motif of the general
consensus of [DE]XXXL[LI] (Letourneur and Klausner, 1992; Bonifacino and Traub, 2003). This
demonstrates the importance of the [LI] in lysosomal targeting of TMEM106B, although other
signals may contribute as well. Substitution of either of the critical leucines/isoleucines by alanine
has been shown to abrogate activities of [DE]XXXL[LI] signals (Letourneur and Klausner, 1992;
Pond et al., 1995). [DE]XXXL[LI] motifs interact with heterotetrameric adaptor proteins, AP-1, AP2, and AP-3 (Ohno et al., 1997; Braulke and Bonifacino, 2009; Hirst et al., 2011). Briefly, AP-1
regulates delivery of proteins from the trans-Golgi network to the endolysosomal system and back
(Braulke and Bonifacino, 2009). AP-2 regulates clathrin-mediated endocytosis from the plasma
membrane (Pearse and Robinson, 1990). AP-3 is found in endosomes and is thought to regulate
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the transport of select proteins in the endolysosomal pathway (Le Borgne et al., 1998;
Dell'Angelica et al., 2000).
I would expect that wild-type TMEM106B would interact with AP-1, AP-2, or AP-3 given
the abrogation of its lysosomal localization by mutation of the [LI] in the potential dileucine motif,
although ultimately, the adaptor protein with which a motif interacts must be experimentally
determined. Initial yeast-two hybrid results from by Stagi et al. using the cytoplasmic domain of
TMEM106B as bait and a prey library derived from human adult brain report that TMEM106B
interacts with the µ2 subunit AP-2 as well as with CLTC (clathrin heavy chain) (Stagi et al., 2014),
both of which play a major role in the formation of coated vesicles (Kirchhausen, 2000;
Pawlowski, 2010). Intriguingly, AP-2 has been shown to complex with other proteins to act as an
autophagic cargo receptor for the amyloid precursor protein cleaved C-terminal fragment, linking
the endocytic pathway to the autophagic degradation pathway in neurodegenerative disease
(Tian et al., 2013). AP-2 has also been shown to be essential for autophagic lysosomal
reformation (ALR), along with clathrin and PtdIns(4,5)P2 (Rong et al., 2012). Stagi et al.’s data is
the first suggesting a potential interaction with AP-2 and will need to be confirmed by other
investigators; notably, affinity for sorting adaptors is low and methods such as yeast two-hybrid,
yeast-three hybrid, and GST-pulldown experiments will be required to explore potential
interactions between TMEM106B and adaptor proteins.
However, understanding the molecular mechanisms underlying the effects of TMEM106B
overexpression will require identification of other key binding partners. This will require the above
methods as well as immunoprecipitation-mass spectrometry. The ENQLVAAA TMEM106B
mutant may serve as a useful comparator in these experiments.
4.1.6

The

endolysosomal/autophagosomal

disturbances

caused

by

increased

TMEM106B are cytotoxic to cells
We began our work with the observation that specific genotypes in TMEM106B are
associated with both increased TMEM106B expression and increased risk for neurodegeneration.
This, in addition to the striking endolysosomal disruption we observed, led us to hypothesize that
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increased levels of TMEM106B might have cytotoxic effects. Indeed, in HeLa cells, TMEM106B
expression, but not LAMP1 expression, resulted in a significant increase in cell death. In parallel
to these data, we observed that GFP-tagged TMEM106B-overexpressing cells “disappear” from
culture within 72h after transfection, whereas cells transfected with GFP-tagged LAMP1 or the
ENQLVAAA TMEM106B mutant remain.
Initial investigations into specific cell death pathways responsible for the observed
cytotoxicity have been negative. Specifically, we and others (Brady et al., 2013) have shown that
TMEM106B overexpressing cells are negative for TUNEL staining, suggesting that apoptotic cell
death pathways do not play a major role in the observed cytotoxicity. However, I note that
compromised lysosomal function results in a deficiency of precursors for biosynthetic pathways
and cellular starvation, which may ultimately have deleterious effects on viability (Schulze and
Sandhoff, 2011). To compensate for impaired degradative capacity, cells have been shown to
initially maladaptively increase basal levels of autophagy (Ballabio and Gieselmann, 2009; Cang
et al., 2014). These compensatory changes may initially help, but may ultimately result in
cytotoxicity. While autophagy is often viewed as beneficial, mediating cellular homeostasis during
stress conditions, inappropriate sustained autophagy has also been shown to induce cell death
(Yu et al., 2004a; Yu et al., 2004b; Yu et al., 2008; Levine and Yuan, 2005). Thus, future
investigations of other cell death pathways which exhibit autophagic vacuolization, including
necroptosis (Basit et al., 2013; Bonapace et al., 2010; Bray et al., 2012) and autosis (Liu and
Levine, 2015; Liu et al., 2013), may be a valuable addition here.
4.1.7

TMEM106B knockdown may alter lysosomal size and trafficking
While my data has focused mainly on the effects on increased TMEM106B, others have

in parallel investigated the effects of TMEM106B knockdown. Notably, knockdown does not result
in changes in expression levels in FTLD-associated proteins TDP-43, progranulin, FUS, or tau
(Schwenk et al., 2014; Brady et al., 2013), and TMEM106B knockdown does not appear to have
neurotoxic effects in primary rat cortical neurons (Schwenk et al., 2014). Investigations into the
role of TMEM106B knockdown on lysosomal positioning and trafficking has yielded some results
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that are concordant and some that are not. The data are concordant in that several groups
demonstrate that TMEM106B knockdown results in changes in lysosomal positioning and
movement within the dendrites of murine neurons. The data are discordant in that one group
report that TMEM106B knockdown results in an increase in retrograde dendritic lysosomes
(Schwenk et al., 2014), while another group find that TMEM106B knockdown results in overall
distally distributed lysosomes, suggesting net anterograde movement (Stagi et al., 2014).
Differences in neuronal populations assessed (mouse cortical versus rat hippocampal) and
lysosomal markers used in live imaging (Rab7 versus LAMP1, which may identify different
subsets of endolysosomal populations) may account for these discordant results.
These data are preliminary as the molecular players responsible for these events still
need to be confirmed; however, they suggest an important role for TMEM106B levels in
lysosomal motility and placement. With respect to my own findings, these data suggest that the
real-time effects of aberrant lysosomal motility and placement might moreover explain the
disorganized lysosomal staining pattern I observed by immunohistochemistry in the soma and
dendrites of cortical neurons from GRN-associated FTLD-TDP postmortem brain samples (Busch
et al., 2013).
Whether this effect on lysosomal position is due to a direct interaction of TMEM106B with
the lysosomal trafficking machinery and motor proteins or is a downstream consequence of
TMEM106B’s effects remains to be fully determined. For example, lysosomal positioning has
been shown to be determined by luminal pH and mTORC1 activity (Johnson et al., 2016;
Korolchuk et al., 2011); thus, the primary defect induced by TMEM106B overexpression could be
due to altered pH, which then in turn affects lysosomal trafficking.
4.2 TMEM106B and C9orf72
I next place into context our discovery that many of the effects of TMEM106B
overexpression can be rescued by concomitant knockdown of C9orf72. Much of the field has
focused on toxic C9orf72 RNA and dipeptide repeats. However, evidence is accumulating that
C9orf72 may normally play a role in the endolysosomal pathway and that reduced levels and/or
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loss of function of C9orf72 may contribute to disease pathogenesis (DeJesus-Hernandez et al.,
2011; Farg et al., 2014; Renton et al., 2011; Ciura et al., 2013; Gijselinck et al., 2012; O'Rourke et
al., 2016).
Homology analyses predict C9orf72 to be a homologue of DENN proteins, which function
as GEFs that activate Rab GTPases (Levine et al., 2013b). In one study, endogenous C9orf72
was reported to co-localize and co-immunoprecipitate with several Rab GTPases involved in
endolysosomal and autophagic transport (Rab1, Rab5, Rab7, and Rab11) in primary cortical
neurons and human spinal cord motor neurons (Farg et al., 2014). While these data are intriguing
as they are the first to link C9orf72 to Rab GTPases, these data imply that C9orf72 co-localizes
with diverse Rabs which are localized to different compartments – Rab1 is involved in
endoplasmic reticulum to Golgi trafficking; Rab5 in endocytic and early endosomal trafficking
(Zerial and McBride, 2001; van der Bliek, 2005) and Rab11 in recycling endosomes as well as
vesicle exocytosis (Takahashi et al., 2012). The authors suggest that it is via interactions with
different sets of protein partners that C9orf72 localizes to these compartments; while this is
possible, this seems unlikely. Thus, the proposed interaction with these Rab GTPases awaits
confirmation by other investigators. Indeed, in contrast to Farg et al.’s findings, Xiao et al. did not
see co-localization of C9orf72 with endosomal, lysosomal, or autophagosomal markers using
house-made and validated C9orf72 antibodies, as compared to the commercial antibodies used
by Farg et al. (Farg et al., 2014; Xiao et al., 2015). Further investigation into C9orf72 must
proceed with caution and attention to validation of antibodies.
However, with regards to evidence for a role for C9orf72 in endolysosomal pathways,
new data from C9orf72 null mice adds to the evidence for this and additionally highlights a
heretofore underappreciated role for its loss in microglia in promoting pro-inflammatory states in
disease pathogenesis. Macrophages and microglia from C9orf72 null mice harbored enlarged
LysoTracker+ and LAMP1+ structures (O'Rourke et al., 2016). Accumulations of LAMP1+
material were also found in microglia from spinal cord and motor cortex tissue from C9orf72associated, but not sporadic, ALS cases. The authors suggest that C9orf72 may function in late
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endosomal to lysosomal trafficking. Specifically, in myeloid cells, C9orf72 may play a role in
phagosome to lysosome maturation, as bone marrow-derived macrophages from C9orf72 null
mice showed enhanced production of reactive oxygen species after feeding of zymosan particles,
indicative of defective fusion of phagosomes to lysosomes (Ma et al., 2014).
Given data suggesting a role for C9orf72 in endolysosomal pathways, as well as the
finding that TMEM106B acts as a genetic modifier in C9orf72-associated FTLD-TDP cases
(Gallagher et al., 2014; van Blitterswijk et al., 2014), we investigated the potential for manipulation
of C9orf72 to rescue or exacerbate the phenotypes associated with TMEM106B overexpression.
We found that knockdown of C9orf72 mitigated the vacuolar phenotype, lysosomal acidification
defect, and cytotoxicity induced by TMEM106B overexpression independent of an effect on
TMEM106B expression levels. These data suggest an interaction between TMEM106B and
C9orf72. The interaction may be direct, or C9orf72 may exert its countereffects on TMEM106B
phenotypes through its predicted GEF function. For the former possibility, identification of both
TMEM106B

and

C9orf72’s

binding

partners

by

previously

discussed

methods

(co-

immunoprecipitation, GST-pulldown, yeast-two hybrid assays) could shed light on whether the
two proteins interact, and domain-mutation experiments as well as use of our ENQLVAAA
TMEM106B mutant could refine our understanding of potential interactions. Alternatively, the
mechanistic basis for the observed rescue of TMEM106B-induced phenotypes by knockdown of
C9or7f2 may be through the predicted GEF function of C9orf72. To investigate this possibility,
the first step would be to determine if C9orf72 exhibits GEF functionality. I would test a panel of
Rab GTPases in a GDP-releasing assay (Yoshimura et al., 2010), prioritizing candidate Rab
GTPases as previously discussed. I would then assess their GTP binding, as GTP binding rapidly
follows GDP release for true GEFs, using radioactive GTPγS (a non-hydrolyzable analog of
GTP). As an alternative to these classical radioactive approaches, recently developed fluorescent
analogs of guanine nucleotides, such as mant (N-methylanthraniloyl) fluorophores, which analogs
exhibit spectroscopic differences when bound or unbound. This would allow for real time analysis
of GEF activity, including kinetic and thermodynamic properties (Cheng et al., 2002; Rossman et
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al., 2002). I would then modulate the activity of any identified GTPases, expecting knockdown of
candidate Rabs or expression of dominant negative Rab GDP-bound versions to exert similar
effects as C9orf72 knockdown, such as smaller LAMP1+ organelles and rescue of TMEM106B
overexpression phenotypes.
One interesting question in the field has been why the C9orf72-expansion disease state
appears to be mitigated by the presence of the TMEM106B major allele (associated with
increased risk for FTD in non-C9orf72-carriers) as opposed to the minor allele (associated with
protection from FTD in non-C9orf72-carriers), resulting in later age at disease onset and death
(van Blitterswijk et al., 2014; Gallagher et al., 2014). Now, the evidence seems to be growing that
loss of the normal C9orf72 may impair endolysosomal trafficking, with detrimental effects that
contribute to disease pathogenesis. This might suggest that elevated levels of TMEM106B, as
associated with the major allele, may work to counterbalance the effects of C9orf72 deficiency
through its effects in the endolysosomal pathway, initially mitigating the onset of disease in the
C9orf72-expansion context. However, increased levels of TMEM106B are, as I have shown,
detrimental to endolysosomal/autophagosomal pathways themselves and disease ultimately
progresses. Taken together, these data highlight the importance of proper balance within the
endolysosomal pathway in the health of neurons and their supporting cells.
We note that implicit in these scenarios discussed above is the assumption that
C9orf72’s normal function matters. Accordingly, our data and the experiments outlined above fall
into the general category of assuming that haploinsufficiency of C9orf72 from repeat expansions
may be a pathogenic mechanism. We have not addressed other major putative mechanisms of
disease, such as the contribution of gain-of-toxicity from the expanded hexanucleotide repeat.
However, we are struck by the fact that two proteins implicated in FTLD-TDP – TMEM106B and
C9orf72 – appear to both act in the same pathways and that knockdown of C9orf72 can rescue
effects of TMEM106B overexpression. If C9orf72 repeat expansions act exclusively by gain-offunction mechanisms through the generation of RNA foci or dipeptide repeats, then the
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interaction of TMEM106B and C9orf72 observed here is simply due to chance. While not
impossible, this seems highly unlikely.
4.3 TMEM106B and progranulin
A third major emerging theme is the relationship between TMEM106B and progranulin. I
have found that TMEM106B expression patterns in GRN-associated FTLD-TDP human frontal
cortex exhibit a much more cytoplasmically dispersed TMEM106B staining pattern, with
TMEM106B immunoreactivity extending into the processes of these neurons, as compared to the
perikaryal pattern found in both neurologically normal controls and FTLD-TDP without GRN
mutations.
The finding of altered TMEM106B expression in this Mendelian subgroup of FLTD-TDP
taken at face value might suggest that GRN haploinsufficiency results in downstream effects on
TMEM106B. However, the answer is likely not this straightforward. Consider, for example, the
genetic modifier study reported by Cruchaga et al. in 2011. In a study of 50 patients with FTLDTDP due to mutations in GRN (GRN-associated FTLD-TDP), the authors found that homozygous
carriers of the risk allele of TMEM106B at rs1990622 showed a mean decrease of the age at
onset of 13 years (p=9.9x10-7), compared to heterozygotes or homozygous carriers of the
protective allele. Additionally, the risk allele associated with lower plasma progranulin levels in
both healthy older adults (p=4x10−4) and GRN mutation carriers (p=.0027) (Cruchaga et al.,
2011). Since TMEM106B genotypes (and therefore expression levels) were found to modify age
at onset for GRN-associated FTLD-TDP, as well as correlating with circulating levels of
progranulin protein, this study suggests that TMEM106B may modulate progranulin effects,
possibly via altered endolysosomal pathways.
A second line of evidence supporting an effect of TMEM106B on progranulin (as opposed
to vice-versa) lies in our direct manipulation of TMEM106B expression in cell culture. We found
that increasing TMEM106B expression results in an increase in the intracellular:extracellular ratio
of progranulin (Chen-Plotkin et al., 2012). Brady et al. saw a similar increase in intracellular
progranulin upon TMEM106B overexpression in N2A cells (a mouse neuroblastoma cell line).
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These data support a relationship between TMEM106B and progranulin. Moreover,
growing evidence supports a major role of progranulin in lysosomal biology. The strongest
evidence comes from the finding that the complete loss of progranulin, as discovered in a human
sibling pair with homozygous c.813_816del (p.Thr272Serfs*10) mutations results in adult-onset
neuronal ceroid lipofuscinosis (NCL) (Smith et al., 2012), implicating the function of the normal
progranulin protein in lysosomal biology. Notably, some Grn-/- mouse models have been found to
exhibit pathological hallmarks of lysosomal dysregulation often found in lysosomal storage
diseases (Ghoshal et al., 2012; Petkau et al., 2010; Wils et al., 2012; Ahmed et al., 2007).
Similarly, GRN-associated FTLD-TDP brain also exhibit many of the pathological findings seen in
tissue derived from NCL brain: increased levels of LAMP1 and LAMP2, the accumulation of
saposin D, and subunit c of mitochondria ATP synthase (SCMAS) (Gotzl et al., 2014).
Progranulin deficiency thus results in significant lysosomal derangements, although why
complete loss of progranulin results in NCL, whereas partial loss results in FTLD is still unclear. I
posit the TMEM106B risk genotype can compound the negative effects of progranulin
haploinsufficiency via several possible scenarios. First, TMEM106B overexpression may impact
the development of disease by specific effects on progranulin and progranulin signaling, impairing
the known neuroprotective effects and lysosomal functions of progranulin (Van Damme et al.,
2008). Second, TMEM106B overexpression-induced endolysosomal/autophagosomal alterations
may further exacerbate existing lysosomal derangements and neurotoxic effects caused by
progranulin deficiency, together resulting in earlier onset of disease.
4.3.1

TMEM106B overexpression may disrupt neuroprotective progranulin pathways
I posit that the endolysosomal/autophagosomal disturbances caused by TMEM106B

overexpression may have direct or indirect effects on progranulin internalization, sorting, and
trafficking. This may impair progranulin’s normal neuroprotective signaling pathway, i.e., the
network of interconnected endosomes and lysosomes which executes spatiotemporal control
over signaling events, delivering the appropriate amount of neurotrophic progranulin “signal” to
different regions of the cell (Sadowski et al., 2009). Proper regulation of this network pathway is
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critical in long and polarized neurons. An example of a pathway that relies heavily on the integrity
of a signaling endosome network is the EGF/EGFR signaling pathway. Endocytosis of
EGF/EGFR activates the EGFR/MAPK signaling pathway, which remains activated until EGFR is
inwardly budded into the intraluminal vesicles of the late endosome, removing the catalytic
domain of EGFR from the cytoplasm (Sorkin and Duex, 2010; Eden et al., 2009). The
neurotrophic effects of progranulin are likely to be similarly dependent on the regulated
internalization of progranulin, with downstream signaling cascades and ultimate termination of
signal through degradation of progranulin in the lysosome. As a consequence, TMEM106B’s
effects on the endolysosomal network could affect the ability to appropriately internalize
progranulin, signal through progranulin, or terminate progranulin signaling appropriately.
Intriguingly, progranulin has been shown to activate signaling pathways known to be dependent
on proper spatial-temporal function of signaling endosome networks (e.g., MAPK, PI3K) (He et
al., 2002; Zanocco-Marani et al., 1999).
As we and others have shown, increased TMEM106B significantly disrupts the
endolysosomal network and lysosomal trafficking in neurons, with knockdown of TMEM106B
increasing and overexpression decreasing lysosomal trafficking in mouse cortical cultures (Stagi
et al., 2014; Schwenk et al., 2014). Thus, perturbations in the endolysosomal pathway as induced
by varying levels of TMEM106B could exacerbate the negative effects of progranulin deficiency
by disturbing the spatio-temporal relationship of signaling endosomes and lysosomes involved in
progranulin signaling pathways, thus disrupting progranulin’s neurotrophic effects. While the
progranulin pathway responsible for its neurotrophic effects has yet to be determined, I note that
progranulin deficiency has been shown to result in decreased mTORC1 activity in frontal cortex in
a Grn-/- mouse model (Tanaka et al., 2013); thus, an intriguing possibility is that the pathway that
TMEM106B overexpression negatively impacts may be mTORC1 itself.
4.4 The endolysosomal/autophagosomal pathway in disease pathogenesis
Overall, emerging data on TMEM106B, progranulin, and C9orf72 highlight a role for all
three of these disease-associated proteins in endolysosomal trafficking and function. In addition,
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rarer, Mendelian forms of FTLD also point to disturbances in the endolysosomal/autophagosomal
pathway and altered trafficking dynamics as a central theme in FTLD.
As shown in Figure 4.3, FTLD-TDP-associated mutations in CHMP2B may impair fusion
of endosomes with autophagosomes and lysosomes; (Urwin et al., 2010; Filimonenko et al.,
2007; Lee et al., 2007); disease-associated mutations in VCP may impair autophagosomal
maturation and transport of ubiquitinated cargo to lysosomes (Ju et al., 2009; Ritz et al., 2011);
moreover, new evidence suggests that C9orf72 expansions may result in impaired endosomal to
lysosomal trafficking due to loss of C9orf72’s normal function (O'Rourke et al., 2016). In addition,
progranulin deficiency has indeed been associated with significant disturbances to lysosomal and
autophagosomal pathways (Petkau et al., 2010; Shacka, 2012; Gotzl et al., 2014). Thus,
impairments in lysosomal function, altered fusion dynamics, and altered vesicular trafficking
emerge as common themes in FTLD. I further note that endolysosomal/autophagosomal
dysfunction may play an important role in other neurodegenerative diseases such as Parkinson’s,
Alzheimer’s, and Huntington’s disease, as discussed in the Introduction (Wong and Cuervo,
2010).
How does TMEM106B fit within this contextual framework? I posit that diseaseassociated

increases

in

TMEM106B

result

in

altered

dynamics

within

the

endolysosomal/autophagosomal pathway. TMEM106B overexpression may do this by impairing
dissolution of the secondary lysosomes (such as autolysosomes/amphisomes), potentially via
impairment of autophagic lysosomal reformation. Alternatively, TMEM106B levels may modulate
one or more Rab GTPases or effectors, increasing trafficking and membrane fusion dynamics to
result in an increase in secondary lysosomes.
The effects of increased TMEM106B may perturb progranulin pathways that are vital to
lysosomal and cellular homeostasis. In addition, TMEM106B may interact with endogenous
C9orf72, and elevated levels of TMEM106B may counterbalance the loss of C9orf72 within the
endolysosomal pathway.
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Figure 4.3:

Figure 4.3: Endolysosomal/autophagosomal dysfunction in neurodegeneration
Mutations in multiple genes involved in the endolysosomal/autophagosomal pathway are
implicated in neurodegeneration and are shown where they have been implicated to impact.
Black text: mutations associated with FTLD. Disease-associated mutations in CHMP2B have
been shown to impair endolysosome-lysosome fusion. Mutations in VCP have been shown to
impair lysosomal fusion with autophagosomes. C9orf72 has been implicated in late endosomal to
lysosomal trafficking, with the disease-associated hexanucleotide expansion resulting in reduced
levels of functional C9orf72 protein. Green text: Alzheimer’s mutations in PSEN1 impair
lysosomal acidification by impairing proper trafficking of a vATPase subunit. Blue text:
Parkinson’s-associated mutations in ATP13A2, a lysosomal P-type ATPase, results in impaired
lysosomal acidification. Mutations in LRRK2 activate a Ca+2-dependent pathway that results in
lysosomal acidification defects and increased autophagosome formation. Against this backdrop of
endolysosomal/autophagosomal disruption, TMEM106B may exert its effects on the
endolysosomal pathway by 1) impairing the dissolution of secondary lysosomes (such as ALs
depicted) 2) increasing secondary lysosomal formation by modulation of endolysosomal Rab
GTPase activity.
AL= autolysosome. AP=autophagosome.

Recent data highlight the important roles of both progranulin and C9orf72 in microglia,
with C9orf72 deficient mice and Grn deficient mice exhibiting pro-inflammatory microglial cytokine
profiles and neurotoxic effects (Tanaka et al., 2013; O'Rourke et al., 2016). These studies
emphasize the growing importance of considering the microglia-neuron interaction in the
pathogenesis of disease. Manipulation of TMEM106B within microglia, and assessment of how
this influences microglial cytokine profiles as well as neuronal toxicity, should be a major focus of
study in future studies attempting to unravel the relationship between TMEM106B and
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progranulin, and TMEM106B and C9orf72.
Finally, an as-yet-unanswered question within the field of FTLD-TDP concerns the
relationship between TDP-43, the major protein forming the pathognomonic inclusions of the
disease, and the various proteins implicated by the genetics in FTLD-TDP. Despite both being
linked to FTLD-TDP ten years ago, a mechanistic link between progranulin and TDP-43 has yet
to emerge. Similarly, few mechanistic connections have been found between TDP-43 and
C9orf72. Our findings suggest one way that TDP-43 may be linked to these various genetic
causes of FTLD-TDP is through endolysosomal/autophagosomal pathway dysfunction.
Aggregates of TDP-43 are reported to be degraded by autophagy as well as by the ubiquitin
proteasome system (Wang et al., 2010; Brady et al., 2011). Thus, if degradative pathways are
affected by, for example TMEM106B expression levels, one major route for the cell to rid itself of
TDP-43 aggregates would be impaired. I note in this context that in addition to the genes
mentioned above, other ALS/FTLD-associated mutations have recently emerged in genes that
are all to various extents related to autophagy. The protein products of UBQNL2, SQSTM1,
OPTN – ubiquilin2, p62, and optineurin respectively – have all been shown to function in
autophagy as autophagy receptors, binding ubiquitinated protein aggregates and directing them
to autophagosomes for degradation (Wagner 2008, Wild 2011).
In the case of these specific, rare, Mendelian causes of ALS/FTLD, the existing evidence
points to defects in autophagic proteins or related proteins that compromise the neuron’s ability to
adequately degrade these protein aggregates, with subsequent toxic effects that cause
neurodegeneration. Increases in TMEM106B expression may similarly compromise degradation
of

protein

aggregates,

to

a

lesser

degree,

through

impairments

to

endolysosomal/autophagosomal function, thus contributing to increased risk for FTLD.
4.5 Future Directions
While the field has made great strides in the preliminary characterization of a protein
otherwise unknown prior to 2010, much is still left to be learned about TMEM106B. Identification
and confirmation of TMEM106B’s binding partners will be vital in fully establishing its function.
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Currently, potential non-overlapping interacting proteins have been reported by two separate
groups. Schwenk et al. identified MAP6 as the only common hit in three independent
immunoprecipitation-mass spectrometry experiments from P15 rat brain, linking TMEM106B to
microtubule-dependent processes. Another group (Stagi et al., 2014) has reported, via yeast twohybrid assays, that TMEM106B can bind to AP-2, CLTC, VPS11, and VPS13D; the latter two
proteins play roles in late endosome to lysosome trafficking (Velayos-Baeza et al., 2004;
Bankaitis et al., 1986). Our preliminary immunoprecipitation-mass spectrometry experiments
demonstrate a potential interaction with vATPase subunits, but our hits do not overlap with these
previously identified proteins. Thus, consensus and independent confirmation are needed for
these and other future potential partners of TMEM106B, and future co-immunoprecipitation
experiments should be ideally performed in frontal and temporal cortex to help elucidate
TMEM106B’s binding partners within disease-relevant tissue.
Notably, TMEM106C was also identified as a potential binding partner of TMEM106B, in
a yeast two-hybrid screen; TMEM106C has 47% amino acid identity and 63% amino acid
similarity with TMEM106B (Stagi et al., 2014). The role of oligomerization of TMEM106B with
family members TMEM106A and TMEM106C, or self-dimerization/oligomerization is also an area
that may be fruitful for future study, especially within the context of how various homo- and
hetero-dimerization events might affect lysosomal pathways, trafficking dynamics, and binding to
other protein partners.
It will also be important to translate the role of TMEM106B from cell culture models into
more clinically relevant patient-derived cells and tissue as well as in vivo models. To that end, the
availability of fibroblasts from patients with GRN-associated FTLD-TDP, C9orf72-associated
FTLD-TDP, FTLD-TDP without either genetic mutation, and FTLD-tau offers potential for
investigation of lysosomal readouts in these cells as well as potential derivatives (e.g. iPSCderived neurons) of these cells. A key aspect of the work described in this thesis is the fact that
effects of TMEM106B manipulation in specific genetic contexts have been explored. With the
advent of genome editing, it is increasingly feasible to create isogenic controls from patient-
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derived cell lines that differ only in whether a mutation (e.g. C9orf72 expansion) is present or
whether a specific gene is silenced. Thus, one can pinpoint with molecular precision, in patientderived cells, what the effects of specific mutations or gene silencing would be. As just one
example, experiments investigating the effect of presence vs. absence of C9orf72 (or C9orf72
expansions) in otherwise isogenic iPSC-derived neurons on the phenotypes triggered by
TMEM106B overexpression (lysosomal morphology and function, cell viability) are feasible and
would add greatly to the clinical relevance of the work described here.
Lastly, the generation and characterization of TMEM106B mouse models may add to our
understanding of TMEM106B. To date, no knockout mouse model for TMEM106B has been
reported, and such a model may help elucidate the function of endogenous TMEM106B. Notably,
Schwenk et al. found that knockdown of TMEM106B in rat cortical neurons results in a striking
loss of dendritic arborization and decreased pre- and post-synaptic marker proteins, suggesting
that a neurological phenotype may likely result from loss of TMEM106B in an animal (Schwenk et
al., 2014). TMEM106B overexpression can also be modeled in an in vivo animal context, which
may allow us to parse the whole organism consequences of the cell biological phenotypes
described in this thesis. Because of the genetic modifier effects reported by us and others for
TMEM106B on phenotype in carriers of C9orf72 expansions (Gallagher et al., 2014; van
Blitterswijk et al., 2014) and GRN mutations (Finch et al., 2011; Cruchaga et al., 2011; Van
Deerlin et al., 2010), crosses between TMEM106B overexpression or TMEM106B null animals
and C9orf72 expansion, C9orf72 null, or GRN null animals may be of interest. Indeed, C9orf72
expansion (Peters et al., 2015), C9orf72 null (Koppers et al., 2015), and Grn null mice (Kayasuga
et al., 2007; Yin et al., 2010; Filiano et al., 2013) have already been generated and reported and
many are striking for the general lack of a clear neurodegenerative phenotype. Should the
manipulation of TMEM106B as a second locus in these existing mouse models bring out a clear
neurodegenerative phenotype, this would strongly support the mechanistic interactions hinted at
in this work and faithfully model the genetic modifier effects observed in human disease.
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4.6 Conclusion
Our work and the work of others demonstrates that TMEM106B is important in
endolysosomal/autophagosomal trafficking and function, that increased levels of TMEM106B may
have toxic effects on cells, and that TMEM106B may interact with C9orf72, which is also
implicated as functioning within the endolysosomal/autophagosomal pathway. Furthermore, we
see that elevated levels of TMEM106B alter progranulin intracellular:extracellular partitioning,
suggesting that disruption of progranulin signaling pathways may also contribute to disease. In
addition to these effects on progranulin, elevated levels of TMEM106B, as seen in carriers of
FTLD-TDP risk genotypes, may result in small alterations in the dynamics of lysosomal or
autolysosomal degradation. These changes may over the lifetime of an individual ultimately result
in failure to clear toxic aggregates from neurons. A relative impairment in the ability to clear toxic
aggregates may then result in increased neuronal toxicity, leading to the neurodegeneration seen
in FTLD-TDP as well as other neurodegenerative diseases.
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